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Abstract 
 
Women‘s Experiences Discontinuing Hormone Therapy for Menopause 
 
 Although many women find relief from menopause through hormone therapy (HT), current 
guidelines recommend that HT be used only for short-term relief of symptoms. Women who attempt 
to stop HT often encounter troublesome recurrent symptoms leading to a diminished quality of life 
(QoL); 25% of women who discontinue eventually resume HT. Unfortunately, there is little 
information for women and their health care providers as to the best way to discontinue HT or how 
to prepare and guide women through this process. An in-depth description of women‘s experiences 
during HT discontinuation and the factors influencing recurrent symptoms, QoL and discontinuation 
outcome would provide knowledge to develop much needed counseling and support interventions. 
The purpose of this study was to explore women‘s experiences discontinuing hormone therapy for 
menopause. 
 This Internet-based mixed-methods study used a dominant Qualitative Descriptive design 
with embedded quantitative QoL measurements. Participants completed the quantitative 
questionnaires online while open-ended questions were completed either online or by telephone. 
Interview data were analyzed through Qualitative Content Analysis; descriptive statistics were used 
to explore the quantitative measures. Participants were stratified by discontinuation status for 
comparison of variations in discontinuation experiences, QoL and influencing factors.  
 Thirty-four women (20 stopped, 9 resumed, 4 tapering) were enrolled. One overarching 
theme--'a solitary journey'--emerged: although all women embarked on this journey, each woman 
traveled her own path. Two subthemes--'burden and interference' and 'appraising risk'--encompassed 
the symptom factors (severity, interference and sensitivity) that influenced women's experiences and 
the manner in which women evaluated their options. Other influencing factors included: readiness 
viii 
 
and reasons for stopping HT, beliefs about menopause and roles. QoL was strongly connected to 
symptoms for many but not all women. Information from health care providers was inconsistent; 
women desired more support from providers and other women.  
 The rich description of women's experiences stopping HT highlights the need for providers to 
assess women's sensitivity to symptoms and readiness to discontinue to determine which women 
might benefit from more support. Greater health literacy would enhance women's understanding of 
HT risks. More research is needed on symptom clusters and interference and strategies for 
minimizing their impact.  
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CHAPTER I 
STATE OF THE SCIENCE 
 
 Menopause is both universal and unique: all women who live long enough will 
experience menopause yet each woman‘s journey through menopause will be unique. Some 
women will navigate this transition with ease while others will be beset by much turbulence 
along the way. For women buffeted by distressing symptoms during their menopause voyage, 
hormone therapy (HT) can offer a haven of symptom relief and improved quality of life (QoL).  
Despite the reduction in symptoms afforded by HT, many women eventually stop taking 
this medication: some discontinue on their own because of side effects while others do so based 
on recommendations by health care providers. However, women who attempt to stop HT often 
encounter troublesome symptoms that may thwart their efforts and cause them much suffering. 
There is little to guide these women, or their health care providers, as to the best ways to prepare 
for and navigate this passage.  
In order to develop better educational and support interventions, further information is 
needed about the HT discontinuation phenomenon. An in-depth description of women‘s 
experiences of HT discontinuation and the factors that may influence this experience either 
positively or negatively would provide this information. Therefore, the purpose of this mixed 
methods study was to describe the experience of discontinuing HT. The specific aims were to:  
1) explore women‘s experiences of HT discontinuation;  
2) describe the personal characteristics and sociocultural contexts that influence 
symptom perception, evaluation and response among women who have attempted to 
discontinue HT;  
3) explore the impact of HT discontinuation on women‘s quality of life; and  
 2 
 
4) discuss women‘s preferences for counseling and support during HT discontinuation.   
This chapter will provide a review of the literature relevant to hormone therapy discontinuation 
and the development of the study purpose and specific aims.  
Background and Significance  
 In order to appreciate the challenges inherent to discontinuing HT, it is essential to 
understand why women experiencing menopause may choose to begin HT. Accordingly, the 
Background and Significance section will describe menopause and its associated symptoms as 
well as provide an overview of the history of HT and the critical event leading to the revelation 
of the gap in the literature of menopause discontinuation.   
Overview of Menopause 
Approximately 2 million women experience menopause every year (North American 
Menopause Society [NAMS], 2007). Defined as a woman‘s final menstrual period (Glossary—
Appendix 1), menopause usually occurs due to the decrease in ovarian function that accompanies 
aging, although for some women it may be a result of surgery, chemotherapy or radiation. The 
average age of natural menopause is 51.4 years; the normal range is 40-58 years. This relatively 
wide range reflects variability in the aging trajectory of the female reproductive system due to 
the impact of factors such as genetics, environmental exposures, and lifestyles and illnesses 
(Burger, Hale, Dennerstein & Robertson, 2008; NAMS, 2007; Santoro, 2005).  
Because of this variability, chronological age cannot be used to define or predict 
menopause status. In order to better identify a woman‘s location in the menopause transition and 
to promote the adoption of a standard nomenclature, a model of reproductive aging was 
developed by the Stages of Reproductive Aging Workshop (STRAW) (Appendix 2) (Sherman, 
2005; Soules et al., 2001).  
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Menopause Symptoms.  The late reproductive and menopausal transition stages, as 
defined by this model, often herald the onset of physical and emotional changes and symptoms 
(Table 1). The prevalence of menopause symptoms is difficulty to determine precisely as it 
varies by symptom, population characteristics, individual perceptions and methodological issues 
such as definitions of symptoms or measurement strategies (Crawford, 2000). While over 85% of 
women report more than one symptom (Woods & Mitchell, 2005), the experience of these 
symptoms is variable and subjective and influenced by factors such as ethnicity, genetics and 
environment (Table 2) (Obermeyer, 2000; Soules et al., 2001). For some women, these 
symptoms are extremely distressing or troublesome. An estimated 10-20% of women will 
ultimately seek health care advice or treatment to help manage their uncomfortable menopause 
symptoms and improve their QoL (Gass, 2006; Woods & Mitchell, 2005).  
Some menopause symptoms are clearly associated with changes in the production of 
reproductive hormones (estrogen and progesterone) resulting from the gradual diminishing of 
ovarian function (Burger et al., 2008). These symptoms include menstrual cycle changes 
(irregular or heavy menstrual bleeding), urogenital symptoms (vaginal atrophy and perhaps 
urinary incontinence) and vasomotor symptoms (hot flashes and night sweats) (NAMS, 2007; 
National Institutes of Health [NIH], 2005). There is also new evidence suggesting that 
fluctuating hormone levels may be in part responsible for the onset or worsening of affective 
disorders (Ryan et al., 2009) although other factors such as life hassles (Smith-DiJulio, Woods & 
Mitchell, 2008) or a past history of behavioral health concerns may also be operational here 
(Freeman et al., 2004; Freeman, Sammel, Lin & Nelson, 2006). 
Vasomotor symptoms (VMS) in particular have received much attention due to the 
frequency with which they are reported and their capacity to be disruptive and uncomfortable 
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(Warren, 2007). During the period of time just prior to and after the final menstrual period 
(FMP), approximately 35-85%  (Utian, 2005) of women, and possibly more (Avis & Crawford, 
2006), experience VMS: sensations of warmth, especially in the upper body, often accompanied 
by flushing, sweating, palpitations, dizziness, and/or feelings of anxiety or panic (Kronenberg, 
1999; NAMS, 2007; Voda, 1997). VMS are thought to be due to a shrinking of the thermoneutral 
zone (TMZ) in the brain due to an increase in norepinephrine. When this TMZ is narrowed, even 
very small changes in core temperature can trigger VMS (Freedman, 2001).  
Although women describe a myriad of other symptoms during their midlife years (Table 
1), there is less evidence for a causal link between these symptoms and menopause. Some 
symptoms may be due to normal age-related changes or illnesses that develop during midlife. 
Others could be the result of menopause-related hormonal changes superimposed on the changes 
associated with aging (NAMS, 2007; Woods & Mitchell, 2005). Whatever the cause, non-
vasomotor symptoms may also be distressing and burdensome, particularly as they occur at a 
time when women may be trying to cope with stressors related to other life transitions such as 
aging parents, children leaving home, changes in employment status, loss of a spouse/life partner 
or even growing older in a youth-oriented society.   
Table 1.  
Menopause-associated symptoms & changes 
Cognitive  
Symptoms 
Decreased memory 
Diminished concentration 
Affective 
 Symptoms 
Mood swings 
Irritability 
Anxiety 
Depression 
Somatic  
Symptoms 
 
Fatigue 
Joint stiffness/pain 
Muscle aches 
Hair loss 
Dry skin and hair 
Acne 
Brittle nails 
Headaches 
Hearing loss 
Breast pain 
Sexual dysfunction 
Dizziness 
Changes in balance 
Weight gain  
Weight distribution changes  
 
 5 
 
Menopause Symptom Burden & Quality of Life. The unpredictability and 
inconvenience of these symptoms can lead to embarrassment, frustration, changes in body 
image, stress and anxiety.  Health care costs may be incurred for medications, testing, 
procedures, and consultations with specialists as well as for over-the-counter medications or 
complementary or alternative medicine (CAM) (Utian, 2005). Symptoms may also have a 
detrimental effect on workplace productivity (Burton, Pransky, Conti, Chen & Edington, 2004; 
Kronenberg, 1999; Utian, 2005) and family, social (Kronenberg, 1999; McVeigh, 2005; Utian, 
2005) and sexual (Kingsberg, 2006; Kronenberg, 1999) relationships. Hygiene and laundry 
products, plus a greater consumption of energy resources for laundry and climate control, can 
add to the financial impact (Utian, 2005). Overall, the burden associated with menopause 
symptoms—fear, uncertainty, disruptions in professional and personal lives, and costly, 
uncomfortable and time-consuming tests and treatments—may be quite high (Kronenberg, 1999; 
Utian, 2005). 
This symptom burden may have a deleterious effect on a woman‘s quality of life (QoL) 
(Utian, 2005; Woods & Mitchell, 2005) which is worrisome as low QoL has been implicated in 
increased mortality among midlife women (Kroenke, Kubzansky, Adler & Kawachi, 2008). 
However, results of studies on the association between menopause symptoms and QoL have 
been conflicting. Women who have more frequent or intense vasomotor and other symptoms 
have indeed described low QoL (Ledesert, Ringa & Breart, 1995; Oldenhaave et al., 1993; 
Williams, Levine, Kalilani, Lewis & Clark, 2008). However, other authors suggest that 
menopause has little impact on overall QoL (Avis et al., 2009; Li, Holm, Gulanick & Lanuza, 
2000). Instead, life hassles and events, or personal characteristics such as education or attitudes 
toward menopause and aging, exert a greater impact on well-being and life satisfaction (positive 
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facets of QoL) than does menopause or accompanying symptoms (Dennerstein, Dudley, Guthrie 
& Barrett-Connor, 2000; Dennerstein, Lehert & Guthrie, 2002; Smith-DiJulio et al., 2008).  
Findings from QoL studies in other disciplines have also demonstrated a lack of 
congruency between symptom reports or tallies and overall QoL ratings (Ferrans, 2007). This 
discrepancy may be due in part to the reliance on symptom checklists to measure QoL: the 
presence of symptoms does not necessarily correspond to a diminished QoL (Dennerstein & 
Helmes, 2001). Because QoL has multiple dimensions (symptoms. functional capacity, health, 
overall QoL) (Wilson & Cleary, 1995), measuring only one dimension does not provide a 
complete representation of QoL and limits comparisons between studies. This raises questions 
about the adequacy of using either menopause-symptom lists or an overall QoL question as the 
sole method of assessing QoL in women at menopause (Adler, 2002; Matthews & Bromberger, 
2005; Wiklund, 1998). Overall QoL questions may minimize the impact of uncomfortable 
symptoms (Twiss et al., 2007; Wiklund, 1998). Conversely, responses on symptom checklists 
may reflect differences in interpretations, judgments, memory or symptom sensitivity which 
may, in turn, be due to variations in contexts such as culture or ethnicity (Crawford, 2007).  
Factors Influencing Menopause Symptoms. All symptoms are influenced by the 
context in which they occur. Symptom experience (perception, evaluation and response) is 
influenced not only by the symptoms themselves (e.g., frequency, intensity, duration) but also by 
an individual‘s personal characteristics (e.g., genetics, weight) and sociocultural environment 
(e.g., ethnicity, social support) (Dodd et al., 2001; Lenz, Pugh, Milligan, Gift & Suppe, 1997; 
Woods & Mitchell, 2005). Although much of the literature has focused on biomedical factors, 
menopause occurs within a sociocultural context that greatly influences the meaning a woman 
attaches to menopause as well as her decisions about symptom management (Kaufert, 1996; 
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Sievert, 2006). Thus personal and sociocultural factors unique to each woman (see Table 2) 
impact on the degree to which menopause-related symptoms are perceived as troublesome or 
disruptive (Avis, Crawford & McKinlay, 1997; Dodd et al., 2001; Kafanelis, Kostanski, 
Komesaroff & Stojanovska, 2009; Lenz et al., 1997; Woods & Mitchell, 2005). 
Table 2.  
Factors associated with menopause symptom tolerance 
More Symptoms and/or Less symptom tolerance 
High frequency & severity of symptoms 
Symptom duration/chronicity 
Symptom sensitivity/distress 
Genetic polymorphisms 
Age 
Smoking 
Stress/higher cortisol levels 
Severe PMS symptoms 
Low self-esteem/self-image 
Negative self-appraisal  
Type A personality 
Sensitivity to public perception 
Negative affect 
Depression/Anxiety 
Higher BMI  
Physical inactivity 
Childhood abuse 
Late perimenopause 
Surgical menopause 
Overall health/other illnesses 
Less social support 
Lower socioeconomic status 
African-American race 
Negative attitudes toward coping strategies 
Negative attitudes toward aging &/or 
menopause 
Greater symptom tolerance 
Asian-American race (fewer symptoms) 
Positive attitudes toward menopause 
Higher self-esteem 
Lower BMI 
Physical activity 
Fewer symptoms 
 
Symptom Management. Numerous strategies exist for managing menopause symptoms. 
Treatment options include: lifestyle modification (e.g. dressing in layers), relaxation practices 
(paced respirations (Freedman, 2005) or Mindfulness-Based Stress Reduction (Carmody, 
Crawford & Churchill, 2006)), CAM (such as herbal supplements or Traditional Chinese 
Medicine) or Western-medicine prescription medications (including antidepressants or anti-
seizure medications). However, the ‗gold standard‘ for relief of menopause symptoms is HT 
containing either estrogen with progesterone (EPT) or estrogen alone (NAMS, 2007).   
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Hormone Therapy 
An estimated 15% of the almost 40 million women in the United States aged 50-74 (U.S. 
Census Bureau, 2000) use HT, primarily for relief of troublesome menopause symptoms 
(Wysowski & Governale, 2004). HT is popular because it effectively mitigates or alleviates 
many menopause-related symptoms such as VMS, sleep disruptions, mood and memory 
disturbances, joint pains, urogenital problems and even skin and hair changes (Barrett-Connor, 
Grady & Stefanick, 2005; NAMS, 2007). 
History of HT. The first attempts to ‗treat‘ menopause with hormone derivatives 
occurred in the 1920s and 1930s (See HT Timeline—Appendix 3) (Houck, 2006; Krieger et al., 
2005; Schulkin, 2008; Watkins, 2007). In 1942, Premarin was introduced to the public for the 
treatment of uncomfortable symptoms due to estrogen ‗loss‘ (Houck, 2006). It became popular in 
part due to books such as Feminine Forever (Wilson, 1966) which touted estrogen as the best 
treatment for the ‗deficiency disease‘ of menopause (MacPherson, 1981; McCrea, 1983) and the 
means by which women could retain their femininity and youthful appearance for as long as they 
lived (Houck, 2006; Schulkin, 2008; Watkins, 2007). Although feminists and other grassroots 
women‘s health activists decried HT as contributing to the medicalization of menopause 
(MacPherson, 1981; McCrea, 1983), many women opted to use HT because their perceptions of 
how they felt and how they looked were improved. 
As findings from numerous observational studies pointed to cardiovascular and bone 
health benefits for women using estrogen, HT became a standard health-promotion prescription 
for mid-life women (Barrett-Connor et al., 2005). Negative sequelae of estrogen use—
endometrial cancer, blood clots, irregular vaginal bleeding, gall bladder disease and even breast 
cancer—were also identified over the years however the perceived reductions in bone, 
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cardiovascular and other health concerns were believed to outweigh any risks (Barrett-Connor et 
al., 2005; Krieger et al., 2005). Women were encouraged to take HT indefinitely to maintain 
good health, relieve symptoms and decrease the risks of illnesses associated with aging.  By the 
mid-1990s it had become the number one dispensed drug product in the United States. 
Critics, however, argued that the observed health benefits were related more to a healthy 
woman effect (observational study participants tended to be in better overall health) (Johannes, 
Crawford, Posner & McKinlay, 1994; Scalley & Henrich, 1993) and that there was no good 
evidence in the form of randomized controlled trials (RCTs) to support the use of HT for health 
benefits. In response, several large RCTs were initiated in the 1990s to assess the level of benefit 
and safety of HT as a primary prevention strategy for cardiovascular disease (Stefanick, 
Cochrane, Hsia, Barad, Liu & Johnson, 2003). The most noteworthy of these studies, because of 
its eventual impact on the use of HT, was the Women‘s Health Initiative (WHI) (Watkins, 2007). 
Women’s Health Initiative. The WHI was a multicenter prospective study consisting of 
several clinical trials plus an observational study (Matthews et al., 1997). Over 27,000 
postmenopausal women between the ages of 50-79 (median = 63) were enrolled in the hormone 
therapy (EPT) arm. Women were randomized to receive either placebo or conjugated equine 
estrogen (CEE) with medroxyprogesterone (MPA). (Women without a uterus received only CEE 
and were part of another study arm.) The primary benefit endpoint was decreased CVD while 
breast cancer was the primary adverse outcome (Barrett-Connor et al., 2005; Reed, Newton & 
LaCroix, 2004).   
 In July 2002, the EPT arm of the WHI was terminated three years early due to evidence 
indicating increased health risks among women taking CEE and progesterone. These risks 
included increases in: cardiac events, p = .05 (particularly in the first year but remaining elevated 
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throughout five years), invasive breast cancer (after 4-5 years HT use), venous thromboembolism 
(increase during the first one-to-two years of use and remaining elevated afterwards) and stroke 
(beginning after year one) (Table 3) (Reed et al., 2004; Writing Group for the WHI Investigators, 
2002). While the risks of breast cancer, stroke and thromboembolism were already known, the 
increase in cardiovascular events was surprising as HT had for so long been promoted for its 
cardioprotective effect. 
Reactions to the WHI. The early halt of the WHI and the findings of potential harms 
from HT were widely heralded in the news media, often gracing the headlines of newspapers and 
national television news (Canales, Breslau, Nelson & Ballard-Barbash, 2008; Foreman, 2002; 
Haas et al., 2006; Kolata, 2002). Focusing on the relative risks, some pundits exhorted women to 
stop taking hormones immediately. Frightened, women turned to their health care providers for 
support and answers. 
However, most providers learned of the study‘s premature halt at the same time and 
through the same lay news sources as their patients and were just as surprised and puzzled 
(Kolata & Peterson, 2002). Without advance knowledge of the findings or new recommendations 
for practice, they were ill equipped to interpret the information and provide appropriate decision-
making support (Canales et al., 2008; Watkins, 2007). Angry, confused and worried, many 
women discontinued HT, either on their own volition or at the urging of family, friends or health 
care providers. 
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Table 3.  
Summary of Results of WHI EPT Trial 
N = 16,608   Ages = 50-79   Mean duration of HT use = 5.2 years 
ENDPOINT 
NUMBER 
(annualized %) 
 
RELATIVE 
RISK 
95% 
CONFIDENCE 
INTERVAL 
ABSOLUTE 
RISK 
(per 10,000 
women/year) 
ABSOLUTE 
BENEFIT 
(per 10,000 
women/year) 
EPT 
(n = 8506) 
PLACEBO 
(n = 8102) 
Coronary 
Heart  
 
Disease 
164 (0.37) 
 
122 (0.30) 
 
1.29 
 
[1.02, 1.63] 
 
7 
 
 
Stroke 
 
127 (0.29) 
 
85 (0.21) 
 
1.41 
 
[1.07, 1.85] 
 
8 
 
 
Pulmonary 
Embolism 
 
70 (0.16) 
 
31 (0.08) 
 
2.13 
 
[1.39, 3.25] 
 
8 
 
 
Breast 
Cancer 
 
166 (0.38) 
 
124 (0.30) 
 
1.26 
 
[1.00, 1.59] 
 
18 
 
 
Colorectal 
Cancer 
 
45 (0.10) 
 
67 (0.16) 
 
0.63 
 
[0.43, 0.92] 
 
 
6 
 
Hip 
Fracture 
 
44 (0.10) 
 
62 (0.15) 
 
0.66 
 
[0.45, 0.98] 
 
 
5 
 
Total 
Mortality 
231 (0.52) 
 
218 (0.53) 
 
0.98 
 
[0.82, 1.18] 
 
  
Global 
Index 
751 (1.70) 
 
623 (1.51) 
 
1.15 
 
[1.03, 1.28] 
 
19-20 extra 
adverse 
advents 
 
 
Sources:  
Manson, 2008 
Writing Group for the WHI Investigators, 2002 
 
Changes in HT use and prescription patterns. Using information obtained from health 
questionnaires completed by women having mammograms at facilities providing data to the San 
Francisco Mammography Registry, Haas and colleagues (2004) looked at HT use before and 
after WHI through May 2003. They found a sharp decline—18% per quarter, 95% CI [-21%, –
16%]—in reported HT use after the WHI results were released (Haas, Kaplan, Gerstenberger & 
Kerlikowske, 2004).  
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Researchers from the Sloane Survey (a random-digit-dial national survey exploring 
medication use) conducted telephone interviews of 3853 female subjects over the age of 50 
between January 2001 and June 2004. Pre-WHI the HT prevalence rate was 29%. However, the 
rate began to drop in early 2003 to a low of 12% by June 2004, representing a 57% post-WHI 
decrease. The most rapid decline occurred in the first half of 2003 after the FDA‘s release of new 
guideline for HT use (Kelly et al., 2005).  
Prescription rates plummeted. There was a 38% decrease, 95% CI [37%, 39%] (Hersh, 
Stefanick and Stafford, 2004) in HT prescriptions dispensed by outpatient pharmacies from 
approximately 90 million prescriptions before July 2002 to only 60 million prescriptions between 
July 2002 and 2003 (Hersh et al., 2004; Wysoski & Governale, 2005). Visits to health care 
providers for HT prescriptions decreased from 32.7%, SE 2.6, in 2002 to 26%, SE 3.2, Χ2 p = 
.002, in 2003 (Hing & Brett, 2006). Most of the decreases in HT prescriptions occurred primarily 
during the first three (Bestul, McCollum, Hansen & Saseen, 2004; Kim et al., 2005) to six (Kelly 
et al., 2005) months after July 2002, stabilizing after six to nine months.  
The largest declines in prescriptions (66%, 95% CI [65, 67%]) were those for the specific 
HT formulation (PremPro) used in the WHI although prescriptions for other types of HT 
products decreased as well (Wysoski & Governale, 2005).  There was also a 33% (95% CI [32, 
34%]) drop in estrogen-only hormone (ET) prescriptions even though the 2002 WHI findings 
only applied to EPT and there were no recommendations for women to stop taking estrogen-only 
hormone preparations (Hersh et al., 2004).  
Drug company promotional spending for HT, especially samples and direct-to-consumer 
advertising, also decreased, paralleling the decrease in HT prescription rates. In the second 
quarter of 2002, $71 million dollars was spent on HT promotion whereas only $55 million was 
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spent in the fourth quarter of 2003, a 37% decrease in the year after the WHI findings. The 
greatest reductions in promotional activities were for PremPro (Majumdar et al., 2004).  
The declines in HT use were reported to be quite similar across socioeconomic and ethnic 
subgroups (Haas et al., 2004; Kelly et al., 2005). Wei et al. (2005) found no significant 
differences in decreases in HT prevalence among African-American (-41.6%), Asian (-38.4%) 
and White (-44.1%) women, between women with a college education (-43.4%) and those 
without (-42.4%), and between women above (-43.7%) and below (-41%) poverty level. A 
sampling of the literature from countries outside the USA reveals similar declines in HT use: 
Canada 28% (Guay et al., 2006), Germany 26%  (Heitmann, Greiser and Doren, 2005), Hong 
Kong 43.5% (Leung, Ling & Tang, 2005), Australia 37.8% (Main & Robinson, 2008) and the 
United Kingdom 65%, p <0.001 (Menon et al., 2007). These results suggest that WHI findings 
were disseminated comparably among diverse groups both nationally and internationally. 
Symptom Recurrence & HT Resumption. While many women who attempted to stop 
HT after the release of the WHI findings encountered only mild or no symptoms (Grady, 
Ettinger, Tosteson, Pressman & Macer, 2003), some women, especially those symptomatic prior 
to initiating HT, did experience recurrent symptoms that proved quite troublesome and 
distressing (Grady et al., 2003; Ockene et al., 2005). Because of these symptoms, approximately 
25% of women who discontinued HT after the WHI chose to resume hormones (Grady et al., 
2003; Helenius, Korenstein & Halm, 2007).  
Some women returned to their prior HT regimen. Others requested lower doses or 
different formulations such as transdermal HT (French, Smith, Holtrop & Holmes-Rovner, 2006; 
Newton et al., 2004), hoping that these might be safer than PremPro. As providers began using 
different HT preparations (Rolnick, Jackson, Kopher & DeFor, 2007), there was a corresponding 
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increase in prescription rates and promotional expenditures for lower dose Premarin and other 
non-Premarin HT products (Majumdar et al., 2004). It was not possible to determine how many 
of these lower dose prescriptions were for women resuming versus tapering HT. There is also no 
data detailing quantitatively how many times women attempted discontinuation or qualitatively 
what is the experience of repeated discontinuation and resumption.  
Current HT Recommendations. Further analyses of the WHI data suggest that the 
cardiovascular risks may be specific to older women initiating HT over 10 years post-menopause 
(10-19 years: RR = 1.22; 20-plus years: RR = 1.71; p = 0.036) while younger women appear to 
be at less risk (RR = 0.89) (Manson, Hsia, Johnson, Rossouw et al., 2003). There is renewed 
speculation that HT may be cardioprotective when initiated within a ‗window of opportunity‘ 
soon after a woman‘s FMP and prior to the age of 60 (Grodstein, Manson & Stampfer, 2006; 
Roussouw et al., 2007). Nevertheless, due to these risks, the current recommendations for HT are 
that it be used for symptom relief only and at the lowest dose for the shortest period of time 
(ideally five years or less) (American College of Obstetrics & Gynecology [ACOG], 2008; 
Ettinger, Barrett-Connor, Hoq, Vader & Dubois, 2006; NAMS, 2008; U.S. Preventive Services 
Task Force [USPSTF], 2005).  
However, the experiences of the women who stopped HT after the WHI revealed a gap in 
the knowledge about HT discontinuation: menopause symptoms do recur after women 
discontinue HT and may be quite troublesome and distressing. Unfortunately, there is little 
information for health care providers as to the best way(s) to prepare, support and guide women 
stopping HT (Grady, 2006). Thus, women who attempt to discontinue HT may do so without 
adequate information about HT benefits and risks, discontinuation methods, or symptom 
management and health promotion strategies.  
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In 2005, an NIH State-of-the-Science Conference Statement on Management of 
Menopause-Related Symptoms called for further research to better describe the personal 
characteristics and self-care strategies associated with fewer symptoms, better symptom 
tolerance and higher QOL during menopause (NIH, 2005). This knowledge would provide 
much-needed information for counseling and supporting women through the menopause 
transition (Simon & Mack, 2003). Similar information is needed about and for women 
discontinuing HT (NAMS, 2008). The post-WHI exodus from HT has provided researchers with 
an opportunity to better understand what happens when women discontinue but this knowledge 
is far from complete and is primarily quantitative. There is little qualitative evidence describing 
women‘s experiences of HT discontinuation: their symptoms, management strategies, QoL as 
well as the overall experience of stopping or stopping and resuming HT.  
Literature Review 
 Some women choose to discontinue HT because of side effects, perceived risks or 
philosophical beliefs about medications or menopause that may be rooted in ethnic or cultural 
values (Horne et al., 2004; Pachter, 1994; Rice, 2005). Others attempt to discontinue because of 
advice from health care providers or family and friends. Until recently, their discontinuation 
experiences have been mostly invisible. Information has begun to emerge about the experiences 
of these women who discontinue HT, as the following review of the literature will demonstrate. 
However, there are still many unanswered questions about this phenomenon. 
HT Discontinuation Experience (Specific Aim 1) 
HT Discontinuation before WHI. Rooted in the context that HT was beneficial, pre-
WHI researchers exploring why women initiated or discontinued HT often did so in an attempt 
to identify ‗barriers‘ to HT use, not to assist those stopping their medications. It was not unusual 
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to find the terms ‗compliance‘ or ‗adherence‘ in the titles or objectives of the articles describing 
these studies (Bjorn & Backstrom, 1999; den Tonkelaar & Oddens, 2000; Ettinger, Li & Klein, 
1996; Faulkner, Young, Hutchins & McCollam, 1998; NAMS, 1998; Regan, Emond, Attardo, 
Parker & Greenspan, 2001). Most ‗noncompliant‘ women stopped HT within 1-2 years after 
initiation primarily because of side effects such as irregular bleeding or breast tenderness 
(Ettinger, Li & Klein, 1996). During 2001, for example, 53% of over 37,000 female members of 
a pharmacy benefits management company discontinued HT within one year of receiving their 
initial prescription (Kim et al., 2005). Little is recorded, however, as to whether or not they 
encountered any difficulties during discontinuation because most never contacted their health 
care providers for support or assistance (Grady, 2006) and very few studies reported recurrent 
symptoms among participants who were ‗noncompliant‘.  
 In a study exploring whether abrupt declines in estrogen levels could induce VMS in 
previously asymptomatic women (N = 40), women without symptoms at baseline did not 
experience VMS after abrupt withdrawal of estrogen (Hammar et al., 1999). While this 
information may be helpful for women who started HT for reasons other than symptom control, 
it is not relevant to the population of women who initiate HT for symptom relief. 
In stark contrast to the above findings, the results of a qualitative study exploring 
women‘s reasons for discontinuing HT (Bond & Bywaters, 1999) served as a harbinger of what 
was to be revealed in the aftermath of the WHI. Participants in this study (N = 16) described both 
the recurrence of VMS and the appearance of new symptoms such as joint pain. Several women 
reported patterns of stopping and resuming HT as they struggled through the experience with 
minimal information, monitoring or support from their health care providers. Some felt isolated 
in their struggles; others expressed disappointment that they were not seen as partners in the 
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decision-making. However, because the focus of this study was also on how to increase 
compliance with HT, no recommendations were made for supporting women trying to 
discontinue HT. It was not until a large percentage of women stopped HT after the WHI that 
researchers began to explore this phenomenon to gain a better understanding of the aftermath of 
HT cessation. 
HT Discontinuation after WHI: Symptom Recurrence. Approximately 30% of women 
who stop HT can expect to experience recurrent symptoms, both VMS and non-VMS, that may 
be quite troublesome (Grady et al., 2003). In one of the first studies to examine symptom 
recurrence, investigators interviewed 670 women in a large northern California HMO soon after 
the release of the WHI findings. All participants were between the ages of 50-69 and had taken 
HT for more than one year. Over half (56%; n = 377) had attempted to stop HT and 70% of these 
women had no or only mild symptoms. However, the remaining 30% described symptoms that 
were very troublesome with flushes (88%) and sweating (76%) being the most common (Grady 
et al., 2003).  
VMS are the most frequently reported recurrent symptom. However, they are not the only 
symptom women experience and women may have more than one symptom (Grady et al., 2003; 
Ness, Aronow & Beck, 2006; Shrader & Ragucci, 2006). Investigators surveyed 8405 
participants from the WHI EPT arm who had been on EPT study pills as of July 2002. Among 
these women, the most commonly reported symptoms were joint pain and stiffness (36.8%); 
VMS were actually third (21%) in overall symptom reports. Over 54%, OR = 3.21, 95% CI [2.9, 
3.56] of women who had joint symptoms prior to the study noted these symptoms recurred after 
stopping study medication, implying aging changes were not the causative factor. Although a 
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causal link between joint discomfort and hormone changes has not been definitively established, 
estrogen seems to have a mitigating effect on joint pain (Ockene et al., 2005). 
Urogenital symptoms are also reported by 25% to 36% of women (Grady et al., 2003; 
Helenius et al., 2007; Ness et al., 2006; Rolnick, Kopher, DeFor & Kelley, 2005). These 
symptoms tend to be more common among older women: in a retrospective chart review (N = 
205), researchers noted women over 65 years old reported urogenital symptoms (24%) more 
often than VMS (5%) (Ness et al., 2006). This is not unexpected as urogenital symptoms tend to 
worsen with time post menopause while VMS ease. Libido changes are less well documented in 
the literature: only one study reported a decrease in libido (25%; N = 101) among the participants 
(Helenius et al., 2007). 
Other recurrent symptoms can include insomnia and fatigue (French et al., 2006; Grady 
et al., 2003; Helenius et al., 2007; Ockene et al., 2005), memory loss and difficulty concentrating 
(Ockene et al., 2005) and miscellaneous somatic symptoms such as weight gain, headaches, 
breast tenderness, skin and hair changes, edema and gastrointestinal symptoms (appetite changes, 
bloating or gas) (Ockene et al., 2005). The gastrointestinal symptoms are particularly noteworthy 
as there is limited information about the effect of HT cessation on the gut although women do 
report changes in gastrointestinal function with hormonal fluctuations (Jacobson, Moy, Colditz 
& Fuchs, 2008).  
Although non-VMS greatly influence the overall symptom experience, QoL and the 
outcome of women‘s attempts to discontinue (Grady et al., 2003), they have not been studied to 
the same extent as VMS (Warren, 2007). Thus, further exploration of these non-vasomotor 
symptoms, their severity and trajectory and the strategies women employ to manage them, would 
also inform the development of symptom management interventions. More information is also 
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needed as to whether certain symptom clusters, combinations, or interactions may be more 
distressing or troublesome.   
Most of the information about recurrent symptoms comes from quantitative studies that 
used symptom checklists to identify symptoms. There is little describing the day-to-day 
experiences of women who discontinue or the impact on their lives, including relationships and 
work. Only one post-WHI study has explored HT discontinuation from a qualitative perspective. 
In this study, 127 women attending a family practice responded to a written questionnaire 
consisting of both structured and open-ended questions related to their post-WHI attitudes and 
HT decision-making. Over half (50/78) of the women who had been taking HT in July 2002 
stopped after the WHI results were released. These women described being very symptomatic 
with moderate to severe hot flashes similar to those experienced before initiating HT (French et 
al., 2006). 
Symptom Similarities and Differences. It has occasionally been assumed that 
discontinuation symptoms will mimic symptoms experienced prior to initiating HT and will 
hopefully be short-lived and less intense (Aslan et al., 2007; Ockene et al., 2005). For many 
women this may be true. The majority (n = 92; 64.3%) of women in a recent Swedish study who 
had been symptomatic before beginning HT (n = 143) reported that recurrent VMS were less 
distressing than their initial symptoms. However, for a few (n = 9; 6.3%) of the women, recurrent 
symptoms were actually worse and more distressing than symptoms prior to HT (Lindh-Astrand, 
Brynhildsen, Hoffman & Hammar, 2009).  
Similarly, three of the nine women participating in a phenomenological study exploring 
the experience of cessation of menses described recurrent symptoms that were more intense and 
debilitating than their initial menopause symptoms. They even referred to these symptoms as 
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‗withdrawal‘ or rebound symptoms and were especially worried about the possible duration of 
these symptoms (Matarese, 2005).  
Although the majority of women who experience uncomfortable discontinuation 
symptoms also have uncomfortable symptoms before initiating HT, for some these symptoms 
may be a new experience. In the aforementioned study by Grady et al. (2003), most of the 
women with troublesome recurrent symptoms also had symptoms prior to initiating HT. 
However, 20% of women with severe symptoms had not been symptomatic at baseline (Grady & 
Sawaya, 2005) unlike the women in the pre-WHI study by Hammar et al. (1999). This difference 
may be a product of the short duration of estrogen in the latter study. However, the findings from 
Grady & Sawaya (2005) underscore the need to prepare all women stopping HT, even those 
asymptomatic beforehand, for the possible onset of uncomfortable symptoms.  
Similarities and differences in symptom experiences before and after HT use have not 
been explored in depth. Further knowledge of these differences and their impact on the outcome 
would be helpful for preparing women for discontinuing HT.  
Symptom Duration. After HT is discontinued, symptoms often recur quickly, within 4-6 
weeks of discontinuance (Gordon et al., 2004). Some women actually report symptoms 
beginning as early as one week (median, interquartile range = 0-4 weeks) after stopping (Grady 
et al., 2003). However, because many of the post-WHI discontinuation studies are cross-sectional 
and were conducted within the first year after the WHI (Grady et al., 2003), there is little 
information about the actual duration of recurrent symptoms. In one recent study, women who 
had been off HT for almost a year still reported some symptoms (Haskell et al., 2009). Recent 
study findings indicate that the trajectory of menopause symptoms in general may be longer than 
previously thought. Among 205 women in a longitudinal Australian study, the average duration 
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of hot flashes was 5.5 years, whether or not HT was used (Col, Guthrie, Politti & Dennerstein, 
2009). It would be helpful to know whether discontinuation symptoms persist in a similar 
manner in order to more effectively prepare and support women.  
Symptom Management Strategies. Women experiencing a recurrence of troublesome 
symptoms may employ a variety of both medication and non-medication symptom management 
strategies. Among WHI-EPT participants (n = 6503) who were queried after the cessation of the 
study (Ockene et al., 2005), almost 46 % tried non-medication strategies; women taking EPT 
study pills used these techniques more than women taking placebo pills (49% versus 41%, p 
<.001). Strategies reported as most helpful included: using fans or air conditioners (95%), 
incorporating yoga, meditation and breathing techniques (94%), wearing cotton or layered 
clothing (93%), socializing more (93%) and drinking more fluids (88%).  
Medication-related strategies include prescription medications such as antidepressants 
(for VMS as well as mood) (Haskell, 2004; Helenius et al., 2007; Kupferer, Dormire & Becker, 
2009; Ness et al., 2006; Ockene et al., 2005; Vegter, Kolling, Toben, Visser & de Jong-van den 
Berg, 2009), antihypertensives and antiseizure medications (Kupferer et al., 2009) and sleep 
medications (Ockene et al., 2005). Prescription vaginal estrogen products were used by women 
experiencing urogenital symptoms (Helenius et al., 2007; Ness et al., 2006). Pharmacy databases 
corroborated a trend toward an increase in prescriptions for vaginal estrogen preparations 
(Premarin cream 118% and Estrace cream 300%) after the WHI (Wegienka, Havstad & Kelsey, 
2006). However, there is little in the literature about therapies women used for recurrent or new-
onset sexual dysfunction concerns (e. g. diminished libido or anorgasmia).  
Approximately 20-30% of women in the post-WHI studies tried CAM products including 
over-the-counter herbal or nutritional supplements such as Black Cohosh, Evening Primrose Oil, 
 22 
 
soy and Vitamin E (Kupferer et al., 2009; Ness et al., 2006; Ockene et al., 2005; Rolnick et al., 
2005; Shrader & Ragucci, 2006). A few women tried alternative medical systems such as 
homeopathy, Traditional Chinese Medicine (TCM) or aryuvedic medicine (Kupferer et al., 
2009). Findings regarding the efficacy of these strategies and modalities to relieve symptoms are 
mixed: some women noted little relief from alternative methods (Rolnick et al., 2005) while 
others found them helpful (Helenius et al., 2007; Kupferer et al., 2009; Shrader & Ragucci, 
2006). Often multiple CAM therapies were used simultaneously making it difficult to determine 
the efficacy of any one method.  
Women turned to CAM because it was perceived as a safe alternative to HT, however 
there are questions and concerns about safety, quality, dosage consistency and side effects with 
many of these therapies. In addition, because women may not report using CAM, and providers 
don‘t always ask, CAM use may not be documented in the medical record (Ness et al., 2006; 
Shrader & Ragucci, 2006) increasing the potential for drug interactions between CAM and 
prescription medications.    
Some women may have opted to try so-called ‗natural‘ hormone preparations: over-the-
counter hormone creams or custom-compounded ‗designer‘ hormones similar to those promoted 
by celebrities (Somers, 2004). Unfortunately, there is no good evidence that these products are 
effective and/or have a better safety profile for breast or endometrial cancer and stroke than does 
FDA-approved HT. Quality and dose consistency are also of concern with these products 
(Patsner, 2009; Pinkerton, 2009). 
HT Resumption.  As previously noted, approximately 25% of women chose to resume 
HT to manage troublesome recurrent symptoms. Women resuming HT often do so quite soon—
within three to six months—after discontinuing (Newton et al., 2008; Wegienka et al., 2006) 
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although more delayed resumptions (9-12 months or more) have also been documented (Grady et 
al., 2003; Haimov-Kochman et al., 2006b; Haskell et al., 2009). Delays in resuming HT may be 
related to symptom duration and/or discontinuing HT by tapering. In the first instance, women 
hoping to remain off HT may not decide to resume until troublesome symptoms are prolonged. 
Women also tend to resume HT when recurrent symptoms are at their peak which occurs later 
for those attempting to taper (Haimov-Kochman et al., 2006b). Some women actually describe 
making more than one attempt to stop HT (Bond & Bywaters, 1999; Helenius et al., 2007) 
underscoring the need for long-term monitoring and support for women discontinuing HT as 
well as further research that will help set expectations of the experience to guide women and 
their health care providers.   
Of the 50 women who had stopped HT in the qualitative study by French et al. (2006), 12 
had already resumed HT at the time of the interviews because of recurrent symptoms, feeling 
that they were not quite ready to quit. Nonetheless, they expressed fears and worries about 
continued use of HT as did the women who had chosen not to discontinue. Five of those who 
resumed stated they were using lower doses in an attempt to taper. Some women who had 
stopped HT were considering resuming. Clearly recurrence of distressing symptoms is a factor in 
HT resumption. 
Factors Influencing the Experience of HT Discontinuation (Specific Aim 2) 
  Many factors influencing women‘s decisions to begin or continue HT were noted in the 
pre-WHI literature. Some of these are similar to the factors associated with either positive or 
negative experiences of menopause (Johannes, Crawford, Posner & McKinlay, 1994; Reynolds, 
Obermeyer, Walker & Guilbert, 2001 & 2002) (see Table 4). Factors associated with more 
symptom burden may predispose a woman to initiate HT whereas women with greater symptom 
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tolerance or fewer symptoms are less inclined to initiate or continue HT. More recently, 
characteristics associated with both discontinuation and resumption of HT are being explored. 
Table 4.  
Factors associated with menopause symptoms and HT use  
Factors Associated with Symptoms Factors Associated with HT Use 
More Symptoms &/or Less symptom tolerance Use of HT 
High frequency & severity of 
symptoms 
Symptom duration/chronicity 
Symptom sensitivity/distress 
Genetic polymorphisms 
Stress/higher cortisol levels 
Severe PMS symptoms 
Low self-esteem/self-image 
Negative self-appraisal 
Type A personality 
Sensitivity to public perception 
Negative attitudes toward aging 
and/or menopause 
Negative attitudes toward coping 
strategies 
Depression/Anxiety 
Negative affect 
Age 
Smoking 
Higher BMI 
Physical inactivity 
Childhood abuse 
Late perimenopause 
Surgical menopause 
Overall health/other 
illnesses 
Less social support 
Lower socioeconomic 
status 
African-American race  
Uncomfortable VMS and other 
symptoms 
Improved QOL on HT 
Higher education 
Higher SES 
Better health 
Caucasian ethnicity 
Greater self-efficacy 
Surgical menopause 
Belief that HT will decrease bone and 
heart health risks 
Greater symptom tolerance Not using HT 
Asian-American race (fewer symptoms) 
Positive attitudes toward menopause 
Higher self-esteem 
Lower BMI 
Physical activity 
Fewer symptoms 
Unpleasant side effects 
Fear of cancer 
Worry about hormones  
Positive attitude toward menopause 
Negative attitude toward medications 
Non-USA countries 
Non-Caucasian ethnicity 
 
Recurrent Symptoms and HT Resumption.  Some post-WHI researchers have sought 
to identify factors predictive of unsuccessful discontinuation in order to target women needing 
closer monitoring and support when stopping HT. Their findings indicate that troublesome or 
severe recurrent symptoms are the most common reason women resume HT (French et al., 2006; 
Grady et al., 2003; Helenius et al., 2007; Ockene et al., 2005). But what factors are associated 
with these symptoms? One common denominator is the presence of symptoms prior to initiating 
HT. In numerous studies (French et al., 2006; Grady et al., 2003; Haimov-Kochman et al., 2006; 
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Helenius et al., 2007; Ockene et al., 2005), women who were symptomatic at baseline were more 
likely to experience uncomfortable symptoms upon discontinuation.  
In the previously discussed study by Grady et al. (2003), troublesome symptoms were 
more likely to reoccur among women who initially started HT for symptom relief than among 
women who began for other reasons (37% versus 26%, t-test p = .01). Within the WHI-EPT 
cohort (N = 8405), the rate of recurrence of moderate or severe VMS was over 50% (n = 503, p 
< .001) when women taking EPT study pills also had VMS prior to entering the study (n = 950) 
(Ockene et al., 2005).  
Other factors typically associated with more troublesome symptoms at baseline have also 
been linked to HT resumption. These include: surgical menopause (Grady et al., 2003; Lawton, 
Rose, McLeod & Dowell, 2003), using ET only (Poisson regression, RR = 2.91, 95% CI [2.77, 
3.06]) (Buist et al., 2004), younger age (Buist et al., 2004; Taylor, MacLennan & Avery, 2006; 
Ockene et al., 2005; Wegineka et al., 2006), starting HT less than three years after the FMP 
(logistic regression, OR 5.0, 95% CI [1.4, 18]) (Barber, Margolis, Luepker & Arnett, 2004) and 
beginning HT for non-health promotion reasons (Grady et al., 2003). Women who have a 
surgical menopause experience more intense symptoms and most women using ET-only have 
had a surgical menopause (Brett & Madans, 1997). Women who started HT primarily for non-
health promotion reasons often did so primarily for relief of uncomfortable symptoms. Women 
starting HT close to their FMP would have been more likely to be symptomatic at baseline as 
would younger women. Thus, women with any of these characteristics could expect to 
experience more distressing symptoms after stopping HT.  
Age may also impact on the experience of recurrent non-VMS. For example, changes in 
memory and concentration are more common in younger women (Ness, Aronow & Beck, 2005; 
 26 
 
Ockene et al, 2005). These women are more likely to still be employed and as a result the 
discomfort, embarrassment and stress associated with recurrent symptoms may impact on their 
work productivity. They also need to rely on memory and concentration skills on the job and 
even small changes in these skills would present challenges and cause distress.  
Symptom combinations may herald particular challenges for some women. Affective 
symptoms—irritability, mood swings, anxiety, panic attacks and even depression—recur more 
often in younger age groups (Helenius et al., 2007; Ness et al., 2006; Ockene et al, 2005; 
Stewart, Rolfe & Robertson, 2004) who are more likely to also be having recurrent VMS. Severe 
VMS have been associated with worse depression symptoms in menopausal women (Reed et al., 
2009). As noted earlier, the fluctuating hormonal mileau accompanying menopause may increase 
the risk of mood disorders or depression, especially among women with pre-existing emotional 
issues (Cohen, Soares, Vitonis, Otto & Harlow, 2006; Freeman et al., 2004; Freeman et al., 2006; 
Ryan et al., 2009). These women may be more vulnerable to recurrence of mood-related 
conditions when estrogen levels drop upon discontinuing HT. Therefore it is critical that 
providers screen women for pre-existing mood disorders prior to HT discontinuation and monitor 
them closely through discontinuation.  
The severity of recurrent symptoms may be influenced by a woman‘s ethnicity. African-
American women have more frequent menopause symptoms than do European-Caucasian 
women (Appling, Paez & Allen, 2007; Avis et al., 2001; Gold et al., 2000). However, only one 
post-WHI study examined HT discontinuation in a non-European American population. Among 
101 African-American and Hispanic HT discontinuers from an inner city internal medicine 
practice, 75% reported recurrent VMS and 42% rated them as severe. Those with more severe 
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symptoms were more likely to have had troublesome symptoms pre-HT and thus more likely to 
resume (Helenius et al., 2007). 
As previously noted, symptom duration may be a factor in HT resumption. In one study 
of 91 Israeli women who stopped taking HT, those whose severe symptoms lasted longer were 
more likely to resume HT (HR 1.22, CI 95%: 1.02-1.46). Women who have severe symptoms for 
a prolonged time may become less tolerant of these symptoms and thus more likely to reinitiate 
HT (Haimov-Kochman et al., 2006b). 
Despite the reoccurrence of troublesome symptoms, some women do not resume HT. In 
the Grady et al. study (2003), approximately 20% of the women who successfully discontinued 
HT also reported having severe recurrent symptoms but it is not clear what factors may have 
promoted greater symptom tolerance among these women. A qualitative approach may help to 
identify some of these important factors. 
Other Factors Influencing HT Resumption. Non-symptom related factors may also 
influence HT resumption. Beliefs about HT risks can impact whether or not women resume. 
Women using HT for many years without complications and women using non-Premarin HT 
perceive themselves to be at lower risk and are more likely to resume (French et al., 2006; Grady 
et al., 2003). The absence of comorbidities (Bosworth et al., 2005) such as cardiovascular disease 
(Haskell et al., 2008; Heller et al., 2005; Newton et al., 2005), hyperlipidemia and diabetes 
(Newton et al., 2005) and/or the perception of a higher fracture risk (Grady et al., 2003; Newton 
et al., 2005) are also associated with an increased likelihood of reinitiating HT. In contrast, 
women who perceive barriers to long-term HT use (risks, expense, side effects, fears of breast 
cancer or having to take medication continuously) are more likely to discontinue (logistic 
regression, n =157, B = 0.150, p < 0.05) (Gerend, Aiken, Erchull & Lapin, 2006).  
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A woman‘s choice of health care provider may play a role in whether she resumes HT. 
Gynecologists are more skeptical of the WHI results (Power, Anderson & Schulkin, 2009). They 
are better able to interpret the findings in terms of relative versus absolute risk and are more 
favorable to HT than internal medicine or family practice physicians (Brett, Carney & 
McKeown, 2004; Power et al., 2009; Williams, Christie & Sistrom, 2005). More experienced 
providers also tend to be wary of the WHI findings (Power et al., 2009; Power, Zinberg & 
Schulkin, 2006) and are more likely to advise women not to discontinue or to resume if 
necessary for recurrent symptoms (Guay et al., 2006).  
As part of their analysis of the data collected from telephone interviews (N = 377), Grady 
et al. (2003) used multivariable logistic regression to develop a set of predictor characteristics to 
better identify women who may encounter more difficulty in stopping HT. The three critical 
factors that emerged were: having a hysterectomy (OR 1.9, 95% CI [1.1, 3.6]), using HT for 
more than ten years (OR 1.2, 95% CI [0.6,2.4]) and starting HT for non-health promotion 
reasons (OR 2.0, 95% CI [0.8, 4.6]). Among women for whom all three factors were present, 
44.3% resumed HT—a seven-fold increased likelihood. When only one or two characteristics 
were noted, the rate of resumption dropped to 25% and when women had none of these 
characteristics, only 9% resumed HT. The primary predictor however was development of 
troublesome or severe symptoms (OR 8.8; 95% CI [1.1, 3.6]) which increased the resumption 
rate fourfold, even when none of the predictor characteristics were present. 
Discontinuation Method. Believing that the method of HT discontinuation can influence 
both symptom recurrence and HT resumption, many physicians advise women to discontinue HT 
by gradual tapering (Bush et al., 2007). However, there is little evidence in the literature to 
support this recommendation. Most studies to date have not reported the method of 
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discontinuation and most of those that have were not randomized: women selected their own 
method of discontinuing and there was no consistency in type and duration of tapering (Haskell, 
2004; Rolnick et al., 2005).  
Few post-WHI studies have specifically attempted to determine whether discontinuation 
method is associated with variations in symptoms and HT resumption; only two were 
randomized. Aslan et al. (2007) randomized 70 women on HT to either an immediate 
discontinuation group or a two-week taper group (n = 35 in both groups). After four weeks, there 
were no differences in either group with respect to frequency and severity of symptoms. The lack 
of significant findings was most likely related to the rapidity of the taper as well as assessing 
symptoms so soon after discontinuation.  
In another randomized controlled trial (RCT), 91 women were randomized to either 
abrupt cessation (n = 50) or a six-month gradual cessation (n = 41) (Haimov-Kochman et al., 
2006a). Discontinuation method did not impact on the overall severity of symptoms or rate of 
resumption. However it did influence the time of symptom onset, peak symptom severity and HT 
resumption. Women who stopped abruptly encountered severe symptoms very soon after 
discontinuing, much worse than the gradually discontinuers (p < 0.0001), and those who 
resumed did so within three months. In contrast, among those who stopped gradually, symptom 
severity worsened dramatically as tapering progressed and by six months these women had VMS 
severity scores surpassing the month 3 symptom scores of those who stopped abruptly (p = .001). 
Most taperers who resumed did so between three to six months (Haimov-Kochman et al., 2006a). 
The results of this study showed a trend (p = 0.67) toward lower resumption rates among 
women who taper (Haimov-Kochman et al., 2006a). In contrast, in the study by Grady et al. 
(2003) women who stopped abruptly (n = 269) were less likely to resume (24%; n = 65) than 
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those who tapered (29%; 32/107) but these findings also did not achieve statistical significance 
(p = .27).   
A recent retrospective observational study (Haskell, Bean-Mayberry & Gordon, 2009)  
produced several surprising findings about the impact of tapering on symptom recurrence and 
discontinuation success. Among 836 postmenopausal female veterans who had discontinued HT 
post-WHI, 75% stopped abruptly while the remainder tapered. Mutivariate analyses showed that 
tapering was associated with younger age (OR 0.97, 95% CI 0.94-0.99), initiating HT for 
menopause symptoms (OR 1.79, 95% CI 1.12-2.87) and longer use of HT (OR 1.65, 95% CI 
1.08-2.51)—all factors associated with more troublesome symptom recurrence and resumption of 
HT. Surprisingly, however, in a multiple logistic regression model these women had lower 
menopause symptom scores (estimates = -0.58, SE = 0.21, p = 0.01) after discontinuation then 
those who stopped abruptly. It is possible that the retrospective study design may have affected 
recall of troublesome symptoms because of the time between discontinuation of symptoms and 
completing the study survey. 
Of particular interest however is the significant association between tapering and later HT 
resumption (OR 2.06, 95% CI 1.20-3.52): even though women who tapered HT tended to have 
fewer symptoms, they were more likely to resume. It is possible that some women may not be 
able to tolerate any degree of symptom recurrence (Haskell et al., 2009) suggesting that there 
may be other factors influencing this experience.  
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Table 5. 
 Factors associated with menopause symptoms, HT use and HT resumption 
Factors Associated with Symptoms 
Factors Associated with 
HT Use 
Factors Associated 
with HT Resumption 
More Symptoms &/or Less symptom 
tolerance 
Use of HT Resuming HT 
High frequency & severity of symptoms 
Symptom duration/chronicity 
Symptom sensitivity/distress 
Genetic polymorphisms 
Age 
Stress/higher cortisol levels 
Severe PMS symptoms 
Low self-esteem/self-image 
Negative self-appraisal 
Type A personality 
Sensitivity to public perception 
Depression/Anxiety 
Negative affect 
Higher BMI 
Smoking 
Physical inactivity 
Childhood abuse 
Late perimenopause 
Surgical menopause 
Overall health/other illnesses 
Less social support 
Lower socioeconomic status 
African-American race  
Negative attitudes toward aging and/or 
menopause  
Negative attitudes toward coping strategies 
Uncomfortable VMS and 
other symptoms 
Improved QOL on HT 
Higher education 
Higher SES 
Better health 
Caucasian ethnicity 
Greater self-efficacy 
Surgical menopause 
Belief that HT would 
decrease bone and heart 
health risks 
*Troublesome 
recurrent symptoms 
*Symptoms at 
baseline 
*Starting HT for non-
health promotion 
*Surgical menopause 
*Estrogen therapy 
only 
*Younger age 
*Tapering HT 
*Gynecology 
provider 
*Using non-Premarin 
HT 
Greater symptom tolerance Not using HT Not resuming HT 
Asian-American race (fewer symptoms) 
Positive attitudes toward menopause 
Higher self-esteem 
Lower BMI 
Physical activity 
Fewer symptoms 
Unpleasant side effects 
Fear of cancer 
Worry about hormones  
Positive attitude toward 
menopause 
Negative attitude toward 
medications 
Non-USA countries 
Non-Caucasian ethnicity 
*Older age 
*Comorbidities 
*Non-caucasian 
ethnicity 
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Although some characteristics predictive of worse symptom experiences and HT 
resumption have been identified, this list is certainly not exhaustive when compared to 
characteristics known to impact on initial menopause symptoms and HT initiation (see Table 5). 
While some of these previously-known factors may still be salient in the discontinuation setting 
there may be other less well-known factors that also influence the experience and outcome of HT 
discontinuation. One possible factor is life transitions: women discontinuing HT after long-term 
use may have sustained life changes or transitions (retirement, loss of partner, illness) that could 
reduce their capacity to cope with hormone withdrawal symptoms (Voda & Ashton, 2006).  
In order to understand why some women are more tolerant of recurrent symptoms, further 
research was needed to identify other factors that may influence the experience and the outcome 
of women‘s discontinuation efforts. A qualitative approach would provide an in-depth 
description of the experience of discontinuing HT and help to uncover other factors influencing 
symptom tolerance and QoL.  
HT Discontinuation and Quality of Life (Specific Aim 3) 
 Quality of life is often used as an outcome measure in research exploring the impact of 
HT on menopause symptoms. In clinical practice, women frequently use this criterion when 
weighing benefits and risks of various treatment options. But here too, findings have been mixed. 
While some studies show great symptom reduction and improvement in menopause-related QoL 
with HT, women‘s overall QoL often shows no significant improvement (Brunner et al., 2005; 
Hays et al., 2003; Hess et al., 2008; Hlatky, Boothroyd, Vittinghoff, Sharp & Whooley, 2002; 
Welton et al., 2008). This may be related to the aforementioned variability in defining and 
measuring QoL. It may also be due to mixed-age study samples: women further from their FMP 
often report greater QoL than perimenopausal or recently post-menopausal women . 
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QoL after HT Discontinuation. Despite the increasing popularity of measuring QoL in 
menopause research, there is limited information from post-WHI studies as to the impact of 
discontinuing HT on QoL and, in turn, the influence of QoL on HT resumption. Specific QoL 
measurements are notably absent from the HT discontinuation literature. Many studies measured 
symptoms only, using checklists (Haimov-Kochman et al., 2006a; Ockene et al., 2005) or chart 
review (Ness et al., 2006). When overall health was measured, no significant relationships were 
found between health status and HT discontinuance or resumption (Grady et al., 2003, Helenius 
et al., 2007). 
As part of the WISDOM (Women‘s International Study of long Duration Oestrogen after 
Menopause) trial, a UK study similar to the WHI, focus groups were conducted to explore 
women‘s HT decisions post-WHI. Although the researchers did not specifically focus on HT 
discontinuation, some participants did discuss their decision regarding HT resumption. The key 
factors in their decision were recurrent symptoms and diminished QoL. For women choosing to 
resume or continue HT, enhancement of QoL (described as feeling or looking better) was a 
benefit that outweighed any risks highlighting the need for further investigation of how women 
themselves define and evaluate QoL in relation to menopause and HT (Welton et al., 2003).  
In the qualitative study by French et al. (2006), women also cited a desire to look or ‗feel 
better‘ as a rationale for resuming or continuing HT. A recent qualitative study of attitudes 
toward HT provides further insight: here participants also reported that HT made them feel better 
but described this in terms encompassing more than symptom relief. They saw HT as helping 
them to perform better in their daily activities, maintain balance and integrity, and preserve their 
self-image, youthful appearance and physical well-being (Kolip, Hoefling-Engels & Schmacke, 
2008). These in-depth descriptions reflect multiple dimensions of QoL and are more closely 
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aligned with the concept of overall QoL, suggesting that women evaluate more than just 
symptoms when assessing QoL. This again implies that measuring symptoms alone is not a 
sufficient measure of QoL (Dennerstein & Helmes, 2001). These findings also demonstrate the 
benefits of a qualitative approach to elicit dimensions of QoL not captured solely through 
quantitative instruments.  
Further research is necessary to assess the impact of HT discontinuation on QoL. The 
question remains however as to how best to measure QoL. A comprehensive approach could 
include both menopause-specific and overall QoL measures combined with qualitative 
interviews to elicit women‘s subjective definitions and descriptions of their QoL during and after 
discontinuing HT (Crawford, 2007). However, no post-WHI studies have used this approach. 
Education and Counseling for HT Discontinuation (Specific Aim 4) 
 Quality of life is one of many factors women consider when making decisions regarding 
HT (Schied, Coleman & Hamm, 2003; Theroux, 2009). These decisions are based on an 
elaborate risk-benefit analysis which includes other factors such as personal and family health 
history and experiences, attitudes toward menopause, aging, and medications and perceived 
advantages and harms of HT (Bravata, Rastegar & Horwitz, 2002; Hunter, O‘Dea & Britten, 
1997; Marmoreo, Brown, Batty, Cummings & Powell, 1997; Theroux, 2009; Walter & Britten, 
2002). Thus, in order to make informed decisions about discontinuing or resuming HT as well as 
symptom management strategies, women need accurate information about HT benefits and risks 
and what to expect when stopping. 
In addition to facilitating decision-making, being better informed may also help improve 
women‘s tolerance of menopause symptoms: among breast cancer survivors with chemotherapy-
induced menopause (N = 31), those who were better prepared and more knowledgeable 
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experienced less symptom distress and uncertainty than women with less preparation (Knobf, 
2008). These findings suggest that women‘s experience of HT discontinuation and the eventual 
outcome may be dependent in part on the information they receive prior to stopping their 
hormone medications. Unfortunately, women‘s knowledge of HT is all too often fraught with 
misperceptions and misinformation and many women overestimate HT‘s possible harms while 
underestimating the benefits (Deeks, Zoungas & Teede, 2008; Johnson, Ozdemir, Hauber & 
Kauf, 2007; Levens & Williams, 2004; Schied et al., 2003). 
Information sources may be responsible for some of women‘s misperceptions. After the 
release of the WHI results, women who stopped HT most often turned to the media (Ettinger, 
Grady, Tosteson, Pressman & Macer, 2003; Haskell, 2004) or their health care providers 
(Barber, Margolis, Luepker & Arnett, 2004; Ettinger et al., 2003; Haskell, 2004) for information 
and advice. However, reports in the lay press often framed the WHI findings negatively, focused 
on breast cancer while downplaying the cardiovascular risks, and presented only relative risk of 
adverse events rather than absolute risk (Canales et al., 2008; Haas et al., 2006). As a result, 
women attributed the risks of HT improperly as they contemplated whether to discontinue or 
resume (Main & Robinson, 2008; McIntosh & Blalock, 2005; Parker-Pope, 2007; Welton et al., 
2003). In addition, few reports distinguished between EPT and ET, which may have contributed 
to the vast numbers of women who stopped ET even though the 2002 results did not apply to 
them (McIntosh & Blalock, 2005).  
Women who turned to health care providers did not fare much better. Because the initial 
WHI reports refuted findings from prior observational studies, calling into question the practice 
of recommending HT for cardiovascular health, providers felt less confident in their 
understanding of the findings (Bush et al., 2007). Some providers also confused relative and 
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absolute risk, resulting in an overestimation of HT-associated risks (Williams et al., 2005). It is 
not surprising therefore that many women expressed dissatisfaction with the level of support and 
advice presented to them. They described the amount of counseling they received from their 
providers as less than adequate (Ettinger et al., 2003; Flanagan, Serrato, Altschuler, Tallamn & 
Thomas, 2005) and verbalized a desire for more consistent information (Breslau et al., 2003).  
Of particular concern is the lack of counseling regarding health promotion behaviors. 
Symptoms are not the only sequelae of discontinuing HT: women may experience other 
physiologic changes that are less obvious but which have profound implications for long-term 
health. It is well known that bone health deteriorates when HT is stopped (Simon, Wehren, 
Ascott-Evans, Omizo, Silfren & Lombardi, 2006). Women may also develop higher lipid levels 
thus increasing cardiovascular risks (Pettee et al., 2007). Furthermore, new evidence suggests 
that women with worse VMS, such as women who begin HT for non-health promotion reasons, 
may be at greater risk of cardiovascular events (Gast et al., 2008; Huang, Sawaya, Vittinghoff, 
Lin & Grady, 2009; Thurston, Sutton-Tyrell, Everson-Rose, Hess & Matthews, 2008). Therefore 
it is critical that women stopping HT initiate lifestyle modifications and/or different medications 
to minimize bone loss (Simon & Mack, 2003) and cardiovascular risk (Pettee et al., 2007).  
Unfortunately, only a smattering of post-WHI studies described whether study 
participants attempted to modify their risks by lifestyle or medication changes, e. g. taking 
calcium and/or bisphosphonates for bone health (Ness et al., 2006: Rolnick et al., 2005; Shrader 
& Ragucci, 2006) or increasing cardiovascular exercise (Ockene et al., 2005; Rolnick et al., 
2005). In fact, less than half of the 142 women in a primary care practice reported discussing 
disease prevention or health promotion with their providers after the WHI. In this study, only 
34% of women at risk for osterporosis (39 of 114) and 26% of women with cardiovascular risk 
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factors (32 of 122) recalled having conversationd with their providers about their risks 
(Schonberg & Wee, 2005).  
Furthermore, as a consequence of the lack of adequate and accurate information, women 
became less trusting of their health care providers (McIntosh & Blalock, 2005; Schonberg, Davis 
& Wee, 2005). This lack of trust extended beyond menopause and HT concerns: 34% of the 
participants in the study by Schonberg et al. (2005) stated they were less willing to take new 
medications to prevent cardiovascular disease. Nonwhite women, who are often at greater 
cardiac risk, were less willing than white women to accept new medications, putting them at 
even greater risk of cardiac events (Schonberg et al., 2005).  
Other negative emotions were also evoked by the fallout of the WHI. In the few 
qualitative studies that mentioned women‘s experiences stopping HT, feelings of grief, guilt, 
fear, isolation and anger also surfaced. Women grieved the loss of their symptom-free life and 
the higher energy and positive attitude they enjoyed on HT (French et al., 2006; Welton et al., 
2003). Those who reinitiated or never stopped expressed worry and fear that they had made the 
wrong decision (Kolip et al., 2009; Welton et al., 2003). Some experienced guilt, as though using 
HT was a secret vice and a few women even voiced anger at HT manufacturers (French et al., 
2006). These powerful emotions have not been described in other studies and speak to the 
usefulness of a qualitative approach to elicit information not yet known or fully understood about 
HT discontinuance (French et al., 2006; Kolip et al., 2009). A deeper understanding of these 
reactions as well as what information women consider critical to know about discontinuing HT 
would help providers to better counsel and support women, ultimately improving their trust, 
minimizing negative reactions and decreasing the health risks for women stopping HT. 
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Table 6.  
Gaps in the knowledge of HT discontinuation 
What is known about  
HT discontinuation 
What is not known about HT discontinuation 
Both VMS and non-VMS can 
recur 
 
 
Does HT merely postpone the menopause transition? 
How similar is the discontinuation symptom experience to 
the pre-HT symptom experience? 
How long do recurrent symptoms last? 
Are there any symptom combinations that cause more 
distress than others? 
 
 
Some predictors of more 
troublesome symptoms have 
been identified 
 
What other factors influence the symptom experience and 
outcome (e.g. coping strategies, life transitions, symptom 
interactions, personal characteristic, sociocultural 
influences)? 
 
 
Some women resume HT 
because recurrent symptoms are 
very troublesome 
What women might be better off not discontinuing HT? 
 
 
QOL influences resumption of 
HT 
 
How does discontinuation impact on both menopause-
specific and overall QoL? 
 
Discontinuation may result in 
reversals in bone and cardiac 
health 
 
What do women know & do about changing health risks 
after stopping HT? 
 
 
Women are unhappy with the 
amount of counseling they 
receive 
 
What are women‘s preferences for counseling and 
education? 
What is the best way to prepare women for this experience? 
What is the best way to discontinue HT? 
 
Summary 
Women stopping HT, either of their own volition or on the recommendations of their 
health care providers, need to be thoroughly prepared with information about how best to 
discontinue, what symptoms to expect, how to manage symptoms,and how to maintain or initiate 
healthy lifestyle behaviors to offset bone and cardiovascular disease risks. Better counseling, 
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symptom management and health promotion strategies are needed to prepare and support women 
through this experience and beyond. Researchers have begun to explore this phenomenon but 
there is still much to be learned (Table 6). An in-depth description of women‘s experiences with 
HT discontinuance, including personal characteristics and strategies associated with greater 
symptom tolerance, quality of life (National Institutes of Health, 2005) and successful 
discontinuation, would provide information for developing education and support interventions 
for assisting women through this experience. Therefore, the purpose of this exploratory 
descriptive study was to describe the experience of discontinuing HT. 
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CHAPTER II 
PURPOSE, PARADIGMS AND FRAMEWORK 
This study was designed to develop an in-depth understanding of the experience of 
discontinuing HT in order to determine how to better prepare and support women attempting to 
cease HT. During the design process, a conceptual framework based on a model developed by 
Woods and Mitchell (2004) was used to undergird this study. This chapter will provide a review 
of the study purpose and aims followed by a discussion of the use of conceptual models in 
research, culminating with a description of the Woods and Mitchell framework. 
Purpose and Specific Aims 
Although HT may provide welcome relief from the troublesome symptoms that may 
accompany menopause, it is only recommended for short-term (five years) use because of risks 
such as stroke, breast cancer, and thromboembolism (NAMS, 2008). Many women will 
eventually attempt to discontinue HT, however recurrent symptoms can make this experience a 
difficult one (Ockene et al., 2005). Unfortunately, there is minimal information as to how best to 
counsel and support women during this experience (Grady, 2006).  
Therefore, the purpose of this mixed methods study was to describe the experience of 
discontinuing HT. It was hoped that through an in-depth description of women‘s experiences of 
discontinuing HT, the study findings would provide information critical for fostering the 
development of much-needed counseling, symptom management and health promotion 
strategies. The specific aims were to:  
5) explore women‘s experiences of HT discontinuation;  
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6) describe the personal characteristics and sociocultural contexts that influence 
symptom perception, evaluation and response among women who have attempted to 
discontinue HT;  
7) explore the impact of HT discontinuation on women‘s quality of life; and  
8) discuss women‘s preferences for counseling and support during HT discontinuation.   
Philosophical Paradigm and Conceptual Framework 
Menopause has often been dichotomized into either a biomedical or sociocultural 
phenomenon and research has reflected that polarized view with investigators approaching 
menopause through an either-or lens. The biomedical tradition is tied to an overarching depiction 
of menopause as a deficiency state: a disease or endocrinopathy best treated by replacing what is 
lost—estrogen (Andrist & MacPherson, 2002; Dickson, 1989; MacPherson, 1981; Rothfield, 
1997; Voda, 1997; Wilson, 1966). In contrast, the sociocultural approach focuses on menopause 
as a normal developmental process that has been culturally defined.  In this view, each woman‘s 
unique psychological, social and cultural characteristics are the primary influences on how she 
navigates this passage (Andrist & MacPherson, 2001; Dickson, 1989; Voda, 1997).  
In truth, both views are reductionistic with neither view alone capturing the totality of 
women‘s experiences through menopause. Women have been confused, angered and silenced 
either by being told that they should take medication for what they perceive as a natural, normal 
process or by having their health concerns or troublesome symptoms dismissed as products of 
social and cultural roles and attitudes (Goldstein, 2000; Voda, 1997). In order to bridge this gap, 
investigators conducting research on women‘s health through menopause must work within 
paradigms and frameworks that give support and structure to explorations of women's complex, 
multifaceted lives.  
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Philosophical Paradigm 
 The philosophical paradigm of pragmatist feminism served as the foundation for the 
proposed study. Pragmatist feminism may be viewed as an intersection of two distinct 
paradigms: feminism and pragmatism (Duran, 1993).  Feminist epistemology focuses on issues 
of gender and how gender influences knowledge and inquiry, rejecting the traditional 
androcentric view of women as products of their reproductive biology and therefore inferior and 
incapable of knowing. This view renders women‘s knowledge and experience invisible (Andrist 
& MacPherson, 2001; Im, 2007; Sullivan, 2007).  
In contrast, a feminist worldview seeks to deconstruct categories that are dichotomous, 
absolute and exclusive and instead to understand how experiences are connected and interrelated 
in order to reveal the complex reality of women‘s lives (Campbell & Bunting, 1999; Rodgers, 
2005). Research rooted within a feminist paradigm is situated within women‘s lived experiences 
and perspectives (Harding, 1987) and thus is subjective and contextual. Feminist-based research 
is nonhierarchical with the researcher always in-relation to the subject-knower as a partner in the 
process of inquiry and knowledge creation. The researcher‘s reflexive sharing of her/his 
experiences with the research and the validation of findings with participants provide further 
insight and understanding of the phenomena (Anderson, 2007; Andrist & MacPherson, 2001; 
Campbell & Bunting, 1999; Harding, 1995; Im, 2007). Feminist scholarship strives to be for 
women (MacPherson, 1983; Hesse-Biber & Leckenby, 2004), integrating knowledge with action 
in order to improve women‘s lives (Andrist & MacPherson, 2001, Campbell & Bunting, 1999; 
Im, 2007). Thus knowledge generated within a feminist epistemology, irrespective of the 
methods used to obtain data, is embodied, reciprocal, intersubjective and relevant. 
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While early feminist researchers and writers favored qualitative research methods in 
order to avoid transforming women‘s experiences into exclusive categories, this reliance on one 
method is reductionistic in itself (Campbell & Wasco, 2000). Quantitative methods are also used 
by feminist researchers who often formulate their questions and hypotheses so that their findings 
will uncover women‘s situated knowledge and influence social change (Harding, 1995; Miner-
Rubino, Jayaratne, & Konik, 2007). In fact, the use of multiple methods of exploration could be 
considered commensurate with women‘s multiple ways of knowing (Leckenby & Hesse-Biber, 
2007; Reinharz, 1992; Stewart & Cole, 2007).  
The philosophical tradition of pragmatism was developed in the United States in the late 
nineteenth century in an effort to find alternative meanings of the nature of knowledge and 
inquiry and, through this new knowledge, bring about social change (Maxcy, 2003). Pragmatism 
rejects Cartesian dualisms and reductionism and seeks to integrate theory and practice, subject 
and object, the natural-physical world and the social-psychological world, mind and body, in 
order to ultimately transform the human condition (Johnson & Onwugbuzie, 2004; Morgan, 
2007; Sullivan, 2007). Traditional assumptions of a fixed Truth are replaced by a belief in 
multiple truths that are contextual, provisional and dynamic (Creswell, 2009; Creswell & Clark, 
2007; Johnson & Onwugbuzie, 2004). Concepts, hypotheses and theories are understood through 
their practical consequences (Hookway, 2008). Knowledge is transactional, rooted in and 
emerging through the interaction of the body-mind of the knower with the objective real world 
(Greene, 2007; Seigfried, 1991; Sullivan, 2001). Of particular relevance to nursing and nursing 
research is that patterns of caring knowledge are developed and strengthened through embodied 
interactions with others (Hamington, 2004). 
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Research from a world view of pragmatism focuses on the experiences and problems of 
living organisms situated within their social, political, and cultural environment (Johnson & 
Onwugbuzie, 2004; Sullivan, 2007). Research consequences or findings become tools for social 
action or change. The research question takes primacy and any research method which can 
answer the question and ultimately transform lives is deemed appropriate (Bryman, 2006; 
Tashakkori & Teddlie, 2003). Pragmatic research is eclectic, holistic and pluralistic. Pragmatic 
researchers are able to look at issues through both macro and micro lens, thus integrating 
empirical and descriptive precision (Onwugbuzie & Leech, 2005)  Not surprisingly, some 
proponents of mixed methods research invoke pragmatism as the philosophical paradigm that 
underpins their efforts to understand the complex realities of human lives (Johnson & 
Onwugbuzie, 2004; Onwugbuzie & Leech, 2005; Tashakkori & Teddlie, 2003).  
The intersections of pragmatism and feminism are fairly obvious. Both reject dualism, the 
concept of a fixed reality or absolute truth, and the superiority of thinking over doing. Both stress 
the importance of embodied experiences, relationships, connections and transactions in the 
creation and emergence of knowledge. Finally, both endorse pluralistic methods for knowledge 
development with the improvement of living conditions or the enactment of social change as the 
ultimate goal (Duran, 1993; Sullivan, 2007; Whipps, 2004). Thus a conjoined pragmatist 
feminist epistemology would replace the dichotomy of the biomedical and sociocultural 
approaches to menopause research with a holistic perspective that reconnects the many facets of 
women‘s experiences. An emphasis on the primacy of women‘s experiences serves as the basis 
for developing knowledge to improve women‘s lives through menopause and beyond. Therefore, 
pragmatist feminism formed the foundation on which was set the conceptual framework that 
 45 
 
provided structure to the mixed methods study on women‘s experiences with HT 
discontinuation. 
Conceptual Framework 
 The conceptual framework that supported this mixed methods study is based upon a 
model developed by Woods & Mitchell (2005) for studying perimenopausal symptoms. 
According to Miles & Huberman (1994), a conceptual framework explains ―…either graphically 
or in narrative form...the key factors, constructs or variables—and the presumed relationships 
among them‖ (p.18). Conceptual frameworks or theories inform every aspect of a study, 
beginning with the choice of a research topic, question and purpose through the selection of a 
design and measurements, and ultimately to the data analysis and re-presentation of the findings 
(Burns & Grove, 2005; Maxwell, 2005; Sandelowski, 1993). Theories or frameworks may also 
be refined through their use within a study as their strengths and weaknesses become more 
readily apparent (Fowler, 2006; Anfara & Mertz, 2006). 
Because this study used a mixed methods approach, the framework had to be applicable 
to both the qualitative and quantitative components (Maxwell & Loomis, 2003). It is important, 
therefore, to understand the role of conceptual frameworks in different types of research, 
particularly in qualitative research which is the dominant approach of the proposed study. 
Conceptual Frameworks in Quantitative Research. In quantitative research, theories 
or frameworks play a critical role in the development of causal or predictive hypotheses derived 
from the research questions. Variables to be studied are operationalized from the concepts of the 
theory and the data are analyzed and discussed in terms of whether they verify or refute the 
theoretically-driven hypotheses (Anafara & Mertz, 2006; Burns & Grove, 2005; Seibold, 2002). 
Because theories or frameworks in quantitative research are typically used in the exploration of 
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differences among variables, they are sometimes referred to as variance theories (Maxwell & 
Loomis, 2003). 
Conceptual Frameworks in Qualitative Research. The role of models or frameworks 
in qualitative inquiry is not dissimilar. As in quantitative research, frameworks help the 
researcher to remain focused during the development of specific aims and research questions and 
more clearly develop interview questions or observational strategies (Ayres, 2007; Fowler, 2006; 
Anafara & Mertz, 2006). A framework helps the researcher to ‗make sense‘ of the data, guiding 
the initial data review and providing a means to organize emerging patterns and even identify 
relationships not previously known or understood (Kearney & Hyle, 2006; Maxwell, 2005; 
Seibold, 2002). Because qualitative research often asks questions about the process, context 
and/or meaning of an event or phenomenon, theories used in this type of research are sometimes 
termed process theories (Maxwell & Loomis, 2003). 
Although the role of frameworks is similar in both types of research, in qualitative 
research the framework may be less rigid and more open and emergent. The amount of structure 
provided by frameworks or theories falls along a continuum from very loose to very tight (Miles 
& Huberman, 1994). For beginning researchers, tighter designs provide more focus, direction 
and manageability (Merriam, 2006), prevent overload and promote generalizability (Miles & 
Huberman, 1994).   
At the same time, frameworks should not be deterministic. While a framework may 
provide direction and guidance, care must be taken to prevent it from becoming prophetic or 
constraining, leading to premature closure (Harris, 2006; Mills & Bettis, 2006). Instead, it is the 
obligation of the researcher to maintain a degree of skepticism and, during continued and 
prolonged engagement with the data, seek out alternative interpretations and explanations. This 
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pattern of continued engagement with and withdrawal from the framework becomes a part of the 
iterative process of qualitative research (Mills & Bettis, 2006), reinforcing the role of the 
researcher as the primary instrument through which the research comes to life (Harris, 2006).   
Rigor or trustworthiness is enhanced through the use of a framework or theory 
(Henstrand, 2006; Kearney & Hyle, 2006). The inherent concepts and relationships provide a 
vernacular for the development of a rich description of the findings (Kearney & Hyle, 2006; 
Anafara & Mertz, 2006). Thus the framework serves to: assist the reader in determining the 
transferability of the findings (Kearney & Hyle, 2006), link the study to the existent scholarly 
literature within the discipline (Ayres, 2007; Fowler, 2006; Harris, 2006), and point the way 
toward future research (Mills & Bettis, 2006).  
Conceptual Frameworks in Mixed Methods Research. In mixed methods research, 
theories or frameworks also link the question with the chosen methods but must be able to 
support both qualitative and quantitative designs. Some mixed methods research studies use two 
or more separate theories for distinct facets of a study: a variance theory for the quantitative 
component and a different process theory for the qualitative inquiry (Maxwell & Loomis, 2003).  
Mixed methods studies may also be informed by a single framework or model that 
combines or integrates both process and variance components. An integrated framework allows 
for the open, inductive process that generates a rich, detailed description of meaning or process. 
It also supports the use of discrete, quantitative measures to explore differences or relationships 
between the theoretically-driven variables. Data derived from the qualitative and quantitative 
components of the research may then be directly compared to provide within-case analysis, 
further interweaving the study findings (Maxwell & Loomis, 2003). The Woods & Mitchell 
(2005) framework served as an integrated model which encompassed both facets of this study. 
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Conceptual Framework. Theoretical or conceptual frameworks informing a study may 
be chosen from existing models or constructed during the development of the study. Frameworks 
are derived from both the literature of the discipline or topic of interest as well as the beliefs, 
experiences, values and goals that the researcher brings to the research process (Maxwell, 2005; 
Merriam, 2009; Miles & Huberman, 1994; Sandelowski, 1991). Concepts, contexts and 
conditions pertinent to the phenomenon are included in the framework (Ayres, 2007). The 
decision to situate the proposed inquiry within a symptom framework was based on the centrality 
of recurrent symptoms in both the literature on HT discontinuation as well as in the narratives 
told by the women seen in the researcher‘s practice.  
The level of discomfort experienced with any symptom is often associated with elements 
of the symptom itself: frequency, intensity, location, and duration/chronicity. This is no less 
applicable to menopause-related symptoms: for example, women describe VMS in terms of how 
often they occur, how severe they are and when they began. However, symptoms are subjective 
experiences and symptom assessment and management models stress the contextual nature of 
symptom experience, perception, evaluation and response (Dodd, Janson, Facione, Faucett, 
Froelicher, Humphreys, et al. 2001; Lenz, Pugh, Milligan, Gift, & Suppe, 1997). Thus a 
symptom model supported the study goals to explore both the symptom experience and the 
influencing factors related to discontinuing HT. 
Several well-established symptom frameworks, including the Theory of Unpleasant 
Symptoms (Lenz, Pugh, Milligan, Gift, & Suppe, 1997) and the University of California/San 
Francisco Symptom Management model (Dodd et al., 2001), were considered for this proposed 
research. They were ultimately rejected because their primary use has been with symptoms 
related to disease conditions. In keeping with the initial premise of this study that menopause is a 
 49 
 
normal developmental transition, a model was needed that would not portray menopause within 
the context of illness or disease. 
The Woods & Mitchell (2005) framework chosen for this study was developed to 
specifically address the experience of perimenopausal symptoms. As a situation-specific model, 
it attempts to downplay the view of menopause as a disease or deficiency state. Instead, it seeks 
to bridge the biomedical-sociocultural chasm that exists in menopause research by viewing 
symptoms as influenced by both personal characteristics and sociocultural contexts.  
The components of the framework as proposed by Woods & Mitchell (2005) include 
three central symptom-related elements—symptom perception, symptom evaluation and 
symptom responses—which are influenced by explanatory models. In addition, the overall 
symptom process is also influenced by both personal characteristics and sociocultural context. 
Figure 1. Woods & Mitchell Conceptual Framework for Understanding Perimenopausal Symptoms  
 
 
(Used with permission from N. F. Woods from ―Symptoms during the perimenopause: Prevalence, 
severity, trajectory, and significance in women's lives‖ by N. F. Woods and E.S. Mitchell, 2005, American Journal 
of Medicine, 118 (Suppl 12B), 14-24.) 
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Symptom Perception. Symptoms are defined in this model, as in many other symptom 
models, as sensations that are different from those ordinarily perceived. Symptom perception 
occurs when a different sensation is noticed. However, perception involves more than just 
observing the occurrence or presence of a sensation: characteristics of the symptom such as 
frequency and severity are also noted as part of perceiving a symptom (Woods & Mitchell, 
2005). Women discontinuing HT often remarked on the intensity of their symptoms (Helenius et 
al., 2007; Matarese, 2005). 
Symptom Evaluation. The evaluation of a symptom refers to the judgements made about 
the meaning a symptom holds for the person experiencing the symptom. Individuals seek to 
know or understand what the cause of the symptom is, whether it is serious and how amenable it 
is to treatment, what consequences may be associated with the symptom, and what the presence 
of the symptom means in their life (Woods & Mitchell, 2005). Women discontinuing HT may be 
uncertain as to whether to attribute symptoms to menopause or aging (NAMS, 2007). 
In addition, women attempting to stop HT may also perceive a decrease in QoL as a 
result of their recurrent symptoms. As previously noted, there is a discrepancy in results of QoL 
research among menopausal women which may be due in part to the multifaceted nature of QoL. 
Components of QoL include not only symptoms, but also other elements such as functional 
status, well-being and health (Bowling, 2005; Wilson & Cleary, 1995). Physical issues, such as 
symptoms or functional status, impact on health while emotional well-being has more impact on 
overall QoL (Ferrans, 2007).  
QoL is also very subjective, based on each person‘s perceptions and evaluations of all 
these dimensions and strongly influenced by sociocultural and environmental contexts (Padilla, 
Frank-Stromberg, & Koresawa, 2004). The multidimensionality of QoL argues for the use of 
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multiple measures to explore the different dimensions (Ferrans, 2007; Padilla et al., 2004).  
Furthermore, because QoL is highly contextual, the most comprehensive measure of QoL may 
be a combination of both qualitative and quantitative methods to obtain both subjective and 
objective data. This approach would help to determine the facet(s) of QoL most influenced by 
HT discontinuation. 
Symptom Responses. In this model, responses may include the person‘s thoughts and 
feelings that have been evoked by the occurrence of the symptom or symptoms. Responses may 
also be manifested externally by an individual‘s behaviors: engaging in self-care techniques or 
symptom management strategies (e.g., lifestyle modifications, over-the-counter nutritional or 
herbal supplements), turning to family, friends or even media sources for advice, seeking 
information or assistance (e.g., medications, counseling, CAM) from health care providers, or 
choosing not to pursue any course of action to address the symptoms (Woods & Mitchell, 2005). 
Some women stopping HT reported being dissatisfied with information from health care 
providers (Ettinger et al., 2003; Schonberg et al., 2005) underscoring the importance of 
determining what information women discontinuing HT want and need to guide and assist them.  
Explanatory Models. Symptom perception, evaluation and response are inextricably 
linked by explanatory models: culturally derived beliefs about what is wrong, how to get care 
and how best to manage symptoms. These explanatory models are responsible for much of the 
variation in how people perceive and define symptoms, the strategies and interventions chosen, 
and the outcomes of the symptoms (Mechanic, 1962; Mechanic, 1986).  They are rooted in an 
elaborate cultural system consisting of three distinct but intersecting sources of knowledge about 
health: popular (family and social/community networks), folk (lay or ethnic healers) and 
professional (complex professional health care services).  These understandings of health impact 
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are embedded within the individual from infancy and influence how individuals monitor their 
physical states, perceive deviations from normal, and apply meaning to the new sensations and 
experiences (Chrisman & Kleinman, 1983; Mechanic, 1962; Mechanic, 1986). 
The application of the culturally mediated definition and meaning drives the choices for 
treatment or symptom management strategies, what to do or not do about any given symptom. 
An individual‘s social network provides options for treatment as well as additional resources 
such as reassurance, social support, or financial assistance. In determining which treatment to 
choose, an individual must weigh the symptom or illness burden against the available resources 
(Chrisman and Kleinman, 1983; Mechanic, 1962; Mechanic, 1986). 
Once this process is initiated, it may continue to cycle as the individual evaluates how 
symptoms respond and change with treatment and whether the treatment recommendations 
should continue to be followed. Evaluation and adherence are greatly influenced by trust in the 
commitment of the helper (Chrisman & Kleinman, 1983). 
Findings from the menopause literature confirm the existence of this socially patterned 
process. There are clear differences in the way menopause symptoms are perceived, defined and 
managed among women from diverse cultures and ethnicities (Gold, Block, Crawford, Lachance, 
FitzGerald, Miracle, et al., 2004; Kaufert, 1996; Lock, 2002). 
Personal Characteristics. The process of symptom perception, evaluation and response is 
postulated to be influenced by physiological factors unique to the individual experiencing the 
symptom(s). These personal characteristics are thought to contribute to the occurrence of 
symptoms and include factors such as genetics (e.g., genetic polymorphisms), biology (high 
BMI), symptom sensitivity (narrowed thermoneutral zone) and demands of daily living (stress) 
(Woods & Mitchell, 2005). From the HT discontinuation literature, characteristics such as age 
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and surgical menopause, both associated with worse symptom recurrence, could be added to this 
component of the model (Grady et al., 2003).  
Sociocultural Context. The model developed by Woods & Mitchell (2005) seeks to 
provide a balanced view by also including the sociocultural context in which women 
experiencing symptoms are situated. Here can be found factors such as social class, culture, 
ethnicity, and social demands of daily living, such as the multiple roles taken on by or imposed 
on many women today. These sociocultural contextual factors may influence the meanings that 
women ascribe to their symptoms as well as their subsequent responses to the symptoms. Post-
WHI studies on HT discontinuation have yielded mixed results as to the influence of 
sociocultural factors on symptom recurrence.   
Relevance to the proposed study. The conceptual model developed by Woods & 
Mitchell (2005) served as an organizing framework for the proposed study. The framework 
helped to the researcher to develop the specific aims and research questions in order to best 
address the study purpose (see Table 7). In addition, the framework assisted in both developing 
the semistructured interview questions and choosing the quantitative measurements that 
answered the research questions. The analysis of the data and discussion of the findings were 
guided by the framework. 
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Table 7.  
Relationship of Research Questions, Specific Aims, Conceptual Framework & Conceptual 
Definitions 
RESEARCH 
QUESTIONS 
SPECIFIC AIMS 
CONCEPTIUAL 
FRAMEWORK 
CONCEPTUAL 
DEFINITION 
What is the experience of 
discontinuing HT? 
Explore women‘s 
experiences of HT 
discontinuation 
Symptom 
experience 
Symptom 
perception 
Awareness of symptom 
frequency & intensity 
Symptom 
evaluation 
Judgements about 
symptoms‘ seriousness, 
treatability, causes & 
consequences 
Symptom 
response 
Feelings, thoughts or 
behaviors that occur as 
a result of the 
symptoms 
What factors do women 
identify as making this 
experience more or less 
manageable? 
Describe the personal 
characteristics and 
sociocultural 
contexts that 
influence symptom 
perception, 
evaluation and 
response among 
women who have 
attempted to 
discontinue HT 
Personal characteristics 
Genetic, molecular & 
physiologic factors that 
may contribute to 
symptoms 
Sociocultural context 
Ethnic, cultural & social 
factors that may 
contribute to symptoms 
How does HT 
discontinuation impact on 
women‘s QoL? 
Do the reports of QoL 
among women who have 
attempted to discontinue 
HT differ depending on 
which dimension of QoL 
is being measured? 
Explore the impact of 
HT discontinuation 
on women‘s quality 
of life 
Symptom evaluation: quality of 
life 
Global sense of life 
satisfaction or well-
being encompassing 
physical, social, 
psychological and 
spiritual domains 
What information do 
women need to help them 
manage symptoms and 
maintain health during 
and after HT 
discontinuation? 
Discuss women‘s 
preferences for 
counseling and 
support during HT 
discontinuation 
Symptom response: seeking 
information  
Sources and adequacy 
of health-related 
information 
 
There are several limitations to the Woods & Mitchell framework. One limitation is that 
there are no connections between personal characteristics and sociocultural context. Because 
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some personal characteristics may be influenced by the sociocultural environment and vice 
versa, the framework might be improved by showing connections or linkages between the two 
components. This would better reflect the pragmatist feminist paradigm which stresses that 
knowledge and caring are built and strengthened through the experiences of human organisms 
transacting with the real world (Hamington, 2004; Seigfried, 1996; Sullivan, 2001).   
 Another limitation is that the framework has not been used to date to support any other 
research or generate any decision-making theories. Because it is still in an early stage of 
development, more elements may need to be added to the model. The exploratory nature of the 
study helped to uncover additional characteristics or contexts that could be added to the model to 
further develop this framework (Fowler, 2006; Maxwell, 2005). 
Summary 
Women who discontinue HT may be beset by troublesome symptoms that could 
negatively impact on their QOL and ultimately drive them to resume HT despite the risks or their 
desires. This experience of recurrent symptoms may be influenced, not only by women‘s 
perceptions, evaluation and responses to these symptoms, but also by their personal 
characteristics and sociocultural contexts. The purpose of the study was to describe the 
experience of discontinuing HT in order to better understand the experience of recurrent 
symptoms and the influencing personal and sociocultural factors. 
The Woods & Mitchell‘s (2005) conceptual framework for studying perimenopausal 
symptoms, undergirded by a pragmatist feminist paradigmatic stance, supported the use of a 
mixed methods approach to allow women‘s perspectives and experiences of HT discontinuation 
to be elicited. It is hoped that the findings will provide the foundation for developing better 
counseling and support guidelines and recommendations for women discontinuing HT.   
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CHAPTER III  
METHODS 
The purpose of the study was to describe women's experiences of HT discontinuation.  A 
mixed methods approach was used to develop an in-depth description of this phenomenon. A 
qualitative research method known as Qualitative Description comprised the primary portion of 
the study, that is, the exploration of women‘s experiences during discontinuation, factors 
influencing the experience and needs for counseling and support before, during and after 
discontinuation. In addition, an embedded quantitative component addressed multiple 
dimensions of QoL for women discontinuing HT. This chapter will discuss the methodological 
details for the study: design, sampling, measures, procedures, data analysis and ethical 
considerations including protection of human subjects. 
Design 
Mixed Methods Design 
A mixed methods design was used to address the questions and specific aims of the 
proposed study. Mixed methods research combines and integrates both quantitative and 
qualitative methods within either a single study (in this instance) or a larger program of research. 
Using different methods within the same study allows multiple facets of a research problem or 
question to be explored in a comprehensive fashion. Quantitative and qualitative data are 
ultimately compared, contrasted and converged in order to develop inferences that are well-
substantiated and valid (Erzberger & Kelle, 2003; Teddlie & Tashakkori, 2003). (See Table 8 for 
a comparison of the three primary research traditions.) 
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Table 8.  
Comparison of Three Research Traditions 
CHARACTERISTIC 
RESEARCH TRADITION 
QUANTITATIVE QUALITATIVE MIXED METHODS 
Philosophical origin 
Logical Positivism, 
Empiricism 
Naturalism, 
interpretivism 
Pragmatism 
Ontology 
Single reality or Truth 
exists 
Multiple realities or 
truths 
Single & multiple realities; 
provisional truths 
Epistemology 
Distance, impartiality, 
independence between 
researcher and 
subjects 
Interaction, 
collaboration, 
intersubjectivity 
between researcher & 
participants 
Practicality 
Axiology Control of biases & 
values, objectivity 
Values inevitable & 
desired; 
intersubjectivity 
Multiple & variable 
perspectives on the role of 
values 
Focus 
Concise, objective, 
reductionistic 
Broad, subjective, 
holistic 
Comprehensive 
Reasoning Logistic, deductive Dialectic, inductive 
InductiveDeductive; 
Abductive 
Basis of Knowing 
Explanation, 
prediction 
Cause & effect 
Meaning, 
understanding 
Discovery & verification; 
Confirmation & 
exploration 
Theoretical Focus Tests theory Develops theory Develops & tests theory 
Methods of 
Measurement 
Questionnaires, scales, 
physiological 
instruments 
Unstructured 
interviews, 
observations; 
researcher as 
instrument 
Qual & Quan; 
Sequence, priority 
Data Numbers Words Narratives & numerals 
Analysis Statistical analysis 
Individual 
interpretation 
Integration 
Findings 
Generalization, 
universal; outcomes 
Context specific; 
unique; 
focus on process 
Transferability 
Comparison, convergence 
(divergence) & 
corroboration 
Rigor Reliability, validity Trustworthiness Inference quality 
Adapted from: Burns & Grove (2005) 
          Creswell & Plano-Clark, 2007 
          Johnson & Onwuegbuzie (2004) 
          Morgan (2007) 
          Teddlie & Tashakkori (2003) 
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 A mixed methods approach is well suited for research that seeks to more fully understand 
complex and multifaceted aspects of human behavior. Mixed methods designs are especially 
useful when different questions about a phenomenon need to be answered, or different 
dimensions of a concept need to be explored, and a single data type is not enough to capture the 
multiple facets of the phenomenon under investigation (Creswell & Plano-Clark, 2007; Greene, 
2007; Johnson, Onwuegbuzie, & Turner, 2007; Teddlie & Tashakkori, 2003). Thus, mixed 
methods is particularly useful for nursing researchers seeking to understand the complicated and 
multidimensional components of the human experience of health and illness (Carper, 1978; 
Sandelowski, 2003; Twinn, 2003). 
There are many typologies of mixed methods research designs (Creswell & Plano-Clark, 
2007; Greene, 2007; Kroll & Neri, 2009; Morgan, 1998; Morse, 1991; Teddlie & Tashakkori, 
2003). The choice of design is dependent on the purpose for using a mixed methods approach. 
Greene (2007) describes five different purposes for mixing methods: triangulation, 
complementarity, development, initiation and expansion. For the proposed study, 
complementarity serves as the purpose for the design. Complementarity refers to the use of 
multiple methods for measuring different facets or dimensions of the same phenomenon. The 
goal is to develop a deeper, broader and more expansive understanding of the phenomenon or 
concept being explored. In this study, influencing factors and QoL of women discontinuing HT 
were explored using both qualitative and quantitative inquiry. 
Ideally, when complementarity is the purpose of the study, the qualitative and 
quantitative findings will overlap to produce a comprehensive description of the topic. In some 
instances, however, the results may instead converge (triangulation) or diverge (initiation). This 
shift in purpose, albeit accidental, may occur through insights gleaned during data analysis and 
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can lead to new interpretations and understandings of the phenomenon. Unanticipated patterns in 
the results may highlight the need for modifications of the qualitative interview guide or point 
toward further explorations of the topic or framework (Greene, 2007).   
The researcher‘s purpose for choosing mixed methods directs the choice of design 
including decisions regarding the sequence (order), weight (priority or dominance) and 
integration (mixing) of the qualitative and quantitative components (Creswell & Plano-Clark, 
2007; Greene, 2007; Morgan, 1998; Morse, 1991). Mixed methods studies with complementarity 
as the purpose may be implemented through either blending or nesting designs (Greene, 2007; 
Happ, Dabbs, Tate, Hrick & Erlen, 2006). The proposed study used a nested design. 
In a nested or embedded design, one component takes primacy (weight) while the other is 
less dominant and plays a supportive or secondary role (Creswell & Plano-Clark, 2007; Greene, 
2007) or addresses a specific subtopic of the research question (Kroll & Neri, 2009). Data are 
typically collected concurrently (sequence) and the different data sets are connected during the 
process of analysis (integration) (Creswell & Plano-Clark, 2007; Greene, 2007).  An important 
consideration with this design is that the nested component adheres to the methodological 
procedures (for example, sampling, rigor) of the primary method (Greene, 2007; Happ et al., 
2006). For this study, a smaller set of quantitative measures was embedded within the larger 
Qualitative Descriptive study therefore decisions about the design and process of the proposed 
study were guided primarily by the qualitative research tradition. 
Because the researcher collects all the data in one phase, this design saves time and is 
more manageable for graduate students or novice researchers whose resources are limited 
(Creswell & Plano-Clark, 2007). In addition, if the different data sets produce convergent or 
divergent findings, as noted above, this actually enhances the inferences that can be drawn from 
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the analysis (Greene, 2007). Challenges to this design include difficulty integrating or 
interpreting results because of different research questions and unequal weighting of the methods 
as well as limited available guidance for resolving discrepancies or divergent findings in the data 
sets (Creswell & Clark, 2007).  
 Qualitative Description. Qualitative research seeks to discover or describe knowledge 
related to meaning, process or experience. Often, but not always, words comprise the data to be 
analyzed and are obtained through observations and/or interviews. Qualitative questioning 
allows participants‘ voices and views to be heard in order to gain in-depth understanding of a 
particular phenomenon (Creswell & Plano-Clark, 2007).  
For this study, the specific qualitative method that was used was Qualitative Description 
(QD). QD is a type of naturalistic inquiry that looks at everyday experiences or events and is 
especially useful when these phenomena have not been fully described, as is the case with HT 
discontinuation. Unlike other qualitative approaches that interpret findings through abstract 
philosophical or theoretical lenses, QD uses a low-inference interpretation that remains closer to 
the actual data in order to identify patterns and themes. This results in a rich and comprehensive 
summary of an event or an experience that is rooted in the point of view of the participant and 
expressed in their everyday language (Sandelowski, 2000b; Sullivan-Bolyai, Bova, & Harper, 
2005). Although QD may appropriate the tone or characteristics of other types of qualitative 
approaches by seeking to describe lived experiences (phenomenology) or developing theories 
(grounded theory), it differs by holding the data and analysis close to the actual experiences of 
the participants (Sandelowski, 2000; Sullivan-Bolyai et al., 2005).  
The analytic strategy best suited for QD is content analysis, a systematic coding and 
summarizing of data in order to achieve an accurate and straightforward rendition of the 
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meanings associated with an experience or an event. Findings are re-presented in a manner that 
best reflects the data and will be most easily understood and relevant for the intended audience 
(Sandelowski, 2000).  
QD may be quite beneficial for helping to improve health outcomes, particularly with 
vulnerable populations. Because QD can provide detailed information about health issues that is 
rooted in the participants‘ sociocultural contexts and reported in their vernacular, it may be more 
culturally congruent than other types of research. Thus it lends itself well to health care 
disparities research, such as conducting needs assessments or developing interventions to 
transform the lives of underserved populations (Sullivan-Bolyai et al., 2005).  
This approach also blends easily with quantitative inquiry to inform mixed methods 
research where the entire study may by undergirded by pragmatism (Greene & Caracelli, 2003; 
Teddlie & Tashakkori, 2003) or a transformative-emancipatory paradigm (Mertens, 2003). QD 
may also reflect frameworks such as feminism (Sandelowski, 2000) or critical theory (Sullivan-
Bolyai et al., 2005). It was particularly appropriate for this study which was built upon a 
foundation of pragmatist feminism, a world view that stresses the importance of allowing 
women‘s voices to be heard. In so doing, their experiences were better understood and will 
ultimately support the development of knowledge for transforming the lives of women 
discontinuing HT (HesseBiber & Leavy, 2007; Leckenby & Hesse-Biber, 2007). To achieve this 
goal, semi-structured interviews were used to explore women‘s overall experiences with 
discontinuing HT, identify contextual factors influencing the experience, develop a better 
understanding of QoL during discontinuation and elicit suggestions for improving the 
preparation and counseling they require for this experience.  
 62 
 
Embedded Quantitative Component. In quantitative research, numerical data are 
obtained in order to describe various elements of a phenomenon, determine associations among 
these elements or variables or identify a cause-and-effect relationship among specific variables 
(Table 8.) (Burns & Grove, 2005). However, when quantitative measures are embedded within a 
larger qualitative study, their purpose is to obtain data that may complement or expand upon 
specific dimensions of the phenomenon of interest. Quantitative data collection methods can 
quickly and efficiently measure personal characteristics, attitudes and other social, behavioral 
and cognitive constructs (Johnson & Turner, 2003; Tashakkori & Teddlie, 1998) that can then be 
compared and contrasted with related qualitative findings. Comparison may occur both across 
and within cases (Ayres, Kavanagh & Knafl, 2003).  
For this study, several quantitative measures were nested within the QD component. 
First, demographic information was collected to both describe the sample and obtain personal 
data relevant to women‘s personal characteristics and sociocultural contexts in accordance with 
the organizational framework (Woods, 2005). In addition, several instruments were used to 
obtain information about dimensions of QoL for comparison within and across-cases (Ayres et 
al., 2003) and across strata (Cohen & Crabtree, 2006; Patton, 2002) thus deepening 
understanding of the phenomenon of QoL during HT discontinuance.  
Sample 
Sampling Strategy 
In order to be congruent with the purpose and design of the proposed inquiry, the sampling 
method was appropriate for a primarily qualitative study (Greene, 2007; Happ et al., 2006). In 
qualitative research, participants are chosen because they hold information pertinent to the 
specific experience, culture or process under investigation (Speziale & Carpenter, 2007). 
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Qualitative sampling strategies are thus labeled ‗purposeful‘ or ‗purposive‘ in that they are 
clearly linked to the purpose of the study. The researcher seeks to identify people who will be 
good sources of the information needed for developing an in-depth description of a particular 
phenomenon (Merriam, 2009; Patton, 2002; Sandelowski, 1995).  
 The qualitative researcher has a wide assortment of purposeful sampling strategies from 
which to choose. As noted above, the choice of strategy is greatly dependent upon the study 
purpose and the types of cases or participants needed to obtain sufficient data for answering the 
research question.  The researcher must also consider whether the sampling procedure is 
adequate to ensure the credibility and transferability of inferences drawn from the data as well as 
whether the strategy is feasible, practical and ethical (Kemper, Stringfield & Teddlie, 2003). 
 Maximum variation sampling is a sampling procedure commonly used by researchers 
conducting QD studies. With this sampling method, participants or cases exhibiting a wide range 
of variation of the phenomenon, or specific aspects of the phenomenon, of interest are 
purposefully selected (Polit & Beck, 2008; Sandelowski, 1995). The characteristics to be 
maximized are typically determined a priori in order to achieve adequate representation of those 
dimensions (Sandelowski, 1995). The resulting diversity of the dimension of interest within the 
sample allows for detailed descriptions of both unique cases and common experiences and 
patterns (Patton, 2002).   
 This study sought to employ maximum variation sampling to obtain a sample of women 
with diverse HT discontinuation experiences, particularly with regard to type of HT used, 
discontinuation method, recurrent symptoms and outcome. Because there may be local or 
regional patterns of HT use (Keating, Cleary, Rossi, Zaslavsky & Ayanian, 1999; Kim et al., 
2005), it was hoped that using the Internet to recruit participants from multiple locales would 
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promote  maximum variation sampling. Efforts were also made to recruit women from diverse 
sociocultural and ethnic backgrounds which also enhances maximum variation. Ultimately the 
lack of ethnic diversity may have precluded true maximum variation within the sample although 
variability of expereinces was still achieved. 
 It is not uncommon for multiple sampling strategies to be used within one study. For 
example, an attempt was also made to use snowball sampling to identify potential participants. 
Chain or snowball sampling is another technique for identifying potential participants through 
key informants in the community or other study participants (Kemper et al., 2003; Patton, 2002). 
In addition, the purposefully selected sample may be further subdivided into subgroups or strata, 
which are also prespecified, in order to compare and contrast the groups along different levels of 
a specific characteristic (Kemper et al., 2003; Patton, 2002; Sandelowski, 2000). The purpose of 
stratification is to illuminate variations rather than commonalities among the subgroups (Patton, 
2002).Therefore, participants were stratified into groups based on HT discontinuation status 
(stopped, tapering and resumed HT) in order to compare influencing factors and QoL. However, 
as there were more women in the discontinued subgroup (20) than in the resumed subgroup (9) 
and only a small number (5) of women who were tapering, the unequal size of the strata  limited 
some comparisons. 
   Because the goal of purposeful sampling is to obtain a sample that will ultimately yield 
findings rich or significant from an informational perspective as opposed to a statistical 
perspective (Sandelowski, 2000), there are no definitive rules or mathematical calculations for 
predetermining the requisite number of participants. Rather, sample size is based on the research 
question and purpose, the participant selection criteria (Merriam, 2009), the rationale behind the 
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sampling strategy chosen (Sandelowski, 1995), the resources available to the researcher (Miles & 
Huberman, 1994; Patton, 2002) and the achievement of data saturation.  
Data saturation or redundancy is the term that indicates no new information relevant to the 
study phenomenon is emerging from the data. The researcher determines saturation has been 
reached when knowledge elicited from new informants is repetitive of what has already been 
discovered and serves to confirm rather than expand upon the findings (Lincoln & Guba, 1985; 
Morse, 1989; Patton, 2002; Speziale & Carpenter, 2007). Sampling continues until data 
saturation or redundancy is attained therefore the final sample size for a qualitative study cannot 
be determined a priori.   
While this perspective is in keeping with the open and evolving nature of qualitative 
inquiry, practicality, guised in the form of grants, budgets or even thesis committees, may 
demand a more definitive projection of the number of participants necessary for answering the 
research question. Patton (2002) recommends both specifying a minimum sample size and 
clearly stating the rationale for choosing that number, with the understanding that the sample—
and sampling plan—may be changed based on emerging information. Furthermore, the 
researcher should describe the criteria that would indicate the need to adjust the sample size 
either up or down. However, because data saturation is situational—new or different information 
could be obtained given another sample, time or context (Morse, 1989)—the researcher should 
discuss in the dissertation how the chosen sample, sample size and/or sampling techniques may 
have impacted on the findings (Patton, 2002).    
QD studies typically have moderate sized samples, often between 20-50 participants 
(Sullivan-Bolyai et al., 2005). This is primarily due to the use of maximum variation sampling 
which requires more cases to maximize the variations of the phenomenon found in the data 
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(Sandelowski, 1995). Based on this guide, this study sought to enroll 30-40 women (meeting the 
eligibility criteria noted in Table 9) who had attempted to discontinue HT as it was thought that 
this number would achieve variation between participants. Saturation of information about the 
HT discontinuation expereince was the primary criteria for determining whether more 
participants need to be recruited. If new themes had continued to emerge from the data once this 
number were enrolled, more participants would have been recruited until only repetitive and 
confirmatory information was being found in the data, however this was not necessary.  
Table 9.  
Inclusion/Exclusion Criteria 
Women eligible for this study: Women not eligible for this study: 
1) are 45 years of age or older;  
2) are in good health; 
3) are in either the late menopause 
transition or postmenopause stage 
as defined by STRAW;  
4) have used HT for a minimum of 3-4 
months; 
5) have attempted to discontinue HT 
(by any method of discontinuation) 
within the past 2 years, regardless 
of outcome; 
6) are able to read, speak and write 
English; and, 
7) have Internet or telephone access. 
1) are younger than 45 years of age; 
2) have health issues such as cancer or 
cardiovascular disease, 
3) have not reached the late 
menopause transition or 
postmenopause stage as defined by 
STRAW; 
4) have used HT for less than 3-4 
months; 
5) have not attempted to discontinue 
HT; 
6) are not able to read, speak and write 
English; and, 
7) do not have Internet or telephone 
access. 
 
The minimum age requirement was set at 45 years old to decrease the possibility that any 
participants may have recently experienced premature menopause (menopause prior to the age of 
40) or Premature Ovarian Failure (POF)—ovarian insufficiency prior to age 40 which leads to 
amenorrhea. These women are at greater risk for early onset of CVD and osteoporosis because of 
earlier withdrawal of ovarian hormones. The current recommendations for discontinuation after 5 
years may not apply to these women when they are early in this process thus they may comprise 
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a different population than was addressed through this study. Currently, there are no clinical trial 
data establishing a maximal length of HT use for these women. However, clinical guidelines 
recommend keeping these women on HT until age 50 and then consider discontinuation (NAMS, 
2010). Based on these guidelines, women who had transitioned through menopause prior to age 
40 but who were now past the age of 50 were deemed appropariate candidates for participation.   
Women in the early menopause transition may still have occasional ovulatory cycles 
therefore any increases or decreases in symptoms may reflect hormonal fluctuations related to 
ovulation not HT discontinuation; this could confound the description of symptom duration. 
Also, because HT may take several months to reach maximum effect, women stopping during 
this timeframe may not have achieved maximum relief of symptoms which could limit 
comparison to recurrent symptoms. 
As the focus of this study was on women‘s experiences with discontinuation, all 
participants must have attempted discontinuation. For the purpose of maximum variation 
sampling, the sample included women who used different discontinuation methods, who made 
multiple attempts to discontinue, who were tapering HT, or who had chosen to resume HT. 
Diversity in symptom experience among participants was also sought.  
As noted in Chapter 1, the duration of recurrent symptoms is unknown as most studies 
were done within a year after the WHI. In order to capture the experiences of women who may 
be symptomatic for longer than a year, and yet still decrease the risk of recall bias, the time range 
was limited to discontinuation within the past two years. 
Because the majority of women in this study were located in areas distant from the 
researcher, the interviews were conducted either online or via the telephone. Therefore all 
participants had to have access to one of these means of communication. In addition, participants 
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were recruited from several menopause-related Internet sites at which all postings are in English 
therefore only participants who can understand and communicate in English were recruited.  
Setting 
 Through the qualitative lens, understanding the meaning that people ascribe to their 
experiences is a critical component of understanding the experiences themselves (Marshall & 
Rossman, 1998). Meaning is derived in part through the setting or context in which an 
experience occurs, thus the setting cannot be overlooked as a powerful influence on the 
inferences that emerge from a study (Illingworth, 2006).   
 The most common interpretation of setting is the location or physical environment 
wherein the participant completes study procedures such as questionnaires, interviews or 
laboratory testing (Burns & Grove, 2005; Speziale & Carpenter, 2007). With qualitative 
interviews, the setting is typically the location where the participant and researcher meet face-to-
face, ideally representing the real-world where the participant experiences and gives meaning to 
the phenomenon being explored. Thus setting includes not only the physical structure(s) where 
the interview occurs but also other aspects of the environment including the community, 
weather, time of day, indigenous language, even the presence of other people in the immediate 
surroundings (Patton, 2002). All of these contexts may impact on the way in which the 
participant experiences or describes the phenomenon, the quality of the interview and the 
feasibility of obtaining an adequate sample size. Therefore it is inherent upon the researcher to 
describe the setting in as much detail as possible (Patton, 2002; Polit & Beck, 2007).  
 However, in this study the interviews were conducted either online or via telephone and 
not face-to-face, therefore the researcher did not have access to information about the 
environment of the participants at the time of their responses. Accordingly, the researcher asked 
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participants to describe their setting: location, time of day, weather and so on. In addition, the 
Internet itself, particularly the group or site from which the participant is recruited, became a 
separate and significant context of communication and interaction between participant and 
researcher (Illingworth, 2006).    
Internet as Research Setting 
 Internet Community. Since the fledging efforts to establish computer-mediated 
communication 40 years ago, the use of computers for communication has grown phenomenally 
into a world-wide network for social, business, scientific and academic interaction (Mann & 
Stewart, 2000). Currently, 79% of the United States population (over 147 million adults) uses the 
Internet for both personal and professional purposes (Madden, 2009).  
 Internet usage varies by both ethnicity and gender. While initially the Internet was used 
primarily by white males, individuals from other ethnic backgrounds have been gaining ground 
and women have essentially caught up with men online. Internet penetration among Asian 
Americans is higher than among any other ethnic group (Im, Shin & Chee, 2008) while half of 
Hispanic Americans and about a third of African Americans are Internet users. Among African 
Americans, more women (60%) than men (50%) are online (Fallows, 2005). 
 Although almost equal numbers of women and men now use the Internet, online activities 
vary by gender. Men are more likely to use the Internet to obtain information and perform 
transactions. Women, on the other hand, go online more for personal enrichment: building social 
contacts and staying connected through emails or other forms of cyber-social networking, 
looking up health/medical information for themselves or others, soliciting support for personal 
and health problems and seeking religious information (as well as getting maps and directions!) 
(Fallows, 2005; Fox, 2007).  
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 Through their Internet interactions and conversations, women may form connections and 
networks that are equally as important as their non-Internet relationships. For example, support 
group participants at two online websites, one for women at high risk for hereditary breast and 
ovarian cancers (Kenen, Shapiro, Friedman & Coyne, 2007) and another for breast cancer 
survivors (Radin, 2006), developed tightly-knit bonds and a deep sense of solidarity. Self-
disclosures and shared confidences reduced their feelings of isolation and promoted the 
development of virtual social communities. Frustrated by health care providers‘ insensitivity and 
limited and conflicting information, women shared knowledge, advice and support, essentially 
creating cyber-families and sisterhoods rooted in an abiding trust. These online communities 
have become part of the networks that serve as sources for the development of culturally derived 
beliefs about symptom perception, evaluation and response (Chrisman & Kleinman, 1983; 
Mechanic, 1962; Mechanic, 1986).  Because of the powerful interpersonal online networks that 
many women develop, the Internet has become an important setting or context that must be 
considered by researchers looking at women‘s health experiences.   
 Internet Research. The use of the Internet for research has been broken into three 
distinct categories: locating resources, completing demographic surveys and conducting 
empirical investigations (Senior & Smith, 1999). This study falls under the third heading. Within 
this category, the Internet may be used as a recruitment resource and/or the repository for the 
actual study materials (Ahern, 2005). 
 Internet Recruitment. Investigators looking to recruit participants through the Internet 
may develop their own website. However, a study website will still need to be advertised in some 
manner as waiting for potential participants to find the site on their own may yield a low 
recruitment rate (Birnbaum, 2004). Therefore, many researchers looking to conduct Internet-
 71 
 
mediated research often avail themselves of the many types of pre-existing online groups to 
recruit participants.  
 The most basic type of group is a listserv: a mailing or discussion list that can be used to 
send email messages to a group of subscribers (Read, 2004). Chat group systems allow real-time 
(synchronous) connections via lines of text sent between members of the group whereas bulletin 
boards or newsgroups are a form of asynchronous communication. In these latter groups, 
members post series of messages related to an overarching theme or topic (Im & Chee, 2001; 
Mann & Stewart, 2000).  
 Another type of asynchronous interaction can be found at discussion boards or forums. 
These groups are typically located on larger websites targeted toward specific populations and 
serve as a place where individuals can post messages related to a particular topic. There are 
usually multiple topics, started either by group administrators or group members. Individuals 
belonging to the group post messages and responses under each topic, thus forming a thread or 
continuous string of messages related to the same topic. The various designs found at different 
websites add another contextual layer to the discussions that take place there and may influence 
the type of participant available for recruitment at each site (Im & Chee, 2001). Therefore, in 
order to determine the feasibility of obtaining an adequate sample size, the researcher should 
explore each potential recruitment site to understand the characteristics of group members and 
the dynamics of the group interactions. 
 A variant of the site-based discussion forum is a networking group. These are large 
websites specifically designed for fostering connections and communication among members. 
Some are primarily for social interactions while others may have a more professional purpose. 
Members of these groups typically have individual pages displaying personal or business 
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information, however there may also be special interest groups within these larger groups. 
Individual members may join or link to these subgroups for further networking opportunities, 
thus forming communities within communities (Golder, Wilkinson, & Huberman, 2007).  
 Recruitment through any of these groups most often involves posting a message about 
and/or a link to the study (Hamilton & Bowers, 2006; Walther, 2002). Interested group members 
would then seek out the researcher or study site for further information. It is important to 
understand however that some groups may have an administrator or moderator that has oversight 
of messages posted in the group. Therefore, prior to posting study information, researchers need 
to determine whether there is a group moderator and request permission from that individual to 
place recruitment information at that site.   
 Messages and postings advertising the study should conform to Netiquette, guidelines for 
courteous online interactions and behaviors, as well as any rules and regulations specific to each 
group (Mann & Stewart, 2000; Sharf, 1999). Because some of these group-based rules may not 
be expressly documented, it would again behoove the researcher to spend time ‗observing‘ the 
posting behaviors of group members to ascertain the interaction nuances of each group. 
Knowledge of group ‗rules‘ as well as the language and hierarchy of communication contributes 
to developing an understanding of the group‘s culture and therefore the setting (Murray & 
Sixsmith, 2002). 
 Internet Research. There are various ways by which a research project may actually be 
conducted via the Internet. As previously noted, an investigator may develop a website 
specifically for the study or instead may use a pre-existing site, such as a university website 
(which may be more convenient for investigators with limited website-building resources). In 
either instance, participants log onto this site to complete the research procedures (Birnbaum, 
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2001). This option may be particularly advantageous for online focus groups where participants 
may post synchronous or asynchronous responses to interview questions posed to the group 
(Selwyn & Robson, 1998). 
 Another option for Internet-based research is to send the qualitative and/or quantitative 
questionnaires electronically either as an email attachment or through an online survey program 
(Selwyn & Robson, 1998). In addition, qualitative researchers may choose to use established 
discussion boards as the setting for their research. One method is to copy text from ongoing 
discussions and posted messages which then become the database for an observational project. 
However, ethical concerns may arise if consent is not obtained from the forum participants as 
this may be seen as a violation of confidentiality (Cotton, 2003a; Eysenbech & Till, 2001; 
Murray & Sixsmith, 2002; Pittenger, 2003; Whitehead, 2007). Alternatives include either 
obtaining permission from the group to use their posts in the study or to begin a new thread or 
topic specifically for the study. This would necessitate approval from the moderator, if there is 
one, as well as a clear statement that by posting in that thread, members are consenting to the 
possible use of their statements for research purposes. 
 Issues in Internet Research. While the Internet offers many attractive options for 
conducting research, it also presents some challenges that need to be considered or addressed 
when deciding whether or not to use this setting for a research project. One advantage is that the 
Internet is more cost efficient in terms of time, money and effort: response time is faster, there is 
no need to wait for recordings to be transcribed, traveling to interviews and associated costs are 
eliminated, and asynchronous data collection reduces time constraints (Im & Chee, 2003). It is 
easier to maintain an audit trail and conduct member checks. Because there is less need to use 
office supplies, online research may also be more environmentally friendly. However, the 
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researcher must be very computer literate with access to additional resources for troubleshooting 
technical problems (Im & Chee, 2003). 
 Internet recruitment initiatives may help to target participants that are well-suited to 
provide answers to the specific research questions (Truell, 2003). However, this may also 
decrease the heterogeneity of the sample. While the Internet has penetrated more and more into 
United States culture, over a quarter of the population, primarily individuals from lower 
socioeconomic levels, are still not regular users (Fallows, 2005). These groups, often most in 
need of health services, are all too often under-represented in research samples thereby limiting 
knowledge of their health issues and health care needs. Women often comprise a large 
proportion of these groups. Internet-mediated research, therefore, has the potential to perpetuate 
women‘s marginalization (Im & Chee, 2001) and disparities in health research and health care. 
 Sample diversity may also be limited (coverage error) because people who have limited 
computer literacy skills, who don‘t express themselves well through writing or who prefer 
greater interaction between the researcher and participant may exclude themselves (Dillman, 
2007). On the other hand, for people too shy to consider face-to-face interviews or focus groups, 
online interviews provide a means for their voices to be heard, an issue especially pertinent for 
women (Illingworth, 2006). The Internet also confers a sense of anonymity not present with 
research conducted in person. It is actually possible that anonymity may promote freedom of 
expression and deeper revelation, even around sensitive topics (Murray & Sixsmith, 1998), and 
thus enhance the richness of the data (Illingworth, 2006). This actually proved to be the case in 
this study: wome were very open in their narratives about topics often deemed 'sensitive' in 
nature such as sexual and behavioral health issues.  
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 In addition to allowing women to discuss very personal issues, the Internet affords the 
researcher an opportunity to recruit potential participants who otherwise would be beyond their 
reach: those with limited transportation, for example, or even individuals from other countries 
(Eysenbech & Till, 2001; Liehr, Takahashi, Liu, Nishimura & Summers, 2004; Mann & Stewart, 
2000). Thus, while sample heterogeneity is a potential concern, this may be counteracted in part 
through the Internet‘s world-wide expanse allowing people, formerly ineligible because of 
personal or geographical constraints, to participate in the discovery of new knowledge.   
 Sampling issues are not the only concerns of the investigator developing an Internet-
based study: s/he will also need to decide on whether data collection will be through email, a 
website or a hybrid. Emails may have an advantage in that the participant can download the 
questions and respond at their own pace, allowing ample time for reflection (Hamilton & 
Bowers, 2006). However with email, consideration must be given to minimizing privacy risks. 
One option is to ask the participant to password protect the completed study materials if possible 
when returning them to the investigator (Hamilton & Bowers, 2006). Secure survey websites 
may provide better privacy and confidentiality protection but participants may not be able to 
complete the questionnaires in stages over time.  
 With online questionnaires, quantitative measurements may need to be reformatted to 
accommodate the online setting and instructions may need to be modified to align with the 
changes in format (Dillman, 2007). Depending on the extent of required revisions, the potential 
exists for these changes to impact on an instrument‘s psychometric properties (Whitehead, 
2007). Also, because of differences between computers—such as resolution and speed—the 
format the researcher sees may differ from what the participant sees (measurement error) 
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(Dillman, 2007). Pilot testing may be warranted for quantitative-dominant studies to evaluate 
reliability and validity of any instrument reformatted for Internet use.  
 The researcher collecting qualitative data must also decide whether to do so 
synchronously or asynchronously. Synchronous interviews or focus groups offer the advantage 
of ‗live‘ conversations occurring within close temporal proximity so that the flow of interactions 
is smoother. However, synchronous interactions may be more social and superficial (Hewson, 
2008) and more difficult to arrange when participants and researchers are located in different 
countries and time zones (as in this study). Time differences are not an issue with asynchronous 
data collection, however, and interruptions are also less likely to be of concern (Beck, 2005). By 
providing both participant and researcher more time to ponder and process their questions and 
responses, asynchronous interviewing may actually promote greater reflexivity and consequently 
enhance the rigor and trustworthiness of the study (Illingworth, 2006).   
 While some Internet research challenges, such as missing data, maturation and participant 
retention are common to all types of survey research, the way in which they are addressed may 
be different for Internet-mediated inquiry. For example, forced responses can minimize the 
potential for missing data (Dillman, 2007) while progress indicators may promote retention 
(Truell, 2003). In fact, because of the use of the above strategies, Internet surveys and 
questionnaires are known to have greater response completeness (Truell, 2003). Embedded 
equivalency questions, follow-up checks and critical appraisal of the informant‘s knowledge of 
the topic are strategies for establishing the authenticity of the participant (Mann & Stewart, 
2000). The potential for multiple submissions may be reduced by techniques such as sending the 
consent to the participant‘s address, only allowing access to the study site through a password 
and not allowing the participant to return to the survey site once the questionnaire is completed. 
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Closely evaluating participant responses, knowledge of the subject matter, and inconsistencies in 
writing style or narrative may help flush out an imposter or multiple authors (Dillman, 2007; 
Mann & Stewart, 2004; Murray & Sixsmith, 2002). The current study employed some of these 
strategies such as mailing the consent form to participants and restricting password access. 
 Lack of response is always a concern in conducting research. When using the Internet for 
recruitment, the interval for sending out follow-up invitations to join the study or other 
recruitment materials should be shorter: 4-7 days is considered appropriate. This short time span 
has been reported to almost double the response rate (Truell, 2003).  
 Unfortunately, it may be difficult to determine actual response rates with online research, 
unless the investigator is recruiting through a very specialized group or sending study invitations 
only to specific individuals. Because some people listed as group members may no longer be 
active in the group, or may misrepresent themselves, numbers of potential recruits may be lower 
than presumed. However, website groups may also be frequented by ‗lurkers‘—individuals who 
read posts and messages but are not yet group members—who may potentially be recruited by 
seeing a study advertisement (Im & Chee, 2001). Because the total pool of potential participants 
may not be able to be accurately determined, some studies report the number of inquiries as an 
alternative.  
 Another challenge facing the online qualitative investigator concerns the nature of the 
interactions. With face-to-face and even telephone interviews, the participant‘s responses—facial 
expressions, gestures, sounds, tone of voice, pauses and displays of emotion—are easy to 
recognize and record within the field notes. Emotional expression is more difficult to gauge 
when interviews occur online. The researcher must look for cues in the writing such as 
repetition, underlining, the use of strong language or symbols such as emoticons (Illingworth, 
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2006; Mann & Stewart, 2000). If these are not present, the researcher may need to resort to the 
use of probes such as ―How did you feel when you wrote that statement?‖  
 Qualitative research is intersubjective in that the researcher‘s perspective or voice is an 
essential component of all facets of the research process, influencing data collection, analysis 
and representation. The reflexive thoughts of the researcher actually become part of the data to 
be analyzed and the knowledge to be created. Trustworthiness or rigor of qualitative research is 
enhanced through the interaction of the researcher with the participants and the study data. While 
Internet-based research may facilitate data management and immersion, participant-researcher 
interaction may be less because of the lack of a physical or embodied presence (Illingworth, 
2006; Im & Chee, 2001). This is a particularly critical issue in feminist research which strives for 
reciprocal relationships between researcher and participants (Im & Chee, 2001). Practices such 
as frequently checking in, sending encouraging emails, and sharing personal insights or 
information can -- and did -- demonstrate the researcher‘s virtual presence and accessibility and 
maintained the participant-researcher connection (Mann & Stewart, 2000). 
 Researchers working from a feminist paradigm strive to decrease power inequities not 
only through their findings but also throughout the research process as well. Using the Internet 
for research on women‘s issues may promote a more equitable relationship between the 
participant and researcher (Im & Chee, 2001). For some people the Internet is more than a tool or 
a place to be with other people. Instead, it constitutes a primary and inseparable part of their 
being in the world, a virtual embodiment that becomes part of their authenticated selves. By 
choosing when, where and how they appear to others, women gain more power in the research 
relationship. They also have a greater sense of control over what they share as online 
communication affords them an opportunity to examine and edit their responses (Illingworth, 
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2006). Rather than restricting the depth of their responses however, the relative anonymity and of 
the Internet allows women to escape the isolation and restrictions of the non-virtual world, 
fostering a sense of freedom and comfort that empowers them to express themselves openly and 
passionately (Cotton, 2003; Illingworth, 2006). In addition to enhancing the richness of the data, 
this freedom of expression may potentially be cathartic and therapeutic as women allow their 
voices and emotions to be heard and validated (Illingworth, 2006).    
 The ability of the researcher to validate women‘s stories, conduct member checks and 
share study findings is enhanced through online research giving women a greater sense of 
ownership of the knowledge resulting from the research (Im & Chee, 2001). This mutual or co-
creation of knowledge is important in balancing the distribution of power between subject and 
researcher and it also provides women with a sense of purpose (Beck, 2005; Im & Chee, 2001). 
The women in Beck‘s Internet study on birth trauma (2005) reported that their desire to help 
other women was a key reason that they chose to tell their stories. This was also true of the 
women in this study. The belief that one is contributing to the development of knowledge that 
may help other women is especially salient for women considering whether or not to enroll in a 
research study. Women opt to participate in research when they possess both an awareness of the 
importance of their involvement and adequate resources for accessing the study, including 
considerations of time constraints (Brown, Long, Gould et al., 2000), which may be facilitated 
when recruitment and study procedures are online.  
 Relevance of the Internet for this Study. As noted earlier, the primary component of 
the proposed study was conducted via the Internet and incorporated both recruitment and data 
collection procedures. First, participants were recruited from a variety of women‘s social and/or 
menopause-focused websites including a listserv, website-based discussion boards and groups at 
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several professional and social networking sites (Appendic D). Using these pre-existing virtual 
communities increased the potential for obtaining a sample appropriate for the study purposes.  
 Secondly, the study incorporated both web-based and email data collection procedures. 
The study instruments were located on the University of Massachusetts Medical School 
(UMMS) Intranet website. The UMMS Survey Tool was an application developed over 10 years 
ago through the Information Services department for the purpose of conducting university-based 
surveys. It has also been used occasionally to conduct off-campus research including previous 
doctoral dissertation research. The researcher completed training in the use of this Survey Tool. 
 The Tool used a web language known as Cold Fusion for the actual survey questions as 
well as HyperText Markup Language (HTML) for additional comments or instructions. Both 
open-ended and preset response questions could be created and questions could be designated as 
required (forced response). All surveys were given an address or URL. Access to the survey 
could be designated as global or open to anyone on the Internet, however this carried the 
potential for a hacker to view participants‘ email addresses. Therefore the scope of the survey for 
this study was done by authentication, that is, a user ID and password created by the researcher 
was required to access this website in order to enhance security and decrease the potential for 
multiple entries. This user information, as well as the Survey Tool URL, was emailed to 
participants (Chabot, 2009, personal communication). Finally, follow-up (asynchronous) emails 
were used for clarification, additional questioning and member checks.  
 These online procedures offered more than just a convenient means for collecting data. 
By providing a setting for reflection and interaction (Illingworth, 2006), the Internet was in 
essence a unique virtual context that fostered intersubjectivity, reflexivity and the emergence of a 
rich description of the HT discontinuation experience. 
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Procedures 
Recruitment 
 Three strategies were used to recruit participants for this study. The primary recruitment 
efforts were through the Internet but were supplemented by traditional methods of community 
recruitment and snowball sampling. All recruitment initiatives continued until data saturation 
was attained. 
 Internet Recruitment. In addition to fostering social communities that can serve as the 
research setting, the Internet offers another advantage for researchers seeking to explore 
women‘s health issues in that women may be more likely to be recruited for research studies 
through the Internet than are men (Im et al., 2008). Because women need to believe that their 
participation provides some benefits (Brown et al., 2000) recruitment literature stressed the study 
purpose of obtaining information to ultimately develop methods to help other women through 
HT discontinuation. 
  The advertisements (Appendix E) describing the study and the inclusion criteria were 
posted on topic threads in the discussion boards and forums at several menopause-related 
websites (Appendix D). The researcher‘s contact information (phone number and UMMS email) 
was provided in the posting. The study was also posted at several professional (advanced 
practice clinicians and women's health) networking sites. 
 Although it is impossible to determine exactly how many members are at each site, it was 
estimated that the combined membership may be over 15,000, although as previously noted this 
number could vary up or down because of lurkers, inactive members, or women being members 
at multiple sites. Because of the large potential population, the postings were staggered to 
 82 
 
decrease the possibility that the researcher would acquire too many inquiries to permit 
responding in a timely fashion.  
 Women interested in participating contacted the researcher to obtain details about the 
study. Responders were screened by inclusion criteria. If eligible and willing to participate, they 
were mailed a fact sheet (Appendix F) with information about the study, two copies of the 
consent form (one to be signed and returned to the researcher and the other for their personal 
records), and a stamped self-addressed envelope for returning the signed consent. Once the 
signed consent was received, the participant was emailed the directions for accessing the UMMS 
survey website as well as a user name and password in order to open and respond to the 
interview and survey questions. 
 Recognizing that not everyone would wish to participate online, the researcher also 
offered the option of participation via telephone. The consent packet was mailed to potential 
telephone participants and when the researcher received the signed consent, the participant was 
called to arrange a mutual time for a telephone interview. The majority of the women who opted 
to participate in a phone interview first completed the quantitative component at the Survey Tool 
and then arrangements were made for the telephone component. 
 If a woman did not return the consent within seven to ten days (Dillman, 2007; Truell, 
2003), she was contacted by email or telephone to confirm continued interest in participating. If 
there was no response, the woman‘s name was removed from the list of potential participants. 
 Traditional Recruitment. In addition to posting advertisements on Internet sites, the 
researcher also used more traditional recruitments efforts as needed. For example, flyers 
(Appendices G & H) announcing the study were placed in community venues within Metrowest 
Massachusetts, an ethnically and socioculturally diverse area comprising communities west of 
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Boston, MA. Letters anf fact sheets (Appendix I) describing the study were also mailed to: health 
care providers (MDs, APCs, and CAM providers) in private practices in these and other 
communities and to Obstetric/Gynecology and/or Behavioral Health providers at UMass 
Memorial Medical Center (Worcester, MA) and Mount Auburn Hospital (Cambridge, MA).  
 Snowball Sampling. Snowball or chain sampling (Kemper et al., 2003) constituted the 
third form of recruitment. Participants were asked to refer other women to the study by giving 
the researcher‘s information to family members, colleagues or friends. In order to make this 
request, however, it was essential that the researcher garner the trust of the participant (Atkinson 
& Flint, 2001) through processes such as openness about the research process and purpose, 
‗listening‘ to cues and changes in tone, delicacy when dealing with sensitive topics, and reflexive 
self-disclosure (Mann & Stewart, 2000).  
 Participant Recruitment Summary. A total of 39 women were enrolled in this study. 
Four women were consented but did not complete the study: three were lost to follow-up after 
signing the consent and one withdrew because of a personal life crisis. One other woman was 
excluded from the study when it became apparent from her interview responses that she did not 
meet eligibility criteria (Figure 2). 
 Participants were recruited through a variety of the above methods: six heard of the study 
from their health care providers and one from a professional colleague of the researcher. Two 
women viewed recruitment cards left by the researcher in community settings. Six participants 
contacted the researcher after seeing an advertisement on professional websites and listservs for 
advanced practice clinicians and two participants were recruited through UMass. The remainder 
were recruited through postings on the Internet (Appendix H), primarily Craig's List (n = 12, 
37.5%) although three women heard of the study through postings on websites for menopausal 
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and midlife women and one woman did learn of the study through a Facebook advertisement. 
Advertising the study online greatly expanded the geographical area from which to recruit 
potential participants. The final sample consisted of 34 women from eighteen states and Canada 
(Appendix  J) .  
 Thirty of the 34 participants completed both the online questionnaire and the follow-up 
questions. Sixteen out of these 30 women completed the follow-up questions online and the 
remainder chose to participate in a telephone interview to answer the follow-up questions. 
Twenty-five participants from the entire sample of 34 women also completed the member check. 
Four participants completed only the questionnaire and were unable to respond to the follow-up 
questions due to time constraints or health-related issues, although two of them did complete the  
Member Check (Figure 2). 
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Figure 2. 
 Enrolllment Flowchart 
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Data Collection, Recording and Management 
 In qualitative and certain typologies of mixed methods research, data collection, 
recording and management are done simultaneously with data analysis. However, for the purpose 
of clarification, each process will be discussed separately. 
 Data Collection. As previously noted, women who consented and chose to participate 
online were instructed how to access the study at the UMMS Intranet website. The researcher 
also offered to answer any additional questions prior to the subjects‘ logging into the website. 
Each subject first completed the demographic questionnaire, then the interview guide and finally 
the quantitative instruments (Floyd, 1993). They were also asked if it would be permissible to re-
contact them for more information, clarification or member checks, as well as their preferred re-
contact medium. 
 At the time of the scheduled telephone interviews, scheduled after the participant had 
completed the quantitative questions online, the researcher again offered to answer any questions 
the participant may have had before beginning the interview. These participants were then 
queried as to whether and how they could be contacted at a later time for member checks or 
additional questions. 
 After each subject completed the questions, either online or by telephone, the researcher 
reviewed the responses for completion and developed further questions or probes based on the 
participant‘s initial responses. The researcher then emailed or phoned participants to clarify 
responses, elicit further details or examples, or probe for more information. It was anticipated 
that participants may need to be re-contacted between one to three times (Beck, 2004; 
McDonough, 2007) in order to achieve a comprehensive understanding of their experiences and 
this was indeed the case. However, because of the brevity of many women's reposnses to teh 
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open-ended questions, it was often necessary to send a series of further prompts and probing to 
the participants to obtain an adequate amount of data. Several of these women chose to 
participate in a telephone interview in order to respond to the questions in more depth leading to 
the need to conduct more telephone interviews than was first anticipated. 
 Retention. One potential concern is retention of participants through the follow-up 
email/telephone process. In face-to-face interviews, silences or pauses during the conversation 
may indicate that a participant is processing or reflecting upon a question. Silences also exist 
with online or telephone studies in the form of non-response to follow-up emails or telephone 
calls but the reason for these silences may be more difficult to ascertain. Lack of a quick 
response may not necessarily indicate a lack of interest in continuing with the study but rather 
competing issues such as busy schedules, technological complications or even the need to take 
time for deeper reflection. Periodic, reassuring emails or calls to ‗check-in‘ may be helpful to 
both facilitate trust and gently prod toward re-contact (Mann & Stewart, 2000). Participants who 
did not respond to check-in calls or emails after one-two weeks were sent an email or called to 
confirm or decline continued participation in the study.  
 As an additional incentive to enhance retention, participants were informed prior to and 
as part of the consent process that follow-up questions may be a part of the study process. They 
indicated whether they were willing to grant permission for the researcher to re-contact them 
after their initial responses. They were also informed at enrollment that compensation would be 
provided ($20 Amazon gift certificate) to participants who completed all components of the 
survey as well as any follow-up communication. 
 Data Recording. Unlike studies incorporating face-to-face interviews or focus groups to 
collect data, this study had less need for recording verbal communication as most of the 
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interviews were completed online. Telephone interviews or follow-up conversations were 
digitally recorded; these recordings were then transcribed by a professional transcriptionist.  
 The researcher also recorded field notes after each interview and maintained a reflexive 
journal to record decisions made during the course of the research. Field notes contained 
observations pertinent to each interview and provide additional context for analyzing women‘s 
experiences for HT discontinuation. For the telephone interviews, these notes included the date, 
time and length of each interview (also noted on the digital file) as well as the participant‘s tone 
of voice and any significant reactions (such as pauses or crying) to specific questions. 
Observations relevant to the online interviews were also recorded: the date and time the 
interview was posted, length of each interview and any cues as to the participant‘s reactions such 
as emoticons or words or phrases that are underlined, italicized or capitalized. The researcher‘s 
own impressions of reading or listening to each interview were also documented. In addition, the 
researcher also included information gathered from observations of the websites where 
participants were recruited, such as a description of the site, its purpose, topics discussed and the 
relative frequency of activity on the site. 
 In addition to the field notes, the researcher maintained a reflexive journal throughout the 
study recording insights, reflections and decisions made about and throughout all facets of the 
research process. Journal entries included notations relevant to the analysis of the data, 
modification of the interview guide or codebook or steps taken to prevent premature closure.  All 
memos, notes and journal reflections were maintained in a notebook and will ultimately be 
transcribed and incorporated into the database.   
 Data Management. The third facet of this interactive data triad is data management, a 
term that refers to the manner in which the data is prepared for analysis (Knafl & Webster, 
 89 
 
1998). Typically, data management consists of devising and adhering to a system of organizing 
the data and should be developed early in the study (Burns & Grove, 2005; Merriam, 2009). In 
the past many researchers did this by hand with elaborate index card systems, although now 
qualitative data management is often enhanced by the use of computer assisted qualitative data 
analysis systems (CAQDAS) (Burns & Grove, 2005).  
 For the current study, the NVivo (initially version 8, later replaced by version 9) system 
was used for qualitative data management as well as to merge the quantitative and qualitative 
data for the integrated analysis. NVivo is a sophisticated CAQDAS for storing, organizing, 
analyzing and retrieving data. Documents, such as journal articles, interview data, field notes and 
even this proposal can be stored in NVivo ‗folders‘and grouped according to their eventual 
utility. In NVivo, ‗nodes‘ are storage areas that contain data. Two types of nodes, case nodes and 
tree nodes—were used. Each participant in a study constitute  a ‗case‘ and all materials relevant 
to that participant, including attribute data such as age and ethnicity are stored in a case node. 
Tree nodes, on the other hand, are hierarchically structured and are used to organize and 
structure emerging ideas and relationships; all data pertinent to particular codes can be filed in 
tree nodes and linked to the source documents which also promotes ease of retrieval of both 
coded and source materials (Bazeley, 2007). The node structure also provides a visual 
mechanism for ascertaining data saturation: when no further nodes are being developed, 
saturation is achieved. Field notes as well as methodological and reflexive memos can also be 
stored in folders, coded and entered into tree nodes. Furthermore, all documents are date and 
time stamped (Bazeley, 2007) which results in a chronology of the researcher‘s decision-making 
processes that is transparent and traceable. 
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  Prior to data collection, an NVivo shell or framework was created with nodes for cases as 
well as folders for field notes and memos. An NVivo codebook (Krippendorff, 2004; Nuendorf, 
2002) was developed based on the concepts of the organizational framework (Woods & Mitchell, 
2005). The codes from the codebook were entered into the framework as tree nodes. Codes that 
emerged inductively from the data were added as data analysis progressed. Collected data, 
transcripts of telephone interviews and narrative text from online interviews  were copied into 
case nodes. Pertinent, field notes and reflexive journal entries were also included in the analysis.  
 A statistical analysis software program, PASW 18 (Predictive Analytics Software, 
formerly known as SPSS), was used for the quantitative data. The quantitative variables were 
also entered into NVivo as case attributes; they were used in the integrated analysis and 
comparison of qualitative and quantitative findings both within and across cases as well as across 
strata (Bazeley, 2007). 
 All electronic data—both quantitative and qualitative—as well as the codebook and the 
data inventory were saved on a separate hard drive. The hard drive, the digital recorder, consent 
forms, the field notes and the reflexive journal were kept in a locked file cabinet in the 
researcher‘s office. 
Measurements 
Specific Aims and Measures 
 This inquiry employed both quantitative and qualitative measurements to address the 
specific aims of the study although not every aim was addressed by both types of measures 
(Table 10). The specific aims were to:  
1) explore women‘s experiences of HT discontinuation—the qualitative semi-structured 
interview elicited information about women‘s lives during and after discontinuing HT 
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including recurrent symptoms as well as similarities and differences between women‘s 
initial menopause experience and that of HT discontinuation;  
2) describe the personal characteristics and sociocultural contexts that influence symptom 
perception, evaluation and response among women who have attempted to discontinue 
HT—both the interview questions and the demographic/QOL measurements were used to 
identify factors that may influence women‘s experiences during discontinuation and 
whether they stopped or resumed HT;  
3) explore the impact of HT discontinuation on women‘s quality of life—various facets 
of QOL were explored and compared through the use of  both quantitative and qualitative 
measurements; and  
4) discuss women‘s preferences for counseling and support during HT discontinuation—
open-ended interview questions were employed to examine the type and source of 
counseling or support women received as well as what information and support women 
desire to prepare them for this experience.   
The online survey began with the demographic questionnaire followed by the open-ended 
interview questions. Upon completion of the narrative responses, participants responded to three 
short quantitative measures: the Menopause Rating Scale, the Hot Flash Related Daily 
Interference Scale and the Well-Being Scale. These instruments are described next, beginning 
with the quantitative measures. 
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  Table 10.   
Relationship of Research Questions, Specific Aims, Conceptual Framework & Operational Definitions  
RESEARCH 
QUESTIONS 
SPECIFIC AIMS 
CONCEPTIUAL 
FRAMEWORK 
CONCEPTUAL 
DEFINITION 
OPERATIONAL 
DEFINITION 
What is the experience 
of discontinuing HT? 
Explore women‘s 
experiences of HT 
discontinuation 
Symptom 
experience 
Symptom 
perception 
Awareness of 
symptom frequency 
& intensity 
Qualitative 
Interview 
 
Menopause 
Rating Scale 
Symptom 
evaluation 
Judgements about 
symptoms‘ 
seriousness, 
treatability, causes & 
consequences 
Symptom 
response 
Feelings, thoughts or 
behaviors that occur 
as a result of the 
symptoms 
What factors do women 
identify as making this 
experience more or less 
manageable? 
Describe the 
personal 
characteristics and 
sociocultural 
contexts that 
influence symptom 
perception, 
evaluation and 
response among 
women who have 
attempted to 
discontinue HT 
Personal characteristics 
Genetic, molecular & 
physiologic factors 
that may contribute 
to symptoms 
Qualitative 
Interview 
 
Demographic 
Questionnaire 
 
Menopause 
Rating Scale 
 
Hot Flash-Related 
Daily Interference 
Scale 
Sociocultural context 
Ethnic, cultural & 
social factors that 
may contribute to 
symptoms 
How does HT 
discontinuation impact 
on women‘s QoL? 
Do the reports of QoL 
among women who have 
attempted to discontinue 
HT differ depending on 
which dimension of QoL 
is being measured? 
Explore the impact 
of HT 
discontinuation on 
women‘s quality of 
life 
Symptom evaluation: 
quality of life 
Global sense of life 
satisfaction or well-
being encompassing 
physical, social, 
psychological and 
spiritual domains 
Qualitative 
Interview 
 
Menopause 
Rating Scale 
 
Hot Flash-Related 
Daily Interference 
Scale 
 
Well-Being Scale 
 
General Health 
and QoL 
Questions 
What information do 
women need to help 
them manage symptoms 
and maintain health 
during and after HT 
discontinuation? 
Discuss women‘s 
preferences for 
counseling and 
support during HT 
discontinuation 
Symptom response: 
seeking information  
Sources and 
adequacy of health-
related information 
Qualitative 
Interview 
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Quantitative Instruments 
Demographic Questionnaire. A questionnaire was developed to collect 
demographic/health information from each participant (see Appendix K). Requested information 
included: age, race/ethnicity, marital status, level of education, occupation, financial strain, 
gravity and parity, number of children, age at menopause, type of menopause, type(s) of HT, 
duration of HT use and the type of health care provider seen for menopause-related care. The 
responses were used to describe the sample however, given that the organizational framework 
includes constructs such as ethnicity, these data were also included in the analysis of factors 
influencing HT discontinuance. 
Menopause-Specific QoL Measures: Menopause Rating Scale. The Menopause 
Rating Scale (MRS) is an 11-item questionnaire encompassing three domains/subscales 
(somatic, psychological and urogenital) of menopause-related symptoms (Appendix L) 
(Schneider, 2002).  Each item represents a symptom or complaint and is rated on a five-point 
Likert scale of severity ranging from 0 (no symptoms) to 4 (very severe symptoms). The severity 
point values of items in each subscale are summed to obtain a score for the three separate 
dimensions. Subscale scores are then added together for the composite or total score (Klaas 
Heinemann et al., 2004; H. P.  Schneider, 2002; H. P. Schneider & Behre, 2003; Zollner, 
Acquadro, & Schaefer, 2005). Higher scores reflect more severe symptoms and supposedly 
diminished QoL. 
In this study, the MRS served a two-fold purpose. First, it helped to compile a list of 
women‘s symptoms and which of those symptoms were most troublesome. While it was 
anticipated that the open-ended interviews would also extract a list or description of the 
symptoms each woman experiences, the MRS may have enabled women to recall symptoms not 
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mentioned in their narratives and occasionally alerted the researcher to probe further about 
symptoms checked but not described. By enhancing the depth of information obtained, the MRS 
also promoted rigor. 
 The second purpose for the MRS was as a QoL measure. Because symptoms are one 
dimension of QoL, symptom information obtained through the MRS was germaine to Specific 
Aim #3 which sought an understanding of how the different dimensions of QoL are affected by 
HT discontinuance.   
 The MRS was developed in Germany in 1992 in response to a growing dissatisfaction 
with existing menopause symptom/QoL measures (Greene, 2002; H. P. Schneider & Behre, 
2003; Zollner, et al., 2005). Items were generated from the developers‘ expert opinion based on 
their clinical practice and also through comparisons to existing instruments (Zollner, et al., 
2005). Initially designed to be administered by the clinician/researcher, the MRS underwent 
further testing in 1996 using a sample of 689 German women 40-60 years of age and was 
adapted into a self-administered format (Heinemann, 2007). It has since undergone extensive 
psychometric testing. 
Factor analysis in a large (over 10,000 women) HT post-marketing study using Varimax 
rotation yielded a four-factor model—Hot Flushes, Soma, Urogenital and Psyche--explaining 
72.2% of the variance (H. P. Schneider, Rosemeier, Schnitker, Gerbsch, & Turck, 2000). Re-
evaluation of the four-factor model and follow-up factor analyses in the same sample at three and 
six month post-treatment intervals led to Hot Flushes and Soma being combined into a Somatic 
subscale (Potthoff, Heinemann, Schneider, Rosemeier, & Hauser, 2000). The other two 
dimensions were renamed ‗Psychological‘ and ‗Urogenital.‘ The three-factor model explains 
59% of the variance and is more stable (H. P. Schneider, Rosemeier, et al., 2000). This same 
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factor structure (Principal component analysis, Varimax rotation) was observed in other large 
multi-nation samples (N = 10297) however the subscale correlations are moderate (r = 0.4 – 0.7) 
when compared to subscale scores (0.7-0.9) suggesting that the subscales are not as independent 
as the factor analyses demonstrate (Heinemann et al., 2004). Thus it may be preferable to use the 
total and not the subscale scores (Heinemann, 2007).  
Internal consistency reliability of the MRS has been good in multiple samples with 
Cronbach‘s alpha ranging from 0.55 to 0.9 for subscale and 0.83 to 0.88 for total scores 
(Heinemann, 2007). Test-retest reliability (Pearson‘s correlation coefficient) ranges from 0.74 to 
0.82 suggesting acceptable consistency of the MRS across time and multiple populations 
(Heinemann, 2007; Schneider et al., 2000b; Zollner et al., 2005). Domain scores do differ 
slightly in some regions which implies that cultural factors may influence a woman‘s perception 
of symptom severity (Heinemann et al., 2004; Heinemann, 2007). 
 Concurrent validity was assessed through a comparison of the MRS with both the 
Kupperman Index (KI), an older menopause symptom scale, and the Short Form-36 (SF-36) a 
QoL measurement.  Both Kendall‘s tau (t-b = 0.75; 95% CI [0.71-0.80]) and Pearson coefficients 
(r = 0.91; CI [0.89-0.93]) (DeVellis, 2003) between the MRS and KI were quite acceptable and  
statistically significant (H. P. Schneider, Heinemann, Rosemeier, Potthoff, & Behre, 2000). 
Associations between the SF-36 domains most relevant to midlife women, somatic (t-b = -0.43, 
95%CI [-0.52, -0.35]; r = -0.48, 95% CI [-0.58, -0.37]) and psychological (t-b = -0.49, 95%CI [-
0.56, -0.41]; r = -0.73,  95% CI [-0.81, -0.65]), and the MRS were also good although 
correlations were lower for other SF-36 domains (H. P. Schneider, Heinemann, et al., 2000). The 
correlations between the SF-36 domains and the MRS prompted the scale developers to describe 
the MRS as a measure of menopause-related QoL. 
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The investigators also looked at the predictive ability of the MRS. By comparing 
‗successful‘ and ‗not successful‘ ratings by both the MRS and physicians, sensitivity (correct 
prediction of a positive assessment) and specificity (correct prediction of a negative assessment) 
were determined to be moderate at 70.8% and 73.5% respectively (K. Heinemann, Assmann, 
Mohner, Schneider, & Heinemann, 2002). 
The MRS is often used as an outcome measure in studies evaluating the efficacy of 
treatments to reduce menopause symptoms, for example, in several German clinical trials of 
alternative herbal remedies, such as Black Cohosh (Frei-Kleiner, Schaffner, Rahlfs, Bodmer, & 
Birkhauser, 2005; Kowalcek, Rotte, Banz, & Diedrich, 2005; Osmers et al., 2005; Uebelhack et 
al., 2006; Wuttke, Seidlova-Wuttke, & Gorkow, 2003). It has also been employed in population-
based studies assessing menopause symptoms (Kakkar, Kaur, Chopra, Kaur, & Kaur, 2007; 
Monterossa, Blumel & Chedraui, 2007). The MRS has been successfully translated and 
culturally-adapted into other languages: English, Spanish, French, Indonesian, Swedish, Turkish, 
Brazilian, and Mexican/Argentinian. The various language versions of the tool are available on 
the internet (L. Heinemann, Potthoff, & Schneider, 2003). 
 The strengths of the MRS include its simplicity and ease of administration and scoring 
(Zollner, et al., 2005). It can be completed in less than ten minutes thus it does not impose undue 
participant burden (Heinemann, 2007). Because the MRS is self-administered, possible threats to 
validity such as investigator-participant interaction and socially desirable responses are reduced. 
Weaknesses include: lack of items to assess irregular bleeding and inability to distinguish 
between true and placebo effects (K. Heinemann, et al., 2002). Also potential difficulty 
differentiating between anxiety and irritability items as well as severe and very-severe ratings 
and assymetry of responses can result in a negatively skewed depiction of menopause symptoms. 
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In fact, when the MRS was compared to the KI, menopause symptoms were attributed more 
often into the moderate and severe range by the MRS (68%) than by the KI (24%) which 
underscores the need for caution when equating symptom checklists with QoL. 
 Menopause-Specific QoL Measures: Hot Flash-Related Daily Interference Scale. In 
this study, the Hot Flash-Related Daily Interference Scale (HFRDIS) (Appendix M) was used as 
an another QoL measure assessing interference in function. An essential component of QoL, 
functional status is defined as a person‘s ability to perform daily living tasks. Function can be 
subdivided into four domains—physical, psychological, social and role—although this list is not 
necessarily exhaustive (Bredow & Peterson, 2004). Symptoms are an important factor in an 
individual‘s functional status, but other factors, such as physical environment or family support, 
may also contribute to the perception of functional ability or disability (Bowling, 2005; Bredow 
& Peterson, 2004). People who have adjusted to a condition or symptoms may no longer 
describe them as restrictive or interfering with day-to-day functions. This may help explain why 
some people with many symptoms still score high on overall QoL measures (Bowling, 2005).     
This seemingly paradoxical pattern of experiencing more symptoms yet reporting a good 
overall QoL has also been observed in the menopause literature. In some studies, the QoL of 
women with severe symptoms is not significantly worse that that of women whose symptoms are 
mild (Carpenter et al., 1998) which may be related to the impact of menopause symptoms on a 
woman‘s functional capacity. However, while menopause symptom/QoL checklists may 
catalogue the frequency and severity of symptoms, they typically do not elicit the degree to 
which symptoms disrupt or interfere with a woman‘s daily functioning.  
The HFRDIS was developed to be a menopause-specific measure of the impact of VMS 
on both functional ability and QoL (Carpenter, 2001). It is a 10-item scale that measures the 
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degree to which VMS interfere with nine daily functions—work, social and leisure activities, 
interpersonal relationships, sleep, mood, concentration, sexuality and enjoyment of life—as well 
as overall QoL (Carpenter, 2001). Each item is scored on a 11-point Likert scale ranging from 0 
(do not interfere or no VMS) to 10 (completely interfere). Responses are based on symptom 
experience over the previous two weeks. Scores for each item are summed then the mean score is 
calculated. A higher overall score (0-3 = mild, 4-6 = moderate, 7-10 = severe; personal 
communication with Dr. J. Carpenter) is indicative of greater interference on daily life and 
potentially worse QoL (Carpenter, 2001; Carpenter & Rand, 2008).  
Two scales assessing the impact of pain or fatigue on daily activities, the Brief Pain 
Inventory and the Fatigue Symptom Inventory, were used as models for the development of the 
HFRDIS (Carpenter, Johnson, Wagner & Andrykowski, 2002). Psychometric testing of this 
instrument was conducted using a sample of 100 women (54 breast cancer survivors and 46 
comparison women) who completed the scale twice (Times 1 and 2) at a six-month interval. 
Internal consistency reliability was examined at both points. Inter-item correlations ranged from 
0.55 to 0.90 (Time 1) and 0.59 to 0.95 (Time 2). Item-total correlations at Time 1 were between 
0.77 and 0.93 and at Time 2 the range was 0.82 to 0.93 (all correlations significant at p < .01).  
Cronbach‘s alpha was the same (0.96) at both measurements points (p < .001 for all). Test-retest 
reliability was not done because of the great potential of VMS to change over time (Carpenter, 
2001). 
Convergent validity of the HFRDIS was mixed: correlations (p < .01 for all) with overall 
VMS severity and bother ratings were high at both time points (r = 0.51 - 0.81) and moderate for 
diary-related frequency and severity (r = 0.33 – 0.69). However, there was only weak-to-
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moderate correlation with symptom duration (r = 0.11 – 0.56) implying that duration is not as 
much a factor in VMS interference as are frequency, severity and bother (Carpenter, 2001). 
At both time points, the HFRDIS scores were higher among women experiencing VMS 
than those who were asymptomatic when compared by t tests (p < 0.001 for all) demonstrating 
known-groups validity. Although interference scores were higher for items pertaining to mood, 
sleep and concentration, all items were affected to some degree by VMS. In addition, the 
HFRDIS scores of women whose VMS increased in frequency between time points were higher 
at Time 2 (F = 8.75, df = 2, p < 0.001) indicating that the scale is sensitive to change in VMS 
interference over time (Carpenter, 2001). 
The Positive and Negative Affect Scale (PANAS) and Profile of Mood States-Short Form 
(POMS-SF) were used to assess construct validity. As could be expected, women‘s scores on the 
HFRDIS at both time points were negatively correlated with positive affect (r =  -0.14 to –0.40) 
and vigor (r =  -0.14 to –0.38) and positively correlated with mood disturbances (r = 0.18 to 
0.52) and negative affect (r = 0.28 to 0.54)  (p < .001 for all correlations). The low-moderate 
level of these correlations suggest that the construct measured by the HFRDIS—interference—is 
not collinear with mood or affect (Carpenter, 2001).  
A subsequent secondary data analysis using Semantic Equation Modeling (SEM) lent 
additional support to some of the psychometric properties of the HFRDIS (Cronbach‘s alpha = 
0.94) showing moderate correlations between interference and symptom severity (r = 0.52, p < 
0.01). In the SEM, interference was predicted by symptom severity (0.66) and in turn predicted 
both positive (-0.56) and negative (0.75) affect (p < 0.01) suggesting that interference as 
measured by the HFRDIS may be a useful outcome index (Carpenter & Rand, 2008).  
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Because it is a relatively new instrument, the HFRDIS has not yet been used extensively 
in the literature although a few recent studies have used the tool to evaluate treatment strategies 
for menopause symptoms. In a randomized-controlled trial (N = 93) testing the effectiveness of 
an herbal supplement for relief of VMS, the HFRDIS demonstrated good test-retest reliability (r 
= 0.76, p < 0.05, two-tailed). Intraclass correlation coefficients were also calculated (r = 0.76, p 
< 0.01) further supporting the reliability of the HFRDIS (van der Sluijs, Bensoussan, Chang & 
Baber, 2009).  It was also used in a pilot study exploring the effects of yoga on menopausal 
symptoms (Booth-LaForce, Thurston & Taylor, 2007) however no reliability data were reported.  
Generic QoL Measures. As previously noted, situation-specific or symptom measures 
alone may not be sufficient for developing a comprehensive understanding of such a complicated 
construct as QoL (Utian, 2005; Wiklund, 1998). The addition of generic health and QoL indices 
complemented the menopause-related QoL measures and provided an opportunity to compare 
the results of both types of measures for each woman discontinuing HT. The use of generic 
measures also allowed for direct comparison of health and QoL measures between HT users and 
non-users (Taylor, MacLennan & Avery, 2006).    
General Well-Being Subscale. Outcome measures in both research and health care tend 
to focus on negative experiences, such as complications, symptoms, even morbidity and 
mortality, or on individuals experiencing deviations from health (Bowling, 2005; Stewart, Ware, 
Sherbourne & Wells, 1992). This is very much in evidence in the menopause specialty where 
much research has been done using symptom checklists and conducted on women experiencing 
troublesome symptoms. As a result, the messages from the literature convey a sense of 
menopause as a negative and distressful experience (Smith-DiJulio, Woods & Mitchell, 2008).  
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Yet many women view menopause as either a natural life event or a positive transition 
suggesting that there is more than one perception of menopause. Indicators of positive 
experiences and outcomes are necessary for restoring balance to the overall perspective of QoL 
(Bowling, 2005). In an effort to counteract the negative connotations associated with menopause, 
some researchers have chosen to measure well-being in women during the menopause transition 
(Dennerstein, Lehert & Guthrie, 2002; Smith-DiJulio et al., 2008).  
      Well-being is considered to be a subjective measure of an individual‘s perceptions of 
their life. It has two separate but related concepts: subjective well-being (e.g., happiness, life 
satisfaction, morale) and psychological well-being (e.g., personal growth, mastery, autonomy) 
(Bowling, 2005). The emphasis of well-being is on positive dimensions of function, not 
symptoms or illness (Smith-DiJulio et al., 2008), thus a well-being scale will provide a 
counterbalance to the more symptom-focused measurements.    
 The four-item subscale to be used in the proposed study is a part of the General Well-
Being Schedule (GWB) developed by Dupuy in 1977 for use in the US Health and Nutrition 
Examination Survey (HANES). The total GWB scale measures both positive and negative 
feelings, states or affect which reflect six dimensions: positive well-being, self-control, vitality, 
anxiety, depression and general health. While much of the initial psychometric analyses have not 
been reported, subsequent studies using the GWB reported high internal consistency reliability 
alphas, ranging from 0.88 to 0.95 (Bowling, 2005; McDowell, 2006). Data from studies 
representing 18 countries and 16 languages (N = 8356) was pooled by the International QoL 
Outcomes Database group; alpha values for all six dimensions of the scale were above 0.7 with 
inter-item coefficients above 0.4  (McDowell, 2006). Test-retest reliability has been lower, 0.68 
to 0.85, perhaps reflecting changes in subjects over time (Monk, 1981). 
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 The GWB has also been shown to have adequate validity with construct validity ranging 
from 0.47 to 0.78. When measured against various depression and anxiety scales, the average 
predictive validity correlations were 0.69 and 0.64 respectively (Bowling, 2005; McDowell, 
2006). In addition, the correlation between the Affectometer, a scale measuring overall happiness 
and well-being, and the GWB was 0.74 (Bowling, 2005).  
In discriminant validity testing, the correlation between the GWB and somatic and 
psychological problem indices was 0.73. Symptoms and self-perceptions of health explained 
31% of the variance in the scores on the GWB (McDowell, 2006) suggesting symptoms alone 
cannot be used as a measure of QoL or well-being. 
Although the overall GWB is often broken down into six possible subscores based on the 
initial proposed dimensions, factor analyses have resulted in other GWB models with 3 or 4 
factors (Bowling, 2005; McDowell, 2006). Because of inconsistent factor analyses and high 
ratings of internal consistency, a recent report (Taylor, Poston, Haddock et al., 2003) has 
suggested that the GWB is unidimensional. Nonetheless, subscales reflecting the six dimensions 
have been used in the literature to assess any or all of the six dimensions. Correlations between 
these subscales and various criterion measures have been mostly good, ranging from 0.65 to 
0.90. Data pooled from a large (n = 8536) international database representing 18 countries and 
16 languages shows alpha values of over 0.7 for all six dimensions (McDowell, 2006). 
The GWB was modified and incorporated into the RAND Mental Health Inventory as 
part of the Health Insurance Study and the later Medical Outcomes Study. A factor analysis 
based on 1209 respondents corroborated the six factor structure (McDowell, 2006). Internal 
consistency scores for the subscales ranged from 0.72 to 0.88. In particular, the well-being 
subscale had an internal consistency (Cronbach‘s alpha) of 0.83 and a one week test-retest 
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reliability of 0.74 (n = 437).  Well-being in general was highly correlated with health: 0.83 
(Brook et al., 1979). Further testing showed an internal consistency coefficient of 0.92, M = 59.2, 
SD 24.3, N = 2862) (Hays, Sherbourne & Mazel, 1995; Stewart et al., 1992). 
One of the benefits of this scale is that it does not include references to physical 
symptoms associated with emotional health issues so there is less likelihood of misinterpretation 
of findings (Bowling, 2005; McDowell, 2006). In fact, psychometric testing demonstrates low 
correlations with physical functioning (r = .14) (Hays et al., 1995) therefore it provides some 
counterbalance to the previous instruments which focus on physical symptoms. In keeping with 
the intent to measure positive aspects of health, the subscale used contains only positively 
worded items (see Appendix N). Participants are asked to respond based on how they have been 
in the past month and their responses are made on a scale of 0 – 5 with higher scores indicating 
higher well-being. A similar well-being scale was used in the Seattle Midlife Women‘s Health 
Study (N = 334) where, between the years 1990 to 2006, alpha ranged from 0.82 to 0.89 (Smith-
DiJulio et al., 2008).  
Measures of Overall QoL and Health. In order to provide a comprehensive 
understanding of QoL through HT discontinuation, overall and health-related QoL (HRQoL) 
were also measured. In essence, both of these concepts are highly subjective and represent a 
synthesizing of multiple and interacting dimensions such as symptoms, function, life satisfaction 
or morale, thus no one clear definition of these concepts has been deemed sufficient or 
acceptable to all disciplines. Despite this lack of a standardized definition, both are widely used 
as outcome measures in clinical research. 
Simplistically speaking, HRQoL refers to an individual‘s general health perceptions or 
assessment of overall health (Bowling, 2005; Ferrans, 2007). It is a valuable adjunct in symptom 
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research: for example, in intervention studies differences between the symptom responses and 
HRQoL responses can point toward the presence of some other mediating factor warranting 
further exploration. The term HRQoL is often used interchangeably with QoL, especially in 
health care research, however, HRQoL is actually a subdimension of overall QoL. Overall or 
global QoL is considered the endpoint or summation of all the other dimensions and may also 
incorporate elements such as material resources and/or spirituality (Bowling, 2005; Ferrans, 
2007; McDowell, 2006).  
Both QoL and HRQoL are commonly measured by single-item questions that require the 
respondent to evaluate his/her life or health in order to choose the best response. The benefit of 
this approach is that it allows participants to respond based on the criteria or dimensions most 
salient in their lives at that moment, rather than on fixed dimensions important to the scale 
developer or researcher (Ferrans, 2007; McDowell, 2006). Therefore, in this study, QoL and 
HRQoL were measured through two global questions drawn from the WHOQOL-BREF Scale 
(Appendix O).  
As implied by the title, the WHOQOL-BREF is an abbreviated form of the WHOQOL, a 
100-item scale developed by the World Health Organization to assess overall QoL. Rather than 
just reporting symptoms or functional ability, the WHOQOL seeks to determine the impact of 
these dimensions on QoL, taking into account the physical, psychological, spiritual, social, 
cultural and environmental status of the respondents (McDowell, 2006). It contains four items 
for each of 24 facets of QoL plus four general items (Bowling, 2005) and over multiple studies 
has shown good internal consistency reliability (Cronbach‘s alpha 0.72 – 0.88) and concurrent 
validity with the SF-36 (0.6 – 0.7) (McDowell, 2006). 
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The WHOQOL-BREF is a 26-item derivation of the 100-item scale, with one item for 
each of the 24 QoL facets and two global questions (the two global questions are not 
incorporated into the scoring of the scale). Psychometric testing of the WHOQOL-BREF shows 
good internal consistency reliability ranging from 0.66 to 0.85. Four week test-retest reliability 
alphas ranged between 0.64 to 0.79. The abbreviated scale correlates well with the WHOQOL 
(alpha = 0.82 – 0.95) and captures 95% of the variance in the total facet score of the longer scale. 
Factor analyses yielded a four-factor model and mean scores and standard deviations are 
available as reference standards for 23 countries (McDowell, 2006). 
Despite their simplicity and subjectivity, single-item summary ratings in general have a 
strong correlation with mortality, even when other risk factors are controlled (McDowell, 2006).  
For example, among women rating their health as poor, the adjusted odds ratio for the prediction 
of four-year mortality was 3.0 – 3.2 (Idler, Kasl & Limke, 1990) indicating strong predictive 
validity. Test-retest reliability correlations on various summary self-rating questions indicated 
kappa coefficients of 0.86 for overall QOL and 0.69 for physical health (McDowell, 2006).  
In this study, the first global question asked the individual to rate her overall QoL while 
the second asked for an assessment of satisfaction with health. Responses are rated along a five-
point scale although the answers differ for each question. For the overall QoL item, responses 
range from 1 = very poor to 5 = very good while the health-related question options range from 
1 = very dissatisfied to 5 = very satisfied (McDowell, 2006).   
Qualitative Interview Guide 
Semi-structured interviews using open-ended questions sought to elicit an in-depth 
description of women‘s experiences of HT discontinuation. Additional prompts were used to 
probe for personal characteristics, symptom management strategies and other factors influencing 
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the discontinuation experience and outcome. Women were also asked to describe their QoL and 
the counseling and support they believed would have been most beneficial for them during this 
experience. This interview guide was revised as new categories emerged during the course of the 
investigation (Appendix P). 
The Qualitative Researcher 
In qualitative research, the researcher is considered the primary instrument in that her/his 
questions, interactions and interpretations form the conduit through which the phenomenon is 
brought to light. Because the researcher actually becomes part of the investigation, her/his 
knowledge, experiences, beliefs, values and biases influence the research process and product 
(Dowling, 2006). All aspects of the inquiry may be influenced: the choice of a research topic and 
question, decisions about methodology and methods, development and adaptation of the 
interview guide, the process of data analysis and the inferences drawn from the findings (Patton, 
2002; Polit & Beck, 2008). In an effort to acknowledge and address these influences, the 
researcher also contributes information—field notes, memos and reflexive journal entries—for 
inclusion in the analysis of the data.  
As previously described, field notes of observations pertinent to the context of the 
interviews and memos illuminating the researcher‘s methodological decisions were maintained 
throughout the research process and were incorporated into the analytic process. The use of the 
NVivo CAQDAS facilitated linking this material to the interview transcripts and coding it in 
conjunction with the text data. In addition to the memos and field notes, pertinent entries from 
the researcher‘s journal were also included in the qualitative data analysis. This journal is one of 
the primary mechanisms for recording and displaying the researcher‘s reflexivity. 
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Reflexivity. Reflexivity refers to the open, honest, critical and thoughtful reflection by 
the researcher about any and all aspects of the research experience and process (Hesse-Biber & 
Leavy, 2006; Polit & Beck, 2008).  However, reflexivity is more than introspection and self-
appraisal; it is also epistemological—inextricably linked to how knowledge is constructed 
(Dowling, 2006). The act of reflexivity should be, not only descriptive (relating the researcher‘s 
reflections) but also analytical (comparing and evaluating the multiple realities emerging from 
the participants‘ narratives and researcher‘s reflections) (Letherby, 2002). It is this analysis that 
brings balance between objectivity and subjectivity (Patton, 2002). During reflexive journaling, 
the researcher acknowledges her/his background, experiences, assumptions, beliefs, values and 
even attributes such as age and gender which may impact on interactions with participants. The 
researcher may examine how these biases and preconceptions can impact on the process and 
quality of the research and describe any strategies used to offset these biases (Beck, 2004; Hesse-
Biber & Leavy, 2006; Lincoln & Guba, 1985).  
Because of its inherent intersubjectivity (Im & Chee, 2003), qualitative research may also 
be reciprocal: that is, the researcher not only influences the research process but may also, in 
turn, be influenced by the experience resulting in a shift in her/his values or perspective. These 
shifts may further influence the process of inquiry therefore they must also be acknowledged. 
Thus reflexivity is a dynamic process requiring that the researcher engage in a moment by 
moment awareness of her/his thoughts and assumptions, what influences them and what they 
may then influence (Dowling, 2006). 
Understanding these reflexive circles (Koch & Harrington, 1998; Patton, 2002) is of 
particular importance in feminist-based research. The inferences constructed from emerging 
knowledge in qualitative research arise in part from the insights and interpretations of the 
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researcher that may lead to the perception that the researcher holds ultimate authority and 
privilege (Freshwater & Avis, 2004). However, the goal of feminist research is to minimize 
power differentials and hierarchical positioning and allow women‘s authentic voices to be heard 
(Dowling, 2006; Hesse-Biber & Piatelli, 2007; Im & Chee, 2003). Strategies that facilitate the 
sharing of stories, such as the researcher providing information about her/his similarities and 
differences from participants (Seibold, 2000), biases and opinions, and even insights from the 
data, can bring balance to the participant-researcher relationship. The inquiry becomes 
collaborative and knowledge is co-created (Dowling, 2006; Hesse-Biber & Piatelli, 2007). It is 
therefore critical that the researcher acknowledge these reciprocal influences, their influence on 
the research process, the repositioning of both researcher and participant within the reflexive 
circle, and any tensions arising from this positionality (Hesse-Biber & Piatelli, 2007). 
The constant sharing and shifting of perspective and influence means that reflexivity is an 
ongoing process rather than an end result (Finlay, 2002). It does not seek to eliminate bias or 
variability or influence, but rather to understand (Maxwell, 2005; Merriam, 2009) and gain new 
perspectives and fresh insights from these variations (Finlay, 2002; Morse et al., 2002). Thus 
reflexivity in feminist research provides a means to recognize the contextual nature of the 
multiple realities and truths of women‘s lives. 
Another advantage of reflexive inquiry is that it can help the fledgling researcher develop 
a deeper understanding of and appreciation for all facets of the research process and ultimately 
become a better researcher (Watt, 2007). Reflexive journaling may also foster an ethical research 
environment by providing a space for recording thoughts about how to address ethical dilemmas, 
sensitive topics, and participant confidentiality as well as the impact of these ethical decisions on 
the study process and outcomes. 
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Patton (2002) suggests a triangulated approach to reflexive journaling by focusing on 
three different perspectives: self-reflexivity, reflexivity about those studies and reflexivity about 
the intended audience (see Table 11). Self-reflexivity involves attention to the perspective and 
voice of the researcher, preferably writing in the first-person to convey a deeper sense of 
intimacy and authenticity. As already noted, reflexivity allows the voices of participants to 
become audible, the second component. Finally, through reflexivity the researcher can consider 
issues such as the influence of stakeholders and how to ensure that findings are presented and 
disseminated to be of greatest use (Patton, 2002). Accordingly, for this study, the researcher 
attempted to incorporate these three perspectives into the reflexive writing.  
Table 11.  
Triangulation of Reflexivity 
REFLEXIVITY 
PERSPECTIVE 
POTENTIAL QUESTIONS FOR CONSIDERATION 
Self-reflexivity 
What do I know and how do I know it? 
What has influenced my perspectives? 
What voice do I use in sharing my perspective? 
What steps am I taking to reflect both critical thinking and creativity? 
Reflexivity about 
participants 
How do they know what they know? 
What shapes their experiences & perspectives? 
How do they perceive me? How do I perceive them? 
How can I be sure I am accurately representing all participant 
realities and exploring all alternative perspectives? 
Reflexivity about 
audience 
How do they interpret & make sense of the findings? Will readers be 
able to follow the thread from philosophical underpinnings through 
discussion of findings? 
What perspectives do they bring? 
How do they perceive me and I, them? 
How will the findings be used? 
Adapted from:  Patton (2002) & Polit & Beck (2008) 
In NVivo, a folder with subcategories addressing these themes was developed for 
reflexive journal entries for data analysis. One of the first entries was the researcher‘s 
experiences and beliefs related to HT discontinuation. Of particular relevance to this 
investigation is the researcher‘s professional experience as a certified Menopause Clinician 
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providing care to peri/menopausal women as part of a Menopause Consultation Service. Some of 
these women have been contemplating or actually experiencing HT discontinuation therefore the 
researcher has had the opportunity to counsel and provide support to these women. These 
encounters have obviously influenced the choice of this research topic as well as decisions 
regarding the research design. They may continue to influence the researcher‘s interpretations of 
the data and relationships with participants and therefore must be acknowledged and explored as 
part of the reflexive process. In addition, the researcher also documented reflections on her own 
experiences as a mid-life woman transitioning through peri/menopause and how that ongoing 
experience shapes her perceptions and beliefs about women‘s choices about HT. 
Data Analysis 
Data analysis integrated both qualitative and quantitative methods. The degree of 
integration varied by specific aims will be discussed below. Online and telephone data were 
initially analyzed separately and compared in order to determine if there were substantive 
differences in the data obtained through each method. It is important to keep in mind that, 
although discussed separately, data collection, management and analysis are not linear but 
actually occurred concurrently, interactively and iteratively. 
Qualitative Content Analysis 
 The primary analytic method of this study was Qualitative Content Analysis. Content 
analysis is viewed as a technique for making inferences from verbal, visual or written data in 
order to describe a phenomenon (Downe-Wamboldt, 1992; Krippendorff, 2004; Weber, 1990). 
The focus of the inferences may include the source of the message, the audience of the message, 
or the message itself (Weber, 1990). Inferences or findings are discovered through a very explicit 
and detailed process of coding and abstraction (Elo & Kyngas, 2007). 
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 With content analysis, large sections of text or other data are systematically coded 
according to a standardized guide or codebook consisting of names and definitions of category 
codes (Cohen & Crabtree, 2006; Neuendorf, 2002; Zhang & Wildemuth, 2009). These text 
sections are then condensed into more manageable segments, which are further compressed or 
grouped into subcategories and finally categories, a process known as abstraction (Elo & 
Kyngas, 2007; Schilling, 2006). Categories, which may or may not be counted, are ultimately 
summarized and described in terms of their manifest (frequency) and/or latent (context, meaning, 
relationship) content (Downe-Wamboldt, 1992; Krippendorff, 2004; Busch et al., 2005; 
Sandelowski, 2000).  
 Although the roots of content analysis may date back as far as the Inquisition of the 17th 
century, the first documented analysis of textual data did not occur until the 18th century in 
Sweden. The increase in production of printed material that occurred at the beginning of the 20th 
century spawned numerous quantitative analyses of mass communication materials, often in an 
effort to identify hidden propaganda. In the second half of the 20th century, content analysis 
spread to other disciplines and other types of data sources, including the Internet. Computers 
have been a boon to content analysts with software programs that can make the task of retrieval 
and categorization of data much more efficient (Krippendorff, 2004). The burgeoning qualitative 
research tradition that began during this period (Greene, 2007) also contributed to the evolution 
of content analysis (Krippendorff, 2004).  
 Qualitative content analysis was first proposed in 1953 by Kracauer who believed that the 
traditional approach to content analysis was so focused on identifying and counting words 
(manifest content) that the meanings within the text (latent content) were lost (Priest, Roberts & 
Woods, 2002). The qualitative variation of content analysis stresses the importance of going 
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beyond the manifest or explicit content to the deeper latent contexts underlying the data. It has 
been employed in the systematic analysis of ethnographic, narrative, conversational and even 
interview data and has become increasingly popular, especially in scholarly disciplines such as 
the social sciences (Krippendorff, 2004) and health care (Cohen & Crabtree, 2006). Content 
analysis can be useful within feminist or other emancipatory paradigms to highlight what is 
absent, oppressed or taken for granted in a culture by analyzing messages promulgated from the 
dominant sector (Leavy, 2007).   
 However, there is still disagreement about the definitions and techniques that comprise 
the qualitative content analysis process. Some argue that qualitative content analysis does not 
exist as a separate entity (Neuendorf, 2002) while others see it as clearly distinct from the 
quantitative form (Mayring, 2000; Morgan, 1993). It has also been suggested that content 
analysis is actually a continuum that includes both qualitative and quantitative approaches. Still 
others contend that all content analysis incorporates both qualitative and quantitative strategies 
and is thus a type of mixed methods inquiry (Leavy, 2007). 
 One of the primary distinctions between qualitative and quantitative content analyses is in 
the amount of data to be analyzed. In comparison to the volumes of textual material analyzed in 
quantitative content analysis, qualitative content analysis is conducted with smaller amounts of 
text (Krippendorff, 2004). Another differences lies in the depth of the analysis. Although the 
focus of quantitative content analysis has expanded to include both manifest (conceptual 
analysis) and latent (relational analysis) content (Busch et al., 2005), it has been posited that the 
qualitative approach goes deeper into the contexts and meanings between and beneath the words 
(Graneheim & Lundman, 2003; Morgan, 1993; Sandelowski, 2000; Weber, 1990). 
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 The manner in which codes are applied and/or categories are summarized is in great part 
responsible for the deeper understandings that arise via the qualitative approach. In content 
analysis, data are analyzed based on a consistent coding schema developed by the researcher(s) 
to identify the concepts within the theoretical framework or research question. With the 
quantitative-dominant approach, the codebook is designed prior to data collection, categories are 
mutually exclusive and adherence is mandatory (Neuendorf, 2002; Zhang & Wildemuth, 2009). 
With qualitative content analysis however, codes are not defined a priori but are generated 
through initial and continued analysis of the data (Hsieh & Shannon, 2005; Morgan, 1993; Polit 
& Beck, 2008; Sandelowski, 2000; Sullivan-Bolyai et al., 2005). This inductive approach (Elo & 
Kyngas, 2007; Mayring, 2000) is more deeply rooted in the contexts of the data and may lead to 
the development of concepts, models or hypotheses to be tested (Hsieh & Shannon, 2005).  
 It is also possible to use a hybrid or deductive analytic approach (Elo & Kyngas, 2007; 
Mayring, 2000) whereby some codes, based on literature, experience or an organizational 
framework, are designated prior to the analysis (Hsieh & Shannon, 2005; Morgan, 1993). As the 
analysis progresses, these codes may be revised or even discarded and other codes added to the 
codebook. A hybrid approach may help to validate or expand upon existing frameworks or 
theories (Hsieh & Shannon, 2005). It may also be particularly useful in a mixed methods study 
where the researcher‘s approach may flow between induction and deduction in her/his efforts to 
answer the research question. 
 There are some qualitative content analyses that actually appear to conform to a more 
traditional quantitative format resulting in frequency counts of the words or concepts being 
investigated. However, these tallies are not the end of the analysis but are rather an intermediate 
or transitional step. Moving from description to interpretation, the researcher proceeds to 
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examine patterns found within the numerical summaries that may point the way toward the latent 
content awaiting exploration and discovery (Crabtree & Miller, 1999; Hsieh & Shannon, 2005; 
Morgan, 1993). Even the categories that emerge through the inductive or hybrid approaches may 
be tabulated in order to detect deeper or different patterns of meaning than those already 
identified and described (Morgan, 1993; Sandelowski, 2000). The enumeration of categories 
through qualitative content analysis may also facilitate comparisons both within and across 
subjects (Ayres, et al., 2003) as well as between groups or strata (Morgan, 1993).  
 Although qualitative content analysis enables an understanding of the deeper meanings 
and relationships within the data (Zhang & Wildemuth, 2009), it remains less interpretative than 
the analytic procedures used in other qualitative research methods such as phenomenology. 
Because findings are typically re-presented using terminology found within the text of the data 
and the codebook, qualitative content analysis is especially appropriate for Qualitative 
Description which results in a rich description couched in the language of the participants 
(Sandelowski, 2000; Sullivan-Bolyai et al., 2005). Therefore, qualitative content analysis was an 
appropriate analytic method for the proposed qualitative-dominant study.  
Data Analysis for this Study 
 For this mixed methods study, qualitative content analysis was the primary analytic 
method. To ensure that the analysis of the data accurately addressed the specific aims of the 
study, a codebook was developed. A hybrid or directed approach was used in the development of 
this coding scheme. Codes corresponding to concepts within the organizational framework, as 
well as standardized information (date, time, length of interview and so on) from the field notes, 
were identified and defined a priori. Codes arising inductively from the data were added to the 
codebook as they are identified. The quantitative measures were also described in the codebook. 
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 The texts were first read, however, without applying any codes in order to obtain a sense 
of the whole experience and to facilitate immersion in the data (Graneheim & Lundman, 2003; 
Hsieh & Shannon, 2005; Woods, Priest & Roberts, 2002). After the initial reading the texts were 
reread and coded (Hsieh & Shannon, 2005). Line by line coding, the reduction of data into 
smaller units of information (Merriam, 2009; Miles & Huberman, 1994), was used to identify 
similar words, phrases or other segments of text that illustrate concepts relevant to the 
predetermined coding classifications in the codebook (Sandelowski, 2000; Sullivan-Bolyai et al., 
2005). As data analysis continued, segments of text bearing the same codes were then clustered 
or collated and systematically organized to facilitate easy retrieval of specifically coded sections 
(Merriam, 2009; Miles & Huberman, 1994). These text segments were coded as free nodes. 
 Once the initial coding was completed, the text was then re-analyzed to inductively code 
data not captured with the existing codes. These text segments were then assigned a label or code 
(Merriam, 2009; Miles & Huberman, 1994) which were derived either from the actual text 
(descriptive) or may have been metaphorical (interpretive), reflecting the corresponding meaning 
or context (Miles & Huberman, 1994). Any new codes were added to the codebook (Hsieh & 
Shannon, 2007). Analysis of each text continued in this iterative fashion until no new codes were 
found in the data. 
 As previously noted, codes were condensed or reduced into subcategories and categories 
(Elo & Kyngas, 2007; Graneheim & Lundman, 2003; Schilling, 2006) and migrated into tree 
nodes. Frequency counts of these categories supplemented the descriptive re-presentation of the 
findings (Bazeley, 2003; Sandelowski, 2000). Cross tabulations were also done to assist in 
comparing categorical themes across strata and against quantitative scores to seek any patterns 
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that may warrant further exploration (Krippendorff, 2004). Ultimately tree nodes were 
structurally clustered by specific aim. 
 Analysis varied by specific aim as described below (Table 12). Although each Specific 
Aim and relevant analysis are discussed sequentially here, in reality the analyses was interactive 
and iterative.  
 Specific Aim #1: explore women’s experiences of HT discontinuation. The content 
analysis process as described above identified categories related to women‘s discontinuation 
experiences and the specific symptoms encountered during and after discontinuation. These 
categories were then used in the development of a rich description of women‘s discontinuation 
experiences. Frequency counts of emergent categories were done to further support the findings. 
Cross tabulations were also computed to explore variations in the experiences of women who 
stop or resume HT by comparing the frequencies of the categories by discontinuation status.  
 Specific Aim #2: describe the personal characteristics and sociocultural contexts that 
influence symptom perception, evaluation and response among women who have attempted to 
discontinue HT. To address this aim, codes related to women‘s personal and sociocultural 
characteristics (e.g., ethnicity) and their symptom experience (symptom description, meaning 
and influencing factors) were applied during the initial analysis of the interview data. Any 
additional codes related to the concepts that emerged from the data were also incorporated into 
the analysis. Some of the qualitatively-derived codes were quantitized into categorical variables 
(e.g., ratings of post-discontinuation symptom severity were quantitized as mild-moderate-
severe) to facilitate further descriptive statistical analysis; these were then added to the 
codebook. Codes were once again enumerated and compared by discontinuation status (strata) to 
allow for the discovery and further exploration of potential new patterns of meaning and context.  
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 Descriptive statistics (means, frequencies and cross tabulations) were run on the 
quantitative data using PASW 18. Responses from the demographic questionnaire were used not 
only to describe the study participants but also as part of the analysis as some of this data was 
pertinent to concepts within the organizational framework. Categories from the qualitative 
analysis were then compared against the quantitative data to look for patterns indicative of 
underlying meanings or relationships in the data. 
 Specific Aim #3: explore the impact of HT discontinuation on different facets of 
women’s quality of life. Both within and across subjects‘ analyses were performed for this 
specific aim. First, women‘s QoL with HT discontinuance was described. MRS and HFRDIS 
scores were collapsed or qualitized into categories (corresponding to the scale choices on the 
MRS and  the aforementioned categories for the HFRDIS). This allowed for  identification of 
groups of women with similar levels or profiles (Sandelowski, 2000) of interference and/or 
symptom severity for further  comparison of experiences. Finally, each woman's MRS and 
HFRDIS  profile  as well as her well-being scores were compared to her qualitative description 
of HT discontinuation-related QoL to identify congruent or divergent results (Erzberger & Kelle, 
2003). This direct comparison provided information to understand the best method(s) for 
assessing QoL in women at menopause. Finally, both qualitative and quantitative results were 
compared by discontinuation strata. 
 Specific Aim #4: discuss women’s preferences for counseling and support during HT 
discontinuation. Emerging and predetermined codes related to menopause information sources 
were used to categorize and describe both the amount of information and support women desire 
with HT discontinuation and the information and support they actually received. These were 
compared to identify any discrepancies between preferred and actual level of support. Any 
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discrepancies may help point the way toward the development of interventions to help women 
during this experience. 
Table 12. 
Data Analysis  
SPECIFIC 
AIM 
ANALYSIS RESULT 
Specific Aim 
#1 
Coding Description of discontinuation experience 
Frequencies Rank order summary of experiences 
Cross tabulations Comparison of experiences by discontinuation status 
Specific Aim 
#2 
Coding Description of symptoms & influencing factors 
Frequencies Rank order summary of symptoms & influencing factors 
Descriptive 
statistics 
Summary of scores of MRS, HFRDIS, well-being & QoL 
Cross tabulations 
Comparison of symptoms & influencing factors with score 
results & discontinuation status 
Specific Aim 
#3 
Coding Description of QoL with discontinuation 
Descriptive 
statistics 
Summary of QoL scores & comparison to qualitative 
description 
Cross tabulations Comparison of QoL by discontinuation status 
Specific Aim 
#4 
Coding 
Description & comparison of women‘s counseling 
preferences and actual counseling received 
 
Rigor and Trustworthiness 
 The goal of health research is to produce knowledge of the highest quality in order to 
benefit society. Rigor, the degree to which study results are reliable and valid and the degree to 
which the reader can have confidence in the findings, enhances the quality of the study. 
Characteristics of a rigorous study include a detailed study design that adequately addresses the 
research question, precision of measurement, adherence to the sampling plan and study protocol, 
systematic analysis and presentation of results in a manner that may be applicable in other 
settings (Burns & Grove, 2005). The traditional criteria for achieving rigor—internal and 
external validity, reliability and objectivity—are rooted in quantitative research (Lincoln & 
Guba, 1985). 
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Validity in Qualitative Research? 
 Qualitative researchers also strive to produce high quality knowledge but differences in 
study procedures such as sampling and data analysis render the above criteria difficult to apply in 
the qualitative setting. In 1985, Lincoln and Guba proposed that trustworthiness should guide the 
evaluation of quality in the naturalistic or qualitative research setting. They described four 
criteria for establishing trustworthiness: credibility, transferability, dependability and 
confirmability. Later they would add authenticity (Guba & Lincoln, 2005). 
 While many qualitative researchers have adopted Lincoln & Guba‘s criteria to evaluate 
the quality of their research proposals and findings, some have criticized these standards as still 
too rooted in the positivist paradigm. Accordingly, numerous other models of trustworthiness 
have been developed, some specific to distinct research methods such as ethnography or 
grounded theory while others are more general in scope (Cohen & Crabtree, 2006; Whittemore, 
Chase & Mandle, 2001).  Most of these models incorporate criteria and procedures such as 
authenticity, reflexivity, and systematic development and implementation of the study design 
(Cohen & Crabtree, 2006) yet emphasize not sacrificing the creative or interpretive dimension 
that is the art of qualitative research (Maxwell, 2005; Morse, 2008; Polit & Beck, 2008; 
Sandelowski, 1993).  Mixed methods research has added to the controversy with terms such as 
inference quality (Teddlie & Tashakkori, 2003) and legitimation (Onwuegbuzie & Teddlie, 
2003; Onwuegbuzie & Johnson, 2006) as alternatives for avoiding the quantitative-qualitative 
validity-trustworthiness dichotomy. 
 Recently, some qualitative researchers have resumed using the terms rigor, reliability and 
validity, arguing that this terminology is applicable to both qualitative and quantitative research 
while the specific criteria or techniques for establishing rigor will differ (Cohen & Crabtree, 
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2006; Morse, Barrett, Mayan, Olson & Spiers, 2002). Decrying that trustworthiness criteria are 
all too often applied a posteriori, they assert that ensuring rigor should be the responsibility of 
the researcher, not the reviewer. Verification strategies, which inform the researcher when to 
modify, continue or bring an ending to a study, should be ongoing and transparent throughout the 
entire inquiry process in order to foster rigor (Creswell, 2007; Morse et al., 2002).  
 Validity in the Proposed Study. Because the proposed study is qualitative dominant, 
rigor was attained by qualitatively-focused validity criteria. Through a synthesis of key validity 
models, Whittemore and colleagues (2001) developed a framework for establishing rigor that 
includes primary and secondary criteria as well as specific techniques for actualizing these 
criteria. This framework guided the researcher in the choice of strategies for ensuring and 
evaluating quality for this study. 
 Within the Whittemore framework, the overarching goal is validity and the four primary 
criteria necessary to achieve this goal are credibility, authenticity, criticality and integrity.  A 
study is credible when the researcher has confidence in the accuracy of the data and the 
inferences drawn from the analysis of the data. In other words, are the findings believable 
(Lincoln & Guba, 1985; Milne & Oberle, 2005; Polit & Beck, 2008; Whittemore et al., 2001)? 
The purpose of a study influences the procedures used to establish credibility (Milne & Oberle, 
2005) thus procedures and techniques that enhance the researcher‘s ability to collect and connect 
with the data also enhance credibility. These techniques may be operationalized at multiple 
points throughout a study, from its inception to its closure.  
 Closely related to credibility, in fact often considered together, is authenticity—the 
degree to which the emic perspective, experience and meaning are reflected and represented in 
the findings (Milne & Oberle, 2005; Polit & Beck, 2008; Whittemore et al., 2001).  Strategies 
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that allow the voices of participants to be distinctly heard and accurately represented as having 
authoritative knowledge of their complex and multifaceted realities (Sandelowski, 1994) again 
span the inquiry process from choice of methodology to presentation of findings (Milne & 
Oberle, 2005).   
 The interrelated criteria of criticality and integrity shift the verification focus from the 
data onto the researcher in an effort to ensure that the researcher‘s assumptions and knowledge 
have not unduly influenced any part of the inquiry (Whittemore et al., 2001). Criticality requires 
that the researcher systematically and critically appraises each decision made throughout the 
research while integrity is manifested when the researcher engages in self-reflection of inherent 
biases and how they may or may not have distorted the inferences drawn from the data (Milne & 
Oberle, 2005; Polit & Beck, 2008; Whittemore et al., 2001). 
 In this study, one of the specific techniques that was used in the pursuit of validity during 
data collection was maximum variation sampling with stratification to allow the multiple 
realities of women‘s experiences with HT discontinuation to be portrayed.  By using QD 
methodology, which stays close to the language of the participants (Sandelowski, 1999; Sullivan-
Bolyai et al., 2005), women‘s own voices were heard (Milne & Oberle, 2005) while the use of 
both qualitative and quantitative QoL measures fostered the emergence of a comprehensive 
description (Greene, 2008) of QoL with HT discontinuation. Participant description summaries 
that combined data from demographic material as well as field notes provided a view of the 
whole person in order to promote contextual understanding (Milne & Oberle, 2005).  Prolonged 
engagement and persistent observation, with both participants and the data, built trust and 
rapport and promoted open and honest disclosure and in-depth narratives (Creswell & Plano-
Clark, 2007; Leckenby & Hesse-Biber, 2007; Milne & Oberle, 2005). Maintaining a reflexive 
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journal and field notes fostered transparency in the decision-making process and illuminated the 
perspective of the researcher and the intersubjectivity with the participants. 
 During the data analysis phase, strategies that were used to achieve validity included the 
use of content analysis which allows for both manifest and latent content to emerge from the 
data. The hybrid content analytic approach, in particular, fostered authenticity as some of the 
codes were data-driven—arising from the participants‘ experiences. Additional strategies that 
promoted rigor include the online interview format which decreased the risk of transcription 
error as well as the use of a codebook (Polit & Beck, 2008) and NVivo (Bazeley, 2009) for 
systematically organizing and coding the data. Stratification of the sample permitted alternative 
points of view to come forth which strengthened the understanding of the HT discontinuation 
phenomenon  (Patton, 2002; Polit & Beck, 2008). Analysis of the memos and reflexive journal 
notes that chronicle the researcher‘s perspective and decision process, was also a part of 
verification (Polit & Beck, 2008; Whittemore et al., 2001). The use of member checks (Appendix 
Q) further ensured that the emic perspective was reflected in the findings (Polit & Beck, 2008).  
 Validation from sources other than the participants and researcher also contributed to the 
rigor of this study. Peer debriefing sessions to review issues such as sampling, coding and 
emerging categories were held with a member of the researcher‘s faculty committee. Another 
strategy, inter-rater reliability, is particularly pertinent to research using content analysis. In large 
primarily quantitative content analysis, inter-rater reliability is determined by the degree of 
agreement between multiple coders and is calculated through a percentage or a kappa statistic. 
The desired level is a kappa of 0.8 to 0.9 (Downe-Wamboldt, 1992). However, in a smaller 
qualitative content analysis with only one researcher, such as a dissertation study, alternative 
approaches are often necessary. Intra-rater reliability, where the researcher recodes sections of 
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the data and then calculates the agreement between the two coding sessions, is one option. 
Another option, used in this study, is to have a second person, in this case a faculty committee 
member, code a small sample of the data (Schilling, 2006). This was done several times during 
the course of data collection and analysis to ensure that the researcher was coding appropriately; 
there was very good correspondance between student and faculty member coding on these 
occasions.  
 Under the heading of presentation of study findings, the rich description of women‘s 
experiences was another mechanism by which validity was achieved. The use of different 
techniques for re-presenting the findings, incorporating both narrative and tabular depictions, 
also helped to enhance the quality of the study. For example, incorporating quotations allows 
women‘s individual voices to be heard while tables help patterns or themes become more visible 
(Creswell & Plano-Clark, 2007; Miles & Huberman, 1994). Recently, some proponents of 
qualitative research have begun calling for more transparency of the steps undertaken to assure 
verification through documentation of these procedures in the scholarly literature (Cohen & 
Crabtree, 2006; Finlay, 2002; Morse et al., 2002; Polit & Beck, 2008; Whittemore et al., 2001).  
 The six secondary criteria included in the Whittemore (2001) framework provide 
additional or supplemental principles to guide the researcher in developing a study that meets 
high quality standards. Whereas the primary criteria are all essential to the development of a 
valid study, the secondary criteria are more flexible and contextual and not always relevant to 
every study. The degree to which they may be included as standards of verification will vary 
depending on the particular study purpose and design (Polit & Beck, 2008; Whittemore et al., 
2001. Some of the techniques for meeting the primary criteria may also be used for supporting 
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the secondary criteria.  The following table lists the secondary criteria and the strategies that 
were used to reflect the supplemental criteria and support the rigor of the study.  
Table 13.  
Secondary Criteria and Related Techniques 
SECONDARY 
CRITERIA 
DEFINITION TECHNIQUES 
Explicitness Documentation of decisions and 
interpretations through careful record 
keeping and detailed results; audit trail 
Field notes, memos and 
reflexive journal 
Transcribing narratives 
verbatim  
Qualitative description 
Use of CAQDAS 
Vividness Rich, clear, faithful, artful and 
compelling presentation of the 
findings  
Comprehensive notes  
Transcribing narratives and 
notes/memos verbatim 
Qualitative description 
Creativity Innovative and imaginative study 
design, data analysis and 
interpretations; craftsmanship  
Use of Internet recruitment 
and online survey website 
Mixed methods design 
Thoroughness Comprehensive and adequate 
sampling, data collection, and analysis 
Prolonged engagement and 
persistent observation 
Mixed methods 
Data saturation 
Stratification of sample 
Reflexive journal and 
decision-making notes 
Congruence Interconnections among all facets of 
the study and to external contexts 
Reflexive journal and 
decision-making memos 
Quasi-statistical analysis 
Sensitivity Respect and concern for study 
participants and attention to ethical 
considerations   
Qualitative description 
Prolonged engagement and 
persistent observation 
Member checks 
Protection of human subjects 
Adapted from: Polit & Beck, 2008; Whittemore et al., 2001 
The use of these strategies to promote rigor allows the reader to understand the 
experience or meaning and then apply the findings. While qualitative research is not 
generalizable in the statistical sense, qualitative scholars argue that the findings can be applicable 
in other contexts or situations. Lincoln & Guba (1985) referred to this as transferability although 
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newer terminology is also emerging here. For example, the term relevance is sometimes used 
instead of transferability when discussing whether qualitative findings can be used elsewhere. 
Another concept found in the literature is whether the study findings permit the drawing of 
extrapolations: speculations or explorations on the applicability of the findings to similar, but not 
identical, contexts (Patton, 2002). Morse (1999) argues that the term generalizability can indeed 
be used with qualitative research however the criteria for evaluation are different from those used 
in quantitative research. Sampling and study designs that foster the collection of adequate data 
and the emergence of a rich description of the phenomenon allow for the study findings to be 
transferred or extrapolated to similar scenarios (Morse, 1999; Patton, 2002). Therefore, in this 
study, maximum variation sampling and strategies that foster in-depth responses on the 
qualitative interview guide promoted qualitative generalizability of the study findings. 
Ethical Considerations 
General Ethical Considerations 
Because the goal of clinical research is to generate knowledge in order to improve the 
health of the human population, it is necessary to use human subjects to obtain this knowledge. 
However those who choose to participate in research for the good of society may incur risk of 
harm, guidelines for conducting ethical research have been established to ensure that study 
subjects are safe and treated with respect. Reports and decision papers such as the Nuremberg 
Code, the Belmont Report and the Declaration of Helsinki and similar documents invoke specific 
ethical principles used to develop and review human subjects research (Ezekiel, Wendler & 
Grady, 2000). Although multiple ethical principles may be applicable throughout the research 
process, the three principles deemed salient by the Belmont Report were respect for persons, 
beneficence and justice (Ezekiel et al., 2000; Frankel & Siang, 1999; National Commission for 
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the Protection of Human Subjects of Biomedical and Behavioral Research, 1979; Penslar & 
Porter, 1993).  
Respect for persons is divided into two components: first, participants should be 
recognized as autonomous or capable of self-determination and second, those with diminished 
autonomy are entitled to receive special protection (National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research, 1979; Penslar & Porter, 1993). Respect 
for persons is rooted in communication and actualized through the three elements of informed 
consent: information, voluntariness and comprehension. The researcher must present details 
about the study and the inherent risks and benefits to each potential participant, evaluating the 
subject‘s ability to comprehend the information and adapting the material as needed for the 
individual. Consent must be voluntary, free from coercion and influence (Frankel & Siang, 1999; 
NIH, 1979; Penslar & Porter, 1993). Other issues to be considered under this principle include 
respect for participant confidentiality and privacy and providing for participant well-being 
(Ezekiel et al., 2000).  
 The principle of beneficence is seen as an obligation to maximize the benefits of a study 
and minimize the risks in order to protect participants from possible harm (NIH, 1974; Penslar & 
Porter, 1993). The benefits, which may be targeted specifically for the participant or more 
globally for the benefit of society, must be favorably balanced against both the probability and 
magnitude of harms arising from participation in the study. This risk-benefit assessment is based 
on a thorough and systematic evaluation of all aspects of the research process, the adequacy of 
the researcher‘s estimations of harms or benefits and consideration of possible alternatives 
(Ezekiel et al., 2000; Gitlin & Lyons, 2004; National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research, 1979; Penslar & Porter, 1993). 
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Finally justice requires fair and equal distribution of the benefits and burdens of research 
and has its application in the selection of participants (Ezekiel et al., 2000; National Commission 
for the Protection of Human Subjects of Biomedical and Behavioral Research, 1974; Penslar & 
Porter, 1993). Research subjects must be selected equitably, with no favoritism or bias and with 
additional considerations for the safety of vulnerable populations. Procedures and treatments 
must also be administered fairly, and both costs and benefits equally distributed to avoid 
perpetuating existing societal injustices. Within the quantitative research tradition, randomization 
and stratification procedures have often been used to achieve equity in participant selection while 
the qualitative researcher may use techniques such as purposeful sampling to obtain a diverse 
sample (National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research, 1979; Penslar & Porter, 1993). 
Ethical Considerations for this Study 
 Applying the above ethical principles to this study became challenging because of the 
primarily online format. While some of the potential barriers to enacting these principles are 
present in all research projects (Walther, 2002), special strategies were required to address these 
issues. It must also be remembered that no research, online or not, can satisfy the guidelines 
completely: there will always be some risks incurred with participation in research. The goal of 
the researcher is to minimize these risks in order to obtain new knowledge that ultimately 
benefits society.   
With regard to respect for persons, one of the primary concerns with online research is 
how to obtain informed consent. Some online studies make use of a statement at the beginning of 
the questionnaire informing the participant that consent is assumed by the very act of completing 
the questions and online interviews. Another option is to provide a box or button for subjects to 
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check indicating that they are voluntarily consenting to participate (Best & Krueger, 2004; Im & 
Chee, 2004; Mann & Stewart, 2004). A third choice, used in the proposed study, was to mail 
participants a consent form (Hamilton & Bowers, 2006). Researcher contact information was 
provided had any questions or need for clarification arisen (Whitehead, 2007) however full 
comprehension may be impossible to determine completely (Frankel & Siang, 1999). Access to 
the study site or scheduling of telephone interviews was not allowed until the consent form was 
returned signed.  
There were several other potential violations of this principle. While it may be assumed 
that an individual presents her authentic self online, it is possible that unbeknownst to the 
researcher, the participant may actually be a member of a vulnerable population (Frankel & 
Siang, 1999; Rhodes, Bowie & Hergenrather, 2003). It was hoped, but not guaranteed, that 
establishing rapport with each participant promoted full disclosure (Mann & Stewart, 2004) and 
careful evaluation of the appropriateness of responses helped to identify if there were any issues 
with comprehension (Dillman, 2007; Mann & Stewart, 2004). Voluntariness may be undermined 
by forced responses therefore participants were allowed to skip some questions (Im & Chee, 
2004). Participants were also informed that they could withdraw from the study at any time. 
Finally study subjects were made aware that confidentiality and privacy cannot be guaranteed 
with Internet-based research. Although the study questions were situated at a secure website with 
restricted access and contact with the researcher was through the firewall-protected University 
email system, no website or computer system is 100% safe from hacking and this possibility was 
written into the consent (Frankel & Siang, 1999; Im & Chee, 2004). 
 When considering beneficence, the researcher recognizes the possibility that some 
women may become emotionally distressed from reflecting on uncomfortable experiences. One 
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way to address this is to have information available about counseling to provide to the participant 
as needed. However, emotional distress is more difficult to ascertain and address with Internet-
based research. The researcher had to be alert to the overall tone of the response, use of italics, 
emoticons or bold type, or even absences/silences (Best & Krueger, 2004; Frankel & Siang, 
1999; Mann & Stewart, 2004). It would have also been difficult to refer a woman to specific 
counselors as many participants were actually in a different state than the researcher (Rhodes et 
al., 2003). A woman experiencing emotional distress would have been advised to seek support 
from a care provider in her locale. Women were also given contact information for the researcher 
if they wished to discuss concerns more intimately. 
 The potential for breaches of privacy and confidentiality must again be addressed, 
especially as the sense of anonymity conferred by the Internet may result in disclosure of very 
personal or intimate information (Cotton, 2003; Illingworth, 2006). Participants need to be made 
aware that their own Internet practices can increase these risks, for example using an old or 
shared computer system (Im & Chee, 2004) and not understanding that records of browsing or 
email exchanges may be saved in the Internet service provider‘s (ISP) logs or in hidden cookies 
on the hard drive (Cotton, 2003; Eysenbach & Till, 2001; Murray & Sixsmith, 2002). 
Furthermore, a participant‘s computer system may be attacked and potentially crippled by a virus 
(Cotton, 2003). To minimize these risks, participants were asked to password protect any 
attachments and to avoid sending emails or logging on from shared computers, if possible. They 
were also encouraged to make sure their computer systems had adequate virus protection and the 
researcher also took this necessary precaution. A fact sheet (Appendix ) describing possible risks 
and how to minimize them was developed for participants. Email messages were copied and 
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pasted into the data management system and then the email with identifying information was 
deleted (Hamilton & Bowers, 2006).  
 Because the consent form was mailed to the participant, anonymity was  not possible 
however subjects were assured that their personal information was known only to the researcher 
and kept in a secure site. Sending the consent also had the potential benefit of minimizing the 
possibility of deception or data fraud which occurs when an individual ‗poses‘ as someone they 
are not in order to gain access to the study (Im & Chee, 2002; Walther, 2002). Although not a 
guarantee of identity, it does provide a hard copy of the written signature which confers some 
protection legally (Hamilton & Bowers, 2006). Because the true identity of online participants 
can never be assured, attempts to achieve equitable and representative selection of study 
subjects—justice—may never be fully realized (Im & Chee, 2002; Im & Chee, 2004).   
Finally, ensuring adequate representation of women from diverse backgrounds was 
difficult to achieve (Conboy, Domar & O‘Connell, 2001; Frankel & Siang, 1999). Conducting 
research online may limit the ability to attract a diverse sample due to limited computer access 
among some sociocultural strata (Im & Chee, 2002). However, the ever increasing use of the 
Internet in the general population may actually offset this limitation (Whitehead, 2007), allowing 
access to various ethnic/cultural/racial populations as well as women in areas remote from the 
researcher who may not otherwise be able to participate (Best & Krueger, 2004; Cotton, 2003; 
Mann & Stewart, 2004). The option for telephone interviews may also make it possible for 
women with limited computer access or literacy to participate. 
Protection of Human Subjects 
Sampling and recruitment strategies must always take into account provisions for 
protection of human subjects (Burns & Grove, 2005). The first steps toward this end for this 
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study was to obtain IRB approval. Discussion board moderators were contacted for permission to 
post study invitations. Prior to participating in the interviews, women read and signed an 
Informed Consent describing the purpose of the study and the benefits and risks. Once the 
consent was returned, they were granted access to the secure, restricted access survey website 
developed by the Information Services department at the University of Massachusetts/Worcester. 
Using this website helped to minimize risks to confidentiality and privacy. The researcher‘s 
school email was used for follow-up questions and member checks. Because this email system is 
secured by more firewalls than personal email accounts, it offered greater protection from 
privacy intrusions. However, as noted earlier, the fact that the Internet is not 100% safe was 
written in the consent (Best & Krueger, 2004; Mann & Stewart, 2004). 
Summary and Conclusions 
 
 The purpose of this study was to explore women‘s experience with discontinuing HT. 
The study used an embedded mixed methods approach to elicit information about women‘s 
symptom experiences, factors influencing the experience, the role of QOL in the outcome, and 
women‘s needs for additional information about HT discontinuance. Women who had attempted 
to discontinue HT were recruited primarily via Internet menopause-related groups and completed 
both qualitative and quantitative questionnaires on-line. Through content analysis, the 
quantitative and qualitative data was integrated, both within and across cases. Study findings 
yielded a rich description of women‘s experiences with HT discontinuation. This description will 
ultimately serve to improve health care for women by providing information to guide the 
development of education and symptom management interventions.  
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CHAPTER IV 
RESULTS 
 
 A mixed methods approach was used to explore women's experiences of discontinuing 
hormone therapy. Because this study was qualitative dominant, the primary methodology was 
Qualitative Description; an embedded quantitative component was also included for the purpose 
of complementarity. As a result of the interviews and survey responses provided by the women 
who participated in this study, a rich description emerged of their experiences, influencing 
factors, QoL, and informational needs.  
 The overarching theme that captures the essence of their experiences is: a solitary 
journey. This theme envelopes two subthemes: symptom experience: burden and interference 
and risk appraisal. These findings will be presented in this chapter, prefaced by a description of 
the sample characteristics. 
Participants 
 A total of 34 women were eligible and participated in this study. Participant ages ranged 
from 47 to 65 with a mean age of 55. The average length of time on HT was 5.5 years. Nine 
women (26.5%) had stopped and resumed, five (14.7%) were tapering, and twenty (58.8%) had 
remained off HT after discontinuing. Several women had stopped and started several times 
before ultimately stopping and were able to share their experiences from the perspective of 
resuming as well as ceasing HT.  
 The sample was predominantly Caucasian, with three African-American women and one 
Hispanic woman. Most participants were married or partnered. Twenty-one  (66%) were working 
full-time. Eleven (34%) were nurses or nurse practitioners. Thirteen (38%) had no children; most 
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(n =16, 47%) of the remainder had either two or three children. Almost half (n = 15; 44%) 
reported no health concerns. Further information about the participants is provided in Table 14. 
Table 14.  
Sample Characteristics.  
 Total 
 (N = 34) 
Internet  
(n = 21) 
Telephone  
(n = 13) 
Age in Years 
   Mean 
   Median 
   Standard Deviation 
   Range 
 
55.03 
55 
4.92 
47-65 
 
54.1 
55 
4.403 
47-63 
 
56.46 
56 
5.456 
48-65 
 
H(1) = p
Ethnicity 
   African-American 
   Hispanic 
   Caucasian 
 
3, 8.8% 
1, 2.9% 
30, 89.2% 
 
3, 14.3% 
1, 4.8% 
17, 81% 
 
 
 
13, 100% 
 
Marital Status 
   Married 
   Widowed 
   Single 
   Separated 
   Divorced 
   Living with partner 
 
21, 61.8% 
3, 8.8% 
3, 8.8% 
2, 5.9% 
4, 11.8% 
1, 2.9% 
 
10, 47.6% 
3, 14.3% 
3, 14.3% 
1, 4.8% 
3, 14.3% 
1, 4.8% 
 
1184.6% 
 
 
1, 7.7% 
1, 7.7% 
 
 
Education in Years 
   Mean 
   Median 
   Standard Deviation 
   Range 
 
16.53 
16.5 
2.688 
10-22 
 
16.1 
16 
3.161 
10-22 
 
17.23 
18 
1.536 
14-19 
t
p = 
(equal variances not 
assumed) 
Occupational Status 
   Working full-time 
   Working part-time 
   Retired 
   Seeking employment 
   Student 
   Other  
 
21, 61.8% 
5, 14.7% 
2, 5.9% 
3, 8.8% 
1, 2.9% 
2, 5.9% 
 
13, 61.9% 
4, 19% 
 
3, 14.3% 
1, 4.8% 
 
 
8, 61.5% 
1, 7.7% 
2, 15.4% 
 
 
2, 15.4% 
 
Financial Strain 
   Very hard 
   Somewhat hard 
   Not very hard at all 
   Refused 
 
4, 11.8% 
8, 23.5% 
20, 58.8% 
2, 5.9% 
 
4, 19% 
4, 19% 
11, 52.4% 
2, 9.5% 
 
 
4, 30.8% 
9, 69.2% 
 
 
HT Status 
   Discontinued 
   Resumed 
   Taper in progress 
 
20, 58.8% 
9, 26.5% 
5, 14.7% 
 
11, 52.4% 
7, 33.3% 
3, 14.3% 
 
9, 68.2% 
2, 15.4% 
2, 15.4% 
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 As described in Chapter 3, analyses of the telephone and online qualitative responses 
were initially conducted separately in order to ascertain whether there were any differences 
between the two types of participants and their experiences. As can be seen in the table above 
(Table 14), sample characteristics do not reveal any major differences between the two groups 
with respect to demographic information. 
Findings 
 The overarching theme that emerged from the analysis of women's narratives was: a 
solitary journey. Every woman in this study had discontinued or attempted to discontinue HT 
within the past two years thus all had chosen to embark on the same journey. Their journeys 
often followed the same sequence, beginning with their menopause transition and decision to 
initiate HT, traveling through the experience of taking HT, then the decision to discontinue and 
the ensuing encounters with symptoms, culminating (for most)  in either HT resumption or 
remaining. It was indeed a 'journey' and several women actually used this word to describe their 
discontinuation experience. 
 However, because women's journeys occurred within the context of their individual life 
circumstances, each woman's path through HT discontinuation was a deeply personal sojourn. 
As a result, there was also variation and individuation in women's journey narratives. Women 
also described thier perception that, while many chose to take the journey, each of them had to 
find her own path to traverse in order to reach her destination.   
 The two conceptual and interactive subthemes (Table 15) encompassed by the 
overarching theme were symptom experience: burden and interference and risk appraisal. 
Women described their discontinuation experiences in terms of the intensity and severity of their 
symptoms and the difficulties and disruptions that symptoms imposed on their lives. Participant
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Table 15. 
 Thematic Findings 
 
A Solitary Journey 
Symptom experience: burden and interference 
Risk appraisal 
SPECIFIC AIM AND 
FRAMEWORK CONCEPT 
                                   FINDINGS 
Specific Aim 1 
Symptom experience: 
perception, evaluation and 
response 
 
The Journey:  
symptoms, suffering  
and surviving 
 
The journey begins: menopause and HT 
At the crossroads: making the decision to stop HT  
Road blocks: roaring back with a vengeance 
Navigating the terrain: managing symptoms 
The journey ends, the journey continues: future plans & life lessons 
Specific Aim 2 
Influential factors: 
sociocultural context and 
personal characteristics 
Influential Factors 
Roles: professional and personal 
Cost, financial strain & options 
Beliefs and expectations: menopause, medications and HT 
Expectations of discontinuation  
Readiness to stop 
Reasons for stopping 
Appraising risks 
Symptom tolerance: burden, interference & sensitivity 
Specific Aim 3 
 
Symptom evaluation:  
Quality of Life 
 
Women's Expertise 
Menopause, HT and QoL: women's words 
Menopause, HT and Qol: across dimensions 
 
 
Specific Aim 4 
 
 
Symptom response:  
seeking information 
 
Seeking knowledge,  
sharing wisdom 
 
Health care providers: information  
Woman to woman 
Health care providers: recommendations 
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also continually compared the risks of their symptoms to the risks of HT when considering the 
best route along their journey.  
 The overarching theme encompassed both the similarity and variability in women's 
stories, the subthemes served as constructs connecting women's journies. It is within each 
Specific Aim that the variability in women's experiences can best be seen. Findings, organized 
by specific aims and incorporating illustrative participant quotations and pertinent quantitative 
results, will be presented in the remainder of this chapter. 
Specific Aim 1: explore women’s experiences of HT discontinuation 
 In order to more fully understand what happens when women discontinue HT, 
open-ended questions about this experience were posed to all participants. Embodied within this 
Specific Aim is the story of women's passage through HT discontinuation 
 The journey: symptoms, suffering and surviving. The chronicle of HT discontinuation 
begins with a discussion of the context and antecedents that led women toward the path of 
discontinuation and continues with a rich description of their experiences during and after 
stopping HT. The three components of symptom experience as found in the organizational 
framework--perception, evaluation and response--as well as the subtheme burden and 
interference can be traced within this description. 
 The journey begins: menopause and HT.  All study participants had completed their 
menopause transition: 30 (88%) had experienced a natural menopause and four (12%) had 
undergone a surgical menopause. All but three reported troublesome menopause-related 
symptoms that arose during this transition. VMS were very common and very distressing: the 
sudden episodes of intense heat were uncomfortable and unsettling and the ensuing sweating was 
distasteful.  Greater frequency or duration of hot flashes added to the discomfort. Sleep 
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disturbances were often attributed to nighttime VMS: women described awakening to soaked 
bedding that required changing, sometimes more than once per night.  Lack of sleep led to 
decreased concentration and memory lapses as well as irritability and moodiness. For a few 
women, diminished sleep also contributed to exacerbation of pre-existing depression.    
 VMS (n = 27, 79%), sleep disruptions (n = 10, 29%), and affective concerns (n = 15, 
44%) were the most frequently described symptoms and commonly occurred together: 21 (62%) 
of the 34 participants reported having at least two if not all three of these symptoms. However, 
they were not the only symptoms that women encountered: participants reported a myriad of 
other symptoms and changes such as vaginal dryness, decreased libido, memory loss, weight 
gain, migraines and even facial paresthesias. Symptoms were disruptive in many aspects of 
women's lives: frequent flushing and sweating caused embarrassment in public situations (work, 
socail gatherings). Forgetfulness and lack of concentration as a result of disturbed sleep 
contributed to worries about work performance. Mood swings and irritability impacted on 
relationships with family, friends and colleagues. Even family members were not immune to the 
effect of women's symptoms as they shared and suffered from the impact of women's mood 
changed, exhaustion and even VMS: "He also had to leave the bed multiple times during the 
worst of it because he said it was like being [in bed with] Pele the volcano goddess."   
 Women began to consider HT when they realized to what degree their symptoms were 
preventing them from functioning in their normal day-to-day activities: 
  ...one day I was walking in the city and I was so exhausted I was holding on a   
  wall to walk because I was really ready to fall over and I just stopped myself and I  
  thought "okay this is not normal, I really should go to the doctor."    
 The three most common reasons for starting HT were symptom relief (n = 31, 91%), 
 138 
 
recommendation by a health care provider (n = 15, 44%) and health promotion (n = 10, 29%). 
Women often reported more than one reason for choosing HT. Of the three women who did not 
have symptoms prior to initiating HT, two began taking HT for health promotion reasons and the 
third for both health promotion and post-hysterectomy symptom prevention, all at the 
recommendation of their health care providers.  
 Initiation of HT sometimes occurred within a few weeks after the onset of symptoms. Yet 
some women endured uncomfortable symptoms for months or even years before beginning HT, 
struggling with the decision because of fears about HT or beliefs that menopause was a natural 
process that should not require medication. When women finally turned to their health care 
providers for support, occasionally after trying 'natural' remedies such as black cohosh or over-
the-counter 'hormone' preparations, it was most often of their own volition. However, family 
members or co-workers occasionally needed to intervene, encouraging women to seek help when 
VMS disturbed their sleep or when mood swings and irritability impacted on work productivity.   
 To the delight of many, HT brought welcome relief of VMS, sleep disturbances and even 
mood issues. Women described improvement in concentration, memory and work performance 
as well as in their personal relationships.Vaginal dryness eased and some women even reported a 
resurgence of libido. More than one woman spoke about HT helping her to feel 'back to normal.' 
As one participant summarized: "HRTs were working great--less irritability, better mood, NO 
HOT FLASHES!, a whole night's sleep, breasts were fuller, sex was better--happy partner, happy 
family." Although not all women experienced a complete elimination of their symptoms, even 
partial relief was beneficial, allowing women to manage their symptoms and regain their ability 
to function with fewer disruptions in their day-to-day lives and personal relationships. 
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 But not all women were happy on HT; some began to experience unpleasant side effects 
such as bleeding, weight gain, bloating, headaches, breast symptoms and even some irritability 
for two participants. Bleeding was especially worrisome as it was usually unpredictable and 
uncontrollable, sometimes prolonged and/or very heavy, and typically necessitated invasive 
procedures (endometrial biopsy, dilation and curettage) for evaluation or management. Several 
participants experienced more than one of these adverse effects. 
 Women also expressed ongoing concern about long-term risks, often arising from their 
awareness of recent study findings, especially those of the WHI. Most of these fears centered on 
the risk of breast cancer although several women also worried about heart disease and stroke 
risks. Two participants also voiced concern about their fear of becoming dependant upon or 
addicted to HT. Eventually concerns about side effects or potential complications from long-term 
use began to interfere with women's lives and peace of mind.     
 At the crossroads: making the decision to stop. Every woman in this study had 
attempted to stop HT. However, there was variability within this universal experience, beginning 
with the reasons why women chose to embark upon this particular path. For some it was because 
of concerns about side effects or long-term health risks. Health care providers occasionally 
suggested that women consider stopping HT although providers differed in how firmly they 
recommended discontinuation: some left the door open for resumption if necessary while others 
insisted that women stop. Several women chose to stop HT when they could no longer afford 
their prescriptions or because transportation or time constraints precluded getting to a pharmacy 
or seeing providers for prescription refills. For a few women, the decision to stop was also fueled 
by a curiosity as to whether they were really 'done' with menopause. Pressure from family or 
friends who were opposed to HT was a motivating factor for several participants and two 
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participants decided to stop HT because they believed they were becoming addicted to the 
medication. Fifteen (44%) of the 34 participants reported more than one reason for stopping. 
 Despite their concerns or doubts about HT, women struggled with the decision to stop 
just as they had struggled with the decision to begin. Some participants contemplated 
discontinuation for several months or longer before finally taking the first steps along that route. 
They spoke of having mixed feelings about stopping, weighing the risk of symptom recurrence 
against the risk of adverse effects. They were aware discontinuation would end their worries 
about HT side effects but could also mean an end to any health benefits and a recurrence of 
menopause symptoms. Several women had actually tried to discontinue HT more than once and 
were well aware of the potential for symptom recurrence as their prior attempts to  discontiue 
had been derailed by the return of symptoms.  
 Women chose to discontinue their medications either by abrupt cessation or 
tapering/weaning, a choice usually made quite arbitrarily. Seventeen women tapered, 11 stopped 
'cold turkey' and five were in the process of tapering. Participants who stopped 'cold turkey' often 
did so because of side effects or because they could no longer afford or obtain their prescription. 
A few women admitted to letting prescriptions lapse to 'see what would happen.' One woman 
was not even aware that there was another method besides stopping abruptly.  
 Among those who chose to discontinue gradually, there was no consistency in tapering 
regimens: women described cutting pills or patches, skipping doses or changing the strength of 
their prescription. Some devised their own tapering schedule while others tapered with the 
guidance of their health care providers. Tapering usually lasted several months although the 
overall tapering duration ranged from three weeks to three years. 
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 Women who had attempted to stop more than once sometimes chose a different 
discontinuation method with subsequent trials. If a previous attempt at stopping abruptly had 
been unsuccessful, the next attempt at discontinuation was often by tapering.     
 Road blocks: roaring back with a vengeance. All study participants experienced 
symptoms after they stopped or while weaning from HT (Table 16). While the symptoms that 
were reported usually represented a recurrence of pre-HT symptoms, sometimes new symptoms 
appeared. Symptoms typically began within days or weeks of stopping or beginning to taper 
although here again there was variation as for some women months elapsed before symptoms 
reappeared or appeared.   
   Table 16.   
   Symptoms after HT discontinuation. 
 
 
Hot 
flashes 
Night 
sweats 
Total 
VMS 
Sleep 
issues 
Affective 
issues 
Memory 
issues 
Urogenital 
Symptoms 
Libido 
Changes 
Frequency 
(%)  
 (N = 34) 
24  
(70.6) 
25 
(73.5) 
28 
(82) 
17  
(50) 
20  
(58.8) 
4  
(11.8) 
12  
(35.3) 
6  
(17.6) 
 
 Most women who had VMS symptoms before HT noticed them again upon stopping 
although for a few women the episodes of intense heat and sweating were new experiences. Half 
of the participants reported sleep disturbances, sometimes but not always associated with 
frequent awakening from night sweats. For eight participants, diminished sleep was a new 
symptom. Lack of sleep led almost inevitably to complaints of fatigue and lack of energy as well 
as decreased concentration, diminished cognition, and emotional lability. Over half of the 
women, five more than pre-HT, reported affective symptoms associated with stopping HT. In 
addition to mood swings and irritability, they also described decreased enjoyment of life, anxiety 
and depressed mood.  
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 Women were very forthright about their mood swings and emotional symptoms, 
expressing both concern and humor in their narratives. Said one participant of her emotional 
volatility: "I jokingly told people that I finally understood the stories about the 'crazy aunt in the 
attic'..." But HT discontinuation sometimes led to more serious repercussions: several 
participants described spiraling into clinical depression as they tapered their medication.  One of 
these women recontacted the researcher one month after completing the study. She reported 
worsening of her depression symptoms to the point that she had to take a medical leave of 
absence from her job. She had to resume her HT and she and her health care provider were still 
struggling to adjust her dose to attain better control of her depression symptoms.  
 As with pre-HT symptoms, VMS, sleep disturbances and affective changes often 
occurred together: of the 32 women who reported having at least one of these three symptoms, 
15 (47%) had two symptoms and nine (28%) had three. The combination of symptoms was 
especially uncomfortable:  
  Thanks to night sweats and accompanying insomnia, I probably did not sleep  
  more than 2 consecutive hours any night that entire summer and fall, which  
  contributed to all the classic sleep-deprivation symptoms: poor memory, irritable,  
  cried too much...And ALWAYS, hot sweaty and miserable... 
 In addition to the above, over one-third of the sample described urogenital changes, 
specifically vaginal dryness and dyspareunia. For six (50%) participants this represented a 
recurrence or worsening of the urogenital symptoms they had noted before HT. One woman who 
had not experienced any menopause-related symptoms before beginning HT reported vaginal 
atrophy as her only discontinuation symptom.  
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 Other symptoms and changes reported by women included headaches (n = 2), decreased 
libido (n = 4), nausea (n = 1) and intense itching (n = 1). Although joint pain was mentioned on 
several occasions, only one woman attributed it to stopping HT; usually joint symptoms were 
associated with other health issues such as arthritis. Three women believed their discontinuation 
symptoms represented a withdrawal phenomenon or 'rebound effect' from stopping HT 
reinforcing the belief that one could become addicted to HT.  
 Although many women had expected their symptoms to recur, they often expressed 
disappointment when symptoms did reappear, especially when they were as bad or worse than 
pre-HT. Some women described a sense of frustration that they were not 'done' with menopause. 
and others felt that symptom recurrence served as an unpleasant reminder that they were aging. 
Disappointment and frustration gradually eased over time and was often replaced by resignation 
or acceptance that they would just have to 'deal' with their symptoms and 'get through' this 
transition. A few women voiced anger that they had not been better prepared.   
 The majority (n = 24, 70.6%) of women rated the intensity of their symptoms as 
moderate to severe. Symptom intensity was reflected in the common refrain "...my symptoms 
roared back with a vengeance." Intensity was also apparent in participants' use of adjectives and 
capital letters, for example: "I also had incredible INSOMNIA and FATIGUE when I tried to 
wean myself from HT..."  
 As symptoms recurred and their intensity increased, women reported more interference 
from their symptoms in their daily lives. Once again, VMS, lack of sleep and mood changes had 
a negative impact on job performance and professional image. VMS that occurred while women 
were working were disruptive, not only because they were uncomfortable, but also because they 
were embarrassing. Women were very sensitive to how their flushed, red faces, wet hair and 
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damp clothing were perceived by their co-workers or clients, and they described sometimes 
being the object of teasing because of their VMS. Fatigue, decreased energy and 'brain fog' from 
lack of sleep limited their capacity to prioritize and concentrate on the job, impeding 
productivity. Emotional lability (mood swings, irritability) also made it more difficult to focus, 
compounding the level of distress. 
 Symptoms also interfered with women's personal relationships. Women were often 
unpleasantly surprised at the rapid mood shifts that provoked negative interactions with family 
and friends: "...I cannot believe how nasty I was/can be to the people I love..." Sexual 
relationships were disrupted: sweating and heat from hot flashes caused women to avoid close 
physical contact with their partners, vaginal dryness led to painful coitus and decreased libido 
had a deleterious effect on women's interest in and desire for intimacy. Several of the women had 
new partners and were very worried about the impact of symptoms on these new relationships. 
For at least one woman, the new occurrence of vaginal dryness was the catalyst that drove her to 
resume HT.  
 The intensity of recurrent symptoms and their ability to interfere in women's lives often 
varied over time. Women who had tapered/were tapering typically reported their symptoms as 
milder in the early stages, increasing in severity as HT dose decreased. For example, one 
participant who had begun tapering HT shortly before her initial interview described only mild 
very manageable symptoms at that time. However, six months into her taper she experienced a 
marked increase in symptom intensity necessitating a suspension in her weaning efforts.  
 Symptom intensity and interference also changed depending on time since stopping, with 
women more distant from discontinuation usually reporting milder, more tolerable or less 
frequent symptoms. Some, in fact, no longer had any symptoms at all. However, once again there 
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was variability in women's experiences: several participants reported persistent (over 1 year) 
VMS or sleep disturbances that were still uncomfortable and burdensome, occasionally eliciting 
a lament of "how long do these go on anyway?!' Prolonged duration of symptoms was 
particularly discouraging. 
 As previously noted, most women who rated the severity of their discontinuation 
symptoms said they were either moderate or severe. In a similar vein, many of the participants 
who compared their discontinuation symptoms to those they had before starting HT described 
discontinuation symptoms as the same or worse than those pre-HT (Table 17). Few women 
perceived their symptoms as mild and/or better than those prior to HT, underscoring the 
discomfort and burden imposed by discontinuation symptoms. 
    Table 17.  
Symptom Intensity and Comparing Pre/Post-HT Symptoms 
Symptom Intensity 
(n = 32) 
Comparing Symptoms Pre/Post-HT 
(n = 29) 
Severe 15 (47%) Worse 8 (29%) 
Moderate 9 (28%) Same 10 (35%) 
Mild 8 (25%) Better 11 (38%) 
 
 Navigating the terrain: managing symptoms. As symptoms came roaring back, women 
employed a variety of strategies in an attempt to decrease symptom discomfort. They tried 
lifestyle measures such as modifying clothing fabrics and dressing in layers, drinking more 
fluids, taking daytime naps, and cooling down with ice collars and fans.  One participant waxed 
eloquent about the VMS-eliminating benefits of soy. However there was little mention about 
other supplements such as black cohosh (although several women had reported these as 
ineffective in the control of their pre-HT symptoms). Only a very few women talked about 
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strategies such as acupuncture, exercise or meditation. Several women spoke of the importance 
of humor and the support of friends.      
 Adopting a determined or 'just deal with it' attitude was another strategy. Women, 
especially those who had tried to stop HT in the past or were concerned about future risks, spoke 
of being resolute in their decision to stop: "I think that my determination obviously is a big part 
of it. I was determined that this was going to succeed..." Another woman stated that she decided 
she was just going "to make it happen" and she did. These women stated matter-of-factly that 
they just accepted or put up with whatever symptoms came their way. One woman spoke of how 
she talked herself out of catastrophizing and over-reacting to VMS by making a conscious effort 
to evaluate symptoms objectively and reminding herself that they were 'just' hot flashes..  
 A few women reported taking other medications, specifically antidepressants, during 
discontinuation that may have helped ease some of their symptoms. Women with urogenital 
symptoms often reported continuing or beginning to use vaginal estrogen. 
 The recurrence of symptoms eventually brought most women to another crossroad: 
having to choose whether to continue or resume. Although some remained adamant about not 
resuming, others expressed uncertainty, once agian weighing the risks of adverse effects against 
the risks of symptoms. Ultimately, nine women (26.5%) chose to resume HT. While most (n =8, 
89%) resumed for relief of their moderate-severe symptoms, several also stated they wanted 'to 
feel better' in general. The majority of those who resumed HT did so eagerly, voicing few or no 
regrets or guilt. However, one woman expressed much disappointment as she felt she had no 
other options: "I went back on prempro because I was miserable...It was a tough decision 
because I hate to be on anything and what I hear about the hormone replacement terrifies me."   
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 The range of time from cessation to resumption ranged from 2-3 weeks to over 6 months. 
The majority of women resumed the same type and dose of HT they had been on prior to 
stopping although several participants, with the advice of their health care providers, made 
adjustments in their regimen in the hopes that reducing the dose would reduce their risks. A few 
women chose not to inform their providers immediately, instead refilling existing prescriptions. 
This was a common practice among the women whose providers had given them carte blanche to 
resume if they needed to do so. (Women who had stopped and started HT several times also 
described resuming HT without consulting their providers during prior attempts, sometimes 
because of time constraints or because they did not want providers to know they had stopped.) 
 The journey ends, the journey continues: future plans and life lessons. The women 
who decided to resume HT reported either complete resolution or a reduction in all their 
symptoms. They spoke of feeling as though their HT-related energy had returned and that they 
were able to enjoy their usual activities once more. Being able to fully participate in daily 
activities gave them back a feeling of control and normalcy. A few vowed that they would 'never 
again' try to discontinue. Others planned to attempt another taper in the future. 
 As previously noted, some women who remained off HT were no longer having 
symptoms while others were still having mild, less frequent and more manageable symptoms. 
Women who had discontinued HT because of side effects or worries about future risks described 
feeling as though they had regained their health. These women also reported gaining a sense of 
control or normalcy although here the focus was related to reclaiming control over their bodies. 
There were numerous comments about feeling less fearful or worried and being more at peace: 
"An equanimity came. I didn‘t realize that I was a little bit concerned about the risks...so there 
was a peacefulness that came with the decision which surprised me." Two women also spoke of 
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feeling calmer or less irritable. Although many women who had stopped were emphatic about 
not resuming, a few admitted to some ambivalence: "The reluctant acceptance of this time has 
mellowed me a bit but a part of me feels defeated..." Acknowledging that HT had controlled their 
menopause symptoms, some women added that they might consider resuming HT if it was ever 
deemed risk-free.  
 The five women who were tapering planned to continue to do so although it was 
uncertain how many planned to completely discontinue: two women were only several weeks 
into their current taper when they participated. One woman had suspended her taper when her 
symptoms made a recurrence six months into the taper and the woman who had struggled with 
recurrent depression actually had to stop tapering because of her relapse. The fifth woman was 
cutting back her dose but admitted that part of her current taper was to placte her health care 
provider and she actually did not plan to stop HT because of concern about recurrent symptoms.  
 The experience of attempting to stop HT served as a learning experience for many 
participants. Some discussed realizing their own sense of vulnerability and that asking for help or 
support from others or through medication was acceptable. Other women reported acquiring a 
better understanding of their strength and ability to persevere as well as a newfound sense of 
trust in their intuition and their bodies' wisdom. Menopause was more deeply appreciated as a 
critical transition in women's lives. 
 Women were also asked to rate their experience of HT discontinuation on a 1-10 (mild to 
severe) scale. As to be expected, women who described greater symptom distress or disruption 
often rated their experience as more severe but this was not always the case. Some very 
symptomatic women actually rated the overall experience as mild, citing other life experiences 
such as family illness or financial problems as more difficult or challenging.  
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 The path of HT discontinuation was clearly distressful for many participants due in great 
part to the recurrence of troublesome and sometimes intolerable symptoms. However, there was 
great variation in the women's HT discontinuation journeys: symptom experiences differed 
between women as well as over time for each woman due to the influence of personal and 
sociocultural factors .   
Specific Aim 2: describe the personal characteristics and sociocultural contexts that 
influence symptom perception, evaluation and response among women who have attempted 
to discontinue HT   
 Because symptom experiences may be influenced by multiple factors, women were asked 
to identify or describe any factors that may have played a role in their experiences and to respond 
to a demographic/lifestyle survey. This Specific Aim continues the story of women's 
discontinuation journeys by describing these factors which emerged through both separate and 
integrated qualitative and quantitative analysis. While some of these factors clearly aligned with 
the conceptual categories (i.e., sociocultural context and personal characteristics) within the 
organizational framework, other factors were not as easily assigned to pre-existing categories 
and may indeed bridge the conceptually defined factors.  
 Influential factors. All participants encountered symptoms upon discontinuing HT.  The 
factors described below contributed to women's experience of symptoms and/or whether they 
chose to resume or remain off HT. The section will include references to the subthemes of 
symptom burden and interference as well as risk appraisal. 
 Roles: professional and personal. Many study participants had high stress and/or high 
profile jobs (e.g. professors, health care providers). They often spoke of needing to be awake, 
alert and functioning at a high capacity while in the workplace. Therefore, symptoms that 
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interfered with work performance, such as memory lapses or fatigue from sleep disturbances, 
were judged as especially bothersome and burdensome. Recurrent symptoms were also poorly 
tolerated when they caused embarrassment in front of peers, compromised office relationships or 
necessitated changes in a woman's work environment (portable fans, open windows). 
 As previously noted, symptoms also had the capacity to negatively transform women's 
interactions with their family members and friends. Irritability and mood swings provoked 
arguments and disagreements, lack of energy and interest led to less enjoyment of and 
participation in social events, and urogenital symptoms threatened sexual intimacy. When these 
occurred, symptoms were again appraised as burdensome.  One participant concisely 
summarized the impact of symptoms on women's life roles: "I couldn't function at work or 
home." Symptoms clearly threatened women's functional ability. 
 Cost, financial strain & options. Approximately one-third (n = 12, 35%) of the sample 
reported some level of financial strain (somewhat or very difficult paying for basics). Only a few 
women had to stop HT because of inability to pay for prescriptions. However, needing to stop 
HT because of financial concerns added a layer of distress to the overall experience as women 
had to contend with both financial difficulties and the additional burden of unwanted and 
uncomfortable symptoms. They realized that some of their control had been taken away. They 
had to make choices between symptom relief and other important issues: for example, 
medications for health concerns such as hypertension or rheumatoid arthritis were deemed more 
important than HT. One woman also described having to choose between HT and going out to 
dinner, something she enjoyed very much. In making these choices, menopause and 
discontinuation symptoms were not weighed as heavily as other health concerns or even lifestyle 
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factors. Ultimately menopause symptoms, while uncomfortable, were not considered an illness 
and taking medication to relieve symptoms of a non-life threatening condition was not an option. 
 Beliefs and expectations: menopause, medications and HT. As women described their 
experiences of contemplating whether or not to begin, discontinue and perhaps resume HT, they 
often invoked their beliefs and expectations of menopause and HT. These beliefs and 
expectations had been shaped in women's sociocultural background long before they themselves 
even entered menopause. Participants described their recollections of family members with 
menopause symptoms and how these images influenced their expectations. Their expectations 
and beliefs were also influenced by the media, peers, and the scientific literature (textbooks, 
medical journals and professional conferences). In addition, several women alluded to a belief 
that their own good health and healthy lifestyle would allow them to navigate menopause 
without the need for any intervention. Because of the variability in their backgrounds, women's 
beliefs about menopause and HT were also quite varied. Overall, twelve (35%) women reported 
having positive expectations about menopause or negative beliefs about HT. A few (n =7, 20%) 
women described a general distrust or dislike of all medications.  
 These beliefs and expectations factored into how readily women chose to begin HT as 
well as adding impetus to the decisions to stop and remain off HT. For example, women who 
stopped HT for reasons such as side effects or concerns about risks often added that had always 
believed menopause was a natural transition or that they had felt negatively about HT. Half of 
the 20 women who remained off HT described having had positive expectations of menopause 
and nine (45%) expressed longstanding negative beliefs about HT. Disliking any type of  
medications in general seemed to serve as reinforcement for discontinuing and not resuming HT.  
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 One noteworthy phenomenon among the participants was a slight shift in attitudes toward 
HT. For women who had felt positively about HT before menopause, the experience had 
reinforced those beliefs whether or not they chose to resume HT. However, several participants 
who had appraised HT negatively prior to menopause reported a moderation of opinion to one of 
cautious approval once they had experienced firsthand how readily HT had eased their 
symptoms. HT might be alright, they opined, but only for a limited time and only if women had 
explored all other options, keeping in mind that symptoms could recur with discontinuation   
 Discontinuation expectations. The majority of participants were expecting some 
symptoms to recur when they stopped HT, having been forewarned either by their providers or 
their own explorations through the lay press and scientific literature. Women who had stopped 
and started HT in the past were already prepared by their prior experiences of symptom 
recurrence. Nonetheless, many women harbored hopes to the contrary. A few women even spoke 
of initiating HT cessation with the belief that their transition through menopause had been 
completed during their time on HT (several had actually been told this by their providers). They 
were naively expecting they would not have to contend with recurrent symptoms. Thus, the 
eventual recurrence of symptoms often brought disappointment, particularly when symptoms 
were as bad or worse than before HT as previously noted. This added more distress for several 
women: "I was disappointed, I was really surprised at how bad they were...I just really thought I 
have been on them for a while maybe I am through it. No such luck."  
 Readiness to stop. Six (18%) participants, including several women who had made 
multiple attempts to stop or who had been on HT for many years, talked about the role of timing 
or 'intuition' in their decisions to stop. They had a sense of being 'ready' to stop, that they had 
reached a point in their lives where discontinuation might be successful. These women were 
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usually successful at stopping HT and most (n = 5, 83%) reported their discontinuation 
symptoms as being mild, not interfering and better than pre-HT symptoms.   
  I knew that I would intuitively know when it was time to come off and it would   
  feel right to me. I wouldn‘t do it out of any kind of negative orientation at all. It   
  would be a positive choice that I made and that is exactly what happened. 
However, despite attributing their success to an intuitive sense of timing, they also 
acknowledged that other forces, such as an awareness that they were approaching the 'safe limits' 
of HT or the resolution of other life stressors, may have played a role in their sense of readiness 
and overall experience.  
 Reasons for stopping. Successful discontinuation of HT was related to both the number 
of reasons for stopping as well as the specific reason for stopping. Participants who remained off 
HT (n = 20) were more likely to report more than one reason for stopping (n = 12, 60%). 
Conversely, the majority of the nine women who resumed HT (n = 5, 56%) cited only one reason 
for discontinuing. The two most common reasons for stopping were concern about long-term 
risks (n = 18, 53%) and HT-related side effects or complications (n = 14, 41%). Women who 
stopped for these reasons were very likely to be successful at stopping: 53% (n = 9) of the 17 
women who stopped because of risk concerns remained off HT. Similarly, 12 (85%) of the 14 
women who stopped because of side effects also remained off HT. In addition, women who 
stopped due to side effects (n = 14) tended to have been on HT for a shorter duration (M = 2.90, 
SD = 3.89) than women who did not have side effects (n = 20; M = 7.33, SD = 4.87), t(32) = -
2.82, p = .008.   
 Appraising risks. Women worried about future complications or dealing with side effects 
often compared these risks against those imposed by disruptive symptoms. Symptoms were 
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perceived as risky because of their capacity to interfere in or disrupt women's daily lives. When 
symptoms were weighed as more risky or threatening than the long-term risks of HT, women 
resumed medication: "I tried to stop, now I am tapering, but to be truthful I do not intend to stop 
completely, I just feel like that feels too risky for me." Conversely, when the impact of side 
effects or worry about long-term risks were seen as more cogent then the threat imposed by 
symptoms, women chose not to resume. This was particularly apparent among several women 
who had stopped and resumed multiple times before finally discontinuing for good: during initial 
attempts at discontinuation, the risk of symptoms outweighed the risks associated with HT. 
However, as the duration of HT use increased, so too did concerns about long-term health issues 
ultimately fueling the determination to stop HT completely.  
 One of the noteworthy aspects of this appraisal was women's tendency to focus on risks 
more than on benefits. While women occasionally acknowledged HT benefits of symptom 
reduction as well as heart and bone health, these factored less into their appraisal than did HT 
and/or symptom risks. Participants spoke of  choosing to "take my chances" with HT risks 
because symptoms were "too risky" to try to manage or they preferred to deal with menopause 
symptoms because of potential long term risks. Thus, appraisal appeared to be less of an analysis 
of risks and benefits and more of a comparison of risks leading women to choose which 
symptom was more manageable: "The hot flashes are still frequent enough & maddening but 
better than dealing with the bleeding."  
 Symptom tolerance. Perhaps the most salient factors influencing both women's 
experiences and the outcome of discontinuation attempts were the symptoms themselves, or 
more specifically specific components of the overall symptom experience. Grouped under the 
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heading symptom tolerance, these critical factors include: number of symptoms, symptom 
intensity, symptom interference and sensitivity to symptoms.  
 Many study participants appeared to exhibit was a heightened sensitivity or awareness of 
their symptoms. This sensitivity was often reflected in the graphic and emphatic manner in 
which they described their experiences, employing devices such as capital letters, vivid language 
and punctuation to demonstrate the intensity of their experience. Women described closely 
monitoring how they felt as they discontinued and were quick to notice the onset of even very 
mild or subtle symptoms. Symptoms became the center of their attention, constantly in the 
forefront of their day-to-day awareness and "all-consuming" as one participant described. In 
addition, women who resumed HT often commented that they could not think of anything that 
helped, or might have helped, to manage their symptoms other than to resume medication. 
Conversely, women who remained off HT were more likely to describe a variety of symptom 
management strategies.  
 Trying to contend with multiple symptoms also impacted on women's perception of their 
experiences. Although most participants reported more than one symptom when they stopped 
HT, women having many symptoms often described them as worse than pre-HT symptoms. 
They also rated the overall discontinuation experience as more severe. In turn, symptoms that 
were reported as more severe appeared to influence whether women resumed HT: two-thirds (n = 
6, 67%) of the nine women who resumed rated the intensity of their recurrent symptoms as 
severe. However, only 30% (n = 6) of the 20 women who discontinued described having severe 
symptoms. 
 Symptom interference, the degree to which women reported symptoms as disruptive, was 
closely linked to symptom intensity. Two-thirds of the sample in the present study described 
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interference from their discontinuation symptoms. The more intense or severe the symptoms, the 
more women were likely to report that symptoms interfered in their lives: 20 of the 24 women 
who reported symptom intensity as moderate or severe after discontinuation also described 
interference from these symptoms. Women were very descriptive in their narratives as to how 
their symptoms served as barriers, particularly within their jobs and relationships, causing great 
distress and diminished enjoyment in their lives. Terms such as 'disruption,' 'couldn't function' 
and 'prevented me from....' revealed the depth to which symptoms interfered with women's 
ability to participate in their daily activities and cope with the stresses inherent in their work.  
 The majority (8, 89%) of the nine women who resumed reported interference while 
discontinuing yet 12 women (60%) who remained off HT also affirmed, often very emphatically, 
how symptpms had interfered as they were discontinuing. Accordingly, the narratives of these 
women were re-examined to further explore whether any additional factors may influence 
women's capacity to tolerate disruptive symptoms.  
 All but one had started HT for symptom relief although all but one had used for less than 
five years; all had more than one symptom with discontinuation. Most reported moderate to 
severe symptom intensity; over half (n=8, 57%) reported affective symptoms in the moderate-
severe range on the MRS. A common denominator among them was that they perceived that they 
had no options other than to discontinue HT (Table 18). Three women were not able to afford 
their prescriptions and one participant was told she needed to stop HT as it was contributing to 
an worrisome increase in blood indices for CVD.  Five were bothered by HT-induced side effects 
(including one woman who believed she was beginning addicted to HT); they had chosen to stop 
when these side effects became more burdensome and difficult to manage. The final three 
women stopped because of deep-seated concerns about risks: because of a family history of 
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breast cancer or stroke, these concerns weighed heavily while they were taking HT and served as 
motivation to discontinue.  
Table 18.  
Women reporting interference who stopped HT 
 
Age 
Age 
at 
FMP 
HT 
Duration 
(in years) 
Number 
of 
symptoms 
 
Symptom 
intensity 
Reason for stopping 
1 57 53 3 6 Moderate Worried about CVA 
2 55 53 1.5 4 Severe Worried about all risks  
3 57 50 0.9 2 Mild Side effects: weight gain 
4 54 50 1.5 5 Moderate Cost 
5 59 39 12 5 Severe Health issue: cardiac 
6 56 50 6 2 Mild Worried about breast cancer 
7 55 51 2 3 Moderate Side effects: weight gain 
8 50 49 1 4 Moderate Side effects: addiction 
9 57 51 4 7 Severe Cost 
10 51 50 2 2 Mild Side effects: migraines 
11 55 52 2 2 Moderate Side effects: bleeding 
12 50 50 2 3 Severe Cost 
   
 As women appraised their symptoms as well as the risks and threats imposed by both HT 
and discontinuation symptoms, they also weighed the impact of these symptom factors and risks 
on multiple aspects of their QoL.  
Specific Aim 3:  explore the impact of HT discontinuation on women’s quality of life 
 In order to look more closely at multiple dimensions of QoL during HT discontinuation, 
women were asked to respond to both open-ended questions and QoL-related instruments. There 
was variability in QoL between participants; there was also variability within individual 
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participants on different domains of QoL.  Specific Aim 3 findings captured women's beliefs 
about QoL and the impact of discontinuing HT. 
 Women's Expertise: Quality of Life. While women often looked to outside resources 
for information about menopause or HT, women themselves were the experts in their own QoL. 
Personal definitions of QoL encompassed many of its different facets, with some women 
focusing on domains of symptom and health-related QoL while others described concepts such 
as well-being or peace of mind. QoL was highly valued and one of the issues women considered 
when weighing risks and benefits. The most commonly reported facets of QoL that women held 
dear were: enjoying being able to do things and participate in activities, good relationships and 
enjoying time with family and friends, good health and peace of mind. 
 Menopause, HT and QoL: Women's Words. Women's discussion of how menopause 
and HT discontinuation impacted on their QoL parallels their discontinuation narrative. For 
many women the two descriptions are nearly superimposed as symptoms were perceived as 
being directly responsible for a decrease in QoL.  
 Menopause symptoms influenced QoL by interfering with women's ability to do the 
things they needed or wanted to do. Decisions to begin HT were often made when women 
appraised their symptoms as disrupting their daily activities or enjoyment of life, their 
relationships and their health (especially emotional health). When these were disrupted, so too 
was  their QoL. Therefore, for the women in this study, QoL was closely connected to their 
ability to function in their multiple roles and enjoy life: symptoms that interfered with functional 
ability interefered with QoL. 
 There was a vast improvement in QoL once HT reduced or eliminated symptoms and 
stabilized sleep and moods. Thus for many women, symptom reduction was a component of 
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improved QoL. Several women noted that HT also provided them with a greater feeling of well-
being or a heightened energy or awareness: "There is an invisible extra dose of joie de vivre that 
seems to be estrogen/progesterone related. Something nearly magical in confidence and approach 
to life..." There was speculation that this sense of 'joie de vivre' was perhaps due to better sleep 
or mood, or possibly to looking better and feeling younger. 
 Given the connection between QoL and symptoms, it was inevitable that discontinuing 
HT also brought changes in QoL that were typically viewed as negative. Recurrence of 
symptoms once again interfered in women's ability to function and juggle their multiple roles. 
When symptoms reappeared, women found themselves again dwelling upon and consumed by 
how miserable they felt as well as how best to manage these negative physical sensations. 
Symptoms that persisted for a long time, plus uncertainty as to their duration, also had a negative 
impact on QoL.  Losing one's HT-induced joie de vivre evoked sadness, adding to the 
unpleasantness of the experience: 
  ...everything lost its shine. I could be in a beautiful garden but would have no  
  interest in smelling the roses – I would just feel annoyed over the heat, thorns...I  
  was much less of a human being, and could give much less to the world... 
 Poor QoL was a primary force behind HT resumption. Although taking HT incurred 
risks, the impact of discontinuation symptoms on QoL was perceived as outweighing the risks of 
HT. QoL was indeed a predominant factor in many women's appraisals of HT benefits and risks.  
 As before, there was variability in women's assessment of QoL. Not all women felt HT 
improved QoL, citing ongoing life stressors as more salient to their QoL than were symptoms. 
For women with HT-induced side effects or worries, stopping HT eliminated their fears and 
physical problems and therefore often enhanced their QoL. They felt as though they had regained 
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their health and control over their bodies. For those women whose symptoms became less-
intense and all-consuming as time passed, QoL also improved.  
 From women's narratives, it was clear that both discontinuation and resumption had the 
potential to influence QoL both positively and negatively. Attention was turned to the 
quantitative analysis in order to more deeply explore the impact of HT discontinuation and/or 
resumption on different dimensions of QoL.  
 Menopause, HT and Qol across dimensions. Not surprisingly, women who had resumed 
HT had the lowest scores on both the MRS and the HFRDIS. When rating symptoms on the 
MRS, the majority of women  reported no or only mild severity for most individual symptoms as 
well as the overall symptom score (n= 20, 59%). Another 32% (n = 11) reported moderate 
overall symptom severity. Approximately 75% (n=25) of participants noted sleep symptoms, 
mostly mild, and 71% (n=24) of participants were still having hot flashes although again, most 
were rated as mild. Over half (79%, n = 28) of the sample acknowledged currently experiencing 
some type of affective symptom (Table 19). Although most were in the mild range, 38% (n = 13) 
were dealing with moderate to severe/extremely severe depression, irritability or anxiety. 
Table 19.  
Frequency of Affective Symptoms  
 Depressed 
Mood 
Irritability Anxiety MRS Psych 
Subscore 
None 17 (50%) 14 (41.2%) 16 (47.1%) 7 (20.6%) 
Mild 7 (20.6%) 10 (29.4%) 7 (20.6%) 14 (41.2%) 
Moderate 5 (14.7%) 6 (17.6%) 6 (17.6%) 7 (20.6%) 
Severe 4 (11.8%) 4 (11.8%) 5 (14.7%) 5 (14.7%) 
Extremely 
Severe 
1 (2.9%)   1 (2.9%) 
 
  A similar pattern emerged on the HFRDIS: eight of the nine women who had resumed 
HT reported that hot flashes caused minimal to no interference in their daily lives with one 
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woman still reporting moderate symptoms (VMS, affective and urogenital symptoms) and 
interference. However, a majority (n = 16, 47%) of the remainder of the participants, including 
both women tapering as well as those who had discontinued, also reported minimal to no current 
symptom interference.  
 Further examination of the HFRDIS scores revealed two additonal noteworthy findings. 
First, it was observed that four other women who had not verbalized interference in their 
narratives actually had interference scores in the moderate to severe range indicative of VMS 
that were currently causing some disruption in their lives. Two of these women stopped HT 
because of side effects, one because of cost issues and the last because of concerns about risk: 
the same concerns as the women who reported interference verbally. Thus when interference was 
elicited both qualitatively and quantitatively, past and present, the total number of women whose 
lives were disrupted by troublesome symptoms yet still remained off HT was 16 (80%). 
Obviously symptom interference was a common consequence of stopping HT although it 
appeared to ease over time. 
 The second finding was the observation that the majority of women with a profile of 
moderate to severe interference from VMS (n = 9, 26%) were experiencing moderate to severe 
interference across all domains of life addressed by the HFRDIS.  Eight of these women 
remained off HT; seven of them also reported moderate to severe symptoms on the MRS. Thus 
there was a small cluster of women who were experiencing challenging symptoms and 
interference from these symptoms yet remained off HT. Of the eight discontinuing women with 
high HFRDIS scores, all described that they 'had' to stop HT related to expense, side effects or 
worry about risk. Four had acknowledged symptom interference in their narratives; the 
remainder, as noted in the previous paragraph, only reported interference quantitatively. The 
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 narratives of these four women (two online interviews, two telephone) were re-explored to 
attempt to understand why they may not have reported interference qualitatively. Three of them 
had stopped HT because of troublesome and disruptive side effects, the fourth because of 
concerns about risks. While all had described discontinuation symptoms in their narratives, they 
also described relief at no longing having to deal with symptoms or risk fears and had made up 
their minds to 'just deal with' their symptoms.  
 The transcripts of four other women with moderate to severe symptoms but reporting 
little interference from VMS were also re-examined. One had no VMS, one had already been off 
HT for a year so her symptoms had diminished and the third had other life concerns that 
interfered more than did her symptoms. The last woman had also adopted a 'just deal with it' 
attitude, describing in detail how she would talk herself out of catastrophizing about her VMS. 
 On the quantitative QoL/well-being questions, over half of the participants rated their 
well-being as good or very good; 70% (n = 24) of women were satisfied or very satisfied with 
their health and 76% (n = 26) perceived their overall QoL to be good or very good. The overall 
QoL responses were consistent with the overall QoL score on HFRDIS and corroborated 
women's verbal reports about their QoL. Once again, higher scores were seen among the women 
who resumed HT.  There was also a trend among women with moderate-extremely severe MRS 
Psychological and Somatic subscores to report greater symptom interference on the HFRDIS and 
scores on the QoL, self-reported health and well-being questions in the moderate range. 
 A closer look at the quantitative data reveals some discrepancies on the QoL scores for 
eight participants. Six of these women reported moderate to severe interference from VMS on 
the HFRDIS and/or moderate symptoms on the MRS yet still rated their overall QoL as good 
(Table 20). Once again, returning to the narratives of these women revealed that half of them had  
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Table 20.  
Women with moderate-high MRS & HFRDIS scores but good overall QoL 
 1 2 3 4 5 6 
Age 54 49 48 55 55 55 
Age at FMP 50 48 46 50 50 51 
HT Duration 
(in years) 
1.5 1.5 0.5 .75 5 4 
Number of 
symptoms 
5 5 1 6 4 7 
Symptom 
intensity 
(qualitative) 
Moderate Severe Severe Moderate 
Mild 
 (on final 
attempt) 
Severe 
Symptom 
interference 
(qualitative) 
Yes No No No 
No 
 (on final 
attempt) 
Yes 
Comparison to 
pre-HT 
symptoms 
worse same same same better worse 
MRSSoma severe severe moderate moderate moderate severe 
MRSPsych moderate mild mild moderate moderate 
extremely 
severe 
MRSUro severe mild moderate moderate severe 
extremely 
severe 
MRSTotal moderate moderate mild moderate moderate severe 
HFRDIS moderate moderate moderate severe moderate severe 
Feeling 
Mostly 
good 
Up and 
down 
Mostly 
good 
Up and 
down 
Up and 
down 
Mostly 
good 
Happy 
Generally 
satisfied 
Generally 
dissatisfied 
Generally 
satisfied 
Sometimes 
Satisfied 
Sometimes 
Satisfied 
Generally 
satisfied 
Interesting 
Things 
Most of the 
time 
Some of 
the time 
Good bit of 
the time 
Some of 
the time 
Some of 
the time 
Most of the 
time 
Cheerful 
Some of 
the time 
Some of 
the time 
Good bit of 
the time 
Good bit of 
the time 
Some of 
the time 
Good bit of 
the time 
Health Status 
Neither 
good nor 
bad 
Neither 
good nor 
bad 
Satisfied Satisfied Satisfied Satisfied 
Overall QoL Good Good Good Good Good Good 
Reason for 
stopping 
Cost 
Side 
effects: 
weight gain 
Side 
effects: 
weight gain 
Side 
effects: 
bleeding 
Worried 
about 
cancer 
Cost 
 
stopped HT because of distressful side effects, specifically weight gain and bleeding. One 
woman was worried about long-term health risks and opted to stop HT to minimize those risks; 
the other two stopped because of cost issues. One of the women (#6) who stopped due to cost  
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also struggled with other health-related symptoms when she entered menopause; this other health 
issue was in better control when she discontinued and thus did not add to her symptom burden. 
She also recently had obtained a new job and returned to school so other non-menopause related 
factors were more critical to her well-being and QoL. (Of note: participants #2-5 represent the 
women who did not report interference in their narratives but did so on the HFRDIS.) For the 
women with high QoL despite moderate to severe symptom intensity and interference, overall 
QoL was more positively influenced by reducing HT-related side effects and concerns about 
risks, finances and other health issues. Several of these women commented that there was more 
to their lives than symptoms or menopause.  
 A similar exploration was conducted of the qualitative data from two women who 
reported poor/very poor overall QoL but little interference. One woman explicitly stated that her 
low QoL was a product of her poor financial situation and not from discontinuing HT. The other 
woman was troubled by longstanding mood issues; it was these symptoms that impacted her 
QoL. Thus, while QoL and symptoms were closely linked for many participants, for a small 
subset other life factors were more salient in their appraisal of QoL.  
 Quality of life was an important issue for the women in this study. Appraisals of QoL and 
the degree to which symptoms interfered with QoL sometimes led to decisions about resuming 
HT. However HT did not always improve QoL nor did the occurrence of symptoms impact on 
overall QoL for some participants.  
 
 
 
 165 
 
Specific Aim 4: discuss women’s preferences for counseling and support during HT 
discontinuation   
 In order to determine what knowledge would be most beneficial along the discontinuation 
journey, study participants were asked open-ended questions about information they received 
and/or desired. Specific Aim 4 addresses these responses. 
 Seeking knowledge, sharing wisdom. The degree to which many women suffered from 
their symptoms and decreased QoL would argue for the need to provide women with up-to-date 
and relevant information as they attempt to discontinue HT. Study participants appraised the 
information they were or were not given, making comparisons to the knowledge they believed 
they needed for managing symptoms and maintaining QoL during HT discontinuation.  
 Health care providers: information. Most (n =30, 88%) women went to MDs for their 
menopause-related health care; four (12%) received their menopause care solely from nurse 
practitioners (NPs). Four other women saw NPs and one saw a nurse midwife (CNM) in addition 
to their MD providers. Other providers included: Doctor of Osteopathy (1), a homeopath (1), 
Doctor of Naturopathy (2) and Traditional Chinese Medicine Practitioner (1). Ten (29%) women 
reported seeing more than one provider.  
 Providers sometimes offered very detailed information about what women could expect 
when stopping HT and suggested strategies for symptom management, including the option of 
resuming HT should recurrent symptoms prove to be intolerable. However, many women did not 
receive much information when they were contemplating or beginning HT discontinuation. In 
some instances, this was because the women had stopped taking their medication without 
informing their providers. In other instances, women stated their providers were aware they were 
stopping but that the information offered was  limited or impersonal. There was a feeling among 
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some participants that they had been left to find their own way, with no resources to guide them 
along this journey. One woman related her belief that the lack of guidance from her provider was 
a contributing factor in her ongoing worry about whether she had made the right decision to 
resume HT: 
  I wish my doctor did talk to me a little bit more about it to put me more at   
  ease...he didn‘t do that with me and I think that scares me even more. I would  
  rather know the worst just so I can make a better decision....      
 There were inconsistencies in the information that participants were given: some women 
were told to stop HT because of the risks whereas other women received the exact opposite 
information. Women often commented about the mixed messages they had encountered about 
HT and how confusing and unsettling this felt when they were trying to make their decisions. 
They were distressed and frustrated that health care had not yet arrived at a definitive answer 
about HT and whether it was harmful or beneficial.  
 Women also acknowledged that they had received limited education about lifestyle 
changes such as exercise and nutrition. Some women were comfortable with this situation. They 
believed that their providers had not discussed these issues with them because they were already 
knowledgeable about health promotion because of their occupation (RNs or NPs) or existing 
exercise regimen.  
 Occasionally providers offered women ongoing support by way of check-in calls during 
and after discontinuation. While some women felt as though additional contact was not 
necessary, others wished their providers had done more outreach, even an occasional email. 
Several women who had not informed their providers about their discontinuation attempts 
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wished in retrospect that they had communicated with their providers so as to avail themselves of 
any support that may have been offered. 
 Not all women wanted their providers to be aware of their discontinuation status: a few 
women chose not to discuss this out of concern about their provider's reaction, especially if it 
became known they had gone against the provider's recommendations. Other participants had not 
informed their health care providers because they did not want to be forced into discussions 
about unpleasant topics such as weight loss.  
 Some of the participants actually verbalized anger. Some expressed anger that they had 
let themselves be talked into stopping by their providers. They were also angry with providers 
for not being more supportive or for not offering adequate and/or accurate information prior to 
discontinuation. Anger was also directed toward medical research that more was not being done 
for women stopping HT or for women's health in general: "...if it was a man‘s issue – it would 
have been dealt with in a more effective way..."  
 Woman to woman. Many women agreed that there was still limited discussion and 
dialogue about menopause among women. This was sometimes attributed to social norms related 
to discussing 'women's issues' in public. However, several participants actually stated that they 
could not talk with family or friends because of differences in opinion about HT and had gone 
against the advice of their social circle when starting HT. They spoke of having fights with 
family members about taking HT and feeling as though they had no one with whom to discuss 
HT questions or concerns. 
 Yet many women spoke of wanting to be able to connect with women like themselves 
who had stopped or were attempting to stop HT. They also desired more educational forums and 
support groups either in person or via online webinars, chat groups or blogs specifically for 
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women discontinuing HT. Through open discussion with other women through any of these 
venues, they believed their experiences would be normalized and they could also share ideas and 
suggestions for making HT discontinuation easier.  
 Almost universally, participants recommended that women contemplating stopping, or 
even starting, HT 'do research' to get as much information as possible prior to making a decision. 
Almost all, even those who held negative beliefs about HT and/or medications, affirmed that 
women should not be hesitant or afraid to start HT, even if only for a short time, because of the 
symptom reduction. However, the decision should be made on an individual basis taking into 
consideration the specific contexts and situations in each woman's life.   
 Health care providers: recommendations. As such, women asserted that health care 
providers need to present updated, consistent and accurate information to women with a 
personalized analysis of each woman's risks and benefits. With a resounding chorus of "listen to 
women!" participants stipulated that health care providers need to take the time to understand 
women's concerns and not minimize their symptoms or QoL: "...it is my job to try to fully 
explain to my physician what my needs are or what my life is...and it is his job to listen to me 
and to use his knowledge and not to be patronizing." 
 Several women did report that their providers had been extremely helpful and supportive 
during this experience. According to the participants, these providers took time to adequately 
educate the women about their options, explaining risks and benefits clearly, suggesting 
strategies for managing symptoms and offering encouragement that transcended simple medical 
care: "I felt (and still feel) very supported by my NP. She was so caring about the moodiness I 
was experiencing, and offered spiritual support as well as medical support." Having a provider 
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who was perceived as caring and supportive was comforting for the women fortunate to have 
access to their services.  
 These participants clearly desired more information and support to guide them along their 
journey of discontinuing HT: this information needs to be rooted in evidence yet personalized 
and relevant in the context of each woman's life. 
Summary 
The findings from this study which included one overarching theme 'a solitary journey' 
and two subthemes reflected each woman's personal and individual experience of discontinuing 
HT. Most women who stopped HT experienced multiple uncomfortable symptoms but the nature 
of the symptoms and their inherent burden and interference varied for each woman. Women 
often appraised risks of symptoms versus HT when considering their options for managing 
symptoms. Factors (roles, finances, expectations of menopause, HT and discontinuation, reasons 
for stopping HT, readiness to stop, and symptom tolerance) that impacted on symptom 
experience and discontinuation were identified and discussed.  QoL was an important 
consideration and symptom interference on QoL often influenced women's choices, but QoL also 
varied both between and within women based on their appraisals of risk. Finally, women desired 
more information about HT discontinuation and menopause in general and preferred that 
information from their health care providers be personalized to support them on their individual 
journeys. These findings provide information that will help to enhance health care practice, 
research and policy in order to better support women stopping HT. 
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CHAPTER V 
DISCUSSION AND IMPLICATIONS 
 
  The purpose of this mixed methods study was to develop an in-depth description of 
women's experience of discontinuing HT. This topic was important because few studies in the 
post-WHI world have described this phenomenon from the viewpoint of the women living 
through this experience. Findings from this study revealed that women stopping HT undertook a 
solitary journey that was influenced by their symptoms and symptom-associated burden and 
interference. Women's tolerance of symptoms and their choice of whether or not to resume HT 
were impacted by numerous factors; critical among these factors was appraisal of the risks 
inherent to both HT and symptoms. QoL was a highly valued component of women's 
experiences and choices and varied between and within participants. Many participants 
expressed a desire for more information and support on this journey from both health care 
providers and other women traveling the same path. 
 The key study findings will be discussed in this chapter in relation to the existing 
empirical literature about HT discontinuation, menopause symptom burden and interference, risk 
appraisal, QoL and menopause-related QoL, and health care and promotion for mid-life women. 
Implications for practice, research and policy will be discussed as will the challenges and 
limitations of the study. 
Discussion  
Sample Characteristics: Comparison to the Literature 
 The 34 women who participated in this study displayed similarities and differences to 
women in other studies on HT discontinuation, especially with regard to the factors related to HT 
use listed in Table 5 (page 31).  Consistent with earlier studies (Grady et al., 2003), most of 
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participants had started HT for symptom relief. Nine (26%) participants had resumed HT, also a 
percentage commensurate with that noted previously (Grady et al., 2003). All had experienced 
symptoms, many recurrent, some new, upon discontinuation. This is a higher number than has 
been seen in the literature where it has ranged between 30% (Grady et al., 2003) to 55% (Ockene 
et al., 2005). However, this may be due to selection bias: the study topic may have attracted 
women who were symptomatic or distressed by their experience and had a story to share.  
 Some of the factors that in this study were associated with a more difficult experience 
and/or whether or not a woman chose to resume HT have also been reported in the literature. 
These factors include troublesome or severe symptoms (Grady et al., 2003), QoL (Welton et al., 
2003), occurrence of HT-related side effects (Reynolds et al., 2001), attitudes toward menopause 
and medications (French et al., 2006), worries about HT risks (Buick et al., 2005), and HT 
expense (Gerend et al., 2006). Another finding also supported by the literature (Ettinger et al., 
1996) was the association between shorter duration of HT use and stopping due to side effects.  
 Factors such as age, type of menopause and co-morbidities were not able to be evaluated 
due to the small sample size. In addition, it was not possible to determine any correspondence 
between symptom experience and discontinuation outcome by type of HT because of the myriad 
types of HT that women were using as well as the fact that quite a few participants had used 
multiple types of HT...and some could not recall the type they had most recently used. 
 Although discontinuation method was postulated as a possible factor, it was not possible 
to make that determination in this study. There was indeed a trend toward women who resumed 
being more likely to have tried to taper (7/9, 78%), as was noted in a study by Haskell et al. 
(2009). However, there were so many disparate tapering methods used (and two of the women 
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who had tapered and resumed had also tried stopping abruptly in the past) that no conclusions 
could be inferred as to whether method of discontinuation was a factor.  
 The small number of non-Caucasian women in this study precluded any assessment of 
the influence of ethnicity. The lower numbers may reflect previous research which indicates that 
fewer women of African-American or Hispanic ethnicity seek medical support for menopause or 
begin HT (Brett & Madams, 1997). However, this could also be indicative of less use of the 
Internet in non-Caucasian populations (Fallows, 2005). 
 Several prior qualitative studies on HT discontinuation revealed some of the feelings that 
stopping HT has evoked among women, including sadness (Welton et al., 2003), worry about the 
decision (Kolip et al., 2009) and anger (French et al., 2006). Similar emotional reactions were 
also expressed by some of the women in this study, corroborating that intense and sometimes 
negative responses can often accompany the experience of discontinuing HT.  
Symptom Burden and Interference 
 For most of the women in this study, discontinuation symptoms were troublesome, 
however the severity and manageability of these symptoms varied depending on the degree of 
symptom-related burden and interference. Burden and interference emerged as one of the 
subthemes based on women's descriptions of their distressful symptoms and the disruptions in 
their day-to-day lives from these symptoms. 
 Symptom burden is considered to be a component of symptom experience and is defined 
as either an individual's total number of symptoms or a product of the total number of symptoms 
and the severity associated with those symptoms (Cleeland, 2007; Gapstur, 2007; Woods, 2010). 
The latter definition allows for measurement and analysis of both quantitative (number of 
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symptoms) and qualitative (symptom severity) data and thus is both subjective and objective in 
nature (Gapstur, 2007).  
 Symptoms that contribute to burden may occur as a result of illness or the treatment of 
that illness; it can also arise from comorbid conditions (Cleeland, 2007). Outcomes of symptom 
burden that continues to worsen or is not alleviated include both physical and emotional sequelae 
such as impaired functional status or QoL, decreased capacity to perform ADL and worsening 
economic status (Gapstur, 2007). 
 Much of the research on symptom burden has been conducted in the fields of oncology 
and cardiology. In women's health, symptom burden has been explored in studies on 
endometriosis and PMDD (premenstrual dysphoric disorder). There has been less focus on 
symptom burden in the menopause literature although that has begun to change in recent years. 
For example, Bolge et al. (2010) studied the burden of insomnia related to nighttime awakenings 
among women with menopause symptoms. Insomnia was associated with an increase in health 
care costs from emergency department visit as well as impaired work productivity and 
diminished health-related QoL. This is comparable to the findings of the present study wherein 
many participants complained bitterly of disturbed sleep and the impact in their lives: fatigue 
related to insomnia resulted in less energy and interest in ADL, hampered women's ability to be 
focused at work and decreased their overall QoL.  
 In addition to symptom severity, participants also reported multiple symptoms which 
amplified their distress and contributed to their symptom burden. In fact, VMS, sleep and mood 
issues often appeared to co-occur and their impact appeared to be more than simply additive. 
This is consistent with research on symptom management wherein multiple symptoms are a 
component of symptom burden (Cleeland, 2007; Woods, 2010). In addition, there is growing 
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interest in studying, not just multiple symptoms, but also groups or clusters of symptoms that 
commonly occur together (Dodd et al., 2011).   
 Symptom clusters have been defined as symptoms that typically share an underlying 
physiology or etiology and usually appear together in response to an illness, condition or 
treatment (Barsevick, Whitmer, Nail, Beck & Dudley, 2006). Research on symptom clusters was 
initiated in the field of oncology where symptoms such as pain, fatigue and nausea were 
identified as a cluster. Symptom clusters have also become a focus of interest in studies on 
symptoms of heart disease, irritable bowel syndrome, PTSD and fibromyalgia to name a few. 
Women's health issues such as PMS have also lent themselves to symptom cluster research: a 
factor analysis of 57 commonly reported PMS symptoms identified four symptom clusters which 
accounted for 42% of the variance in premenstrual symptoms (Woods, Mitchell & Lentz, 1999).  
 Many of the studies on symptom clusters have used factor analysis to explore co-
occurring symptoms although cluster analysis, which groups cases or individuals with similar 
symptoms, has also been used. Looking at cases can help to identify subgroups with similar 
symptoms or patterns of symptom severity in order to target specific interventions toward these 
subgroups (Barsevick et al., 2006). In the present study, it was possible to qualitatively identify a 
cluster of women with high symptom severity and interference from VMS which led to deeper 
analysis of the interview data revealing that an attitude-based approach to dealing with 
discontinuation symptoms was helpful for some women. This finding may point toward 
recommendations for both research and practice interventions that foster the development of 
greater efficacy among women to self-manage discontinuation symptoms.   
 Symptom cluster research has started to appear more often in the field of menopause 
where traditionally, symptoms have been studied as single and/or separate entities. Woods, 
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Mariella and Mitchell (2006) used cluster analysis to explore depressed mood symptoms in 
women transitioning through menopause. The researchers identified six patterns or clusters of 
depressed mood symptoms. Most of the clusters demonstrated stable mood with no/minimal 
depressed mood symptoms which should offer some comfort to women that menopause does not 
increase their risk for depression. A small cluster (10%) of women with low and worsening 
moods, most often predicted by a history of previous depression, was also identified. Although 
the present study was not able to evaluate mood changes over time, 38% (n = 13) of participants 
rated their psychological symptoms as moderate to severe/very severe. Given that previous 
depression is a predictor of depressed mood, it would be prudent to carefully screen women for a 
prior history of mood issues before they stop HT.  
 Menopause symptoms have also been explored through latent class analysis (Cray, 
Woods & Mitchell, 2010) which is a model-based approach to cluster analysis. From a sample of 
103 mid-life women, the researchers identified four distinct patterns of symptom severity of five 
common menopause-related symptoms; 13% of these women (n = 14) rated all their symptoms 
as high, 65% (n = 67) as low. Ten (10%) were in the high level for joint ache-concentration 
problems group while the remaining women (n = 12, 12%) scored high in severity for VMS-joint 
ache-sleep disruptions. The women in the current study also seemed to exhibit variability within 
their clusters of symptoms: although many noted VMS, sleep and mood concerns, the prevailing 
symptom or symptoms was different for many women.  
 In the study by Cray et al. (2010), women with more severe VMS-joint ache-sleep 
disruptions had higher cortisol levels while those with greater job stress were more likely to be in 
the groups with high levels of symptom severity. In the present study, only three women (9%) 
had current overall high severity symptoms ratings although 15 (44%) stated their symptoms 
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with discontinuation were very severe. Many of these women reported being in high stress jobs 
and believed their symptoms impacted negatively on their work lives. The increased worry about 
work performance added to the level of stress perhaps setting up a vicious cycle of symptoms 
contributing to more work stress leading to a more distressful symptom experience.  
 Finnegan, Shaver, Zenk, Wilkie & Ferrans (2010) have developed a symptom cluster 
model that incorporates the concept of systemic stress which is characterized by emotional 
arousal (e.g. chronic worry, uncertainty) and physiological activation (elevated levels of cortisol 
and proinflammatory cytokines). Systemic stress can be influenced by factors such as life strain 
and negative affect and may, in turn, amplify the burden of symptoms such as fatigue, disturbed 
sleep, mood issues and difficulty concentrating. Although this model has been used primarily in 
oncology, it may have benefits for the development of both research and interventions targeting 
menopause and HT-discontinuation symptom clusters.  For example, a recent study by Carmody 
et al. (2011) explored the use of mindfulness-based stress reduction (MBSR) in women with 
VMS; the results demonstrated a significant reduction in both stress and symptom bother which 
persisted for at least three months after participation in the program.  
 While symptom severity and multiple/clustered symptoms contributed to symptom 
burden with HT discontinuation, symptom interference also emerged as a factor in women's 
experience. Symptom interference is defined as the degree to which symptoms disrupt or impede 
an individual's ability to participate or function in their in daily activities (Woods, 2010). 
Interference is a key consideration in symptom appraisal and may serve as a mediator between 
symptom perception and seeking help for symptom management (Hunter & Mann, 2010). In the 
present study, interference was a major factor in women's overall discontinuation experience, 
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making HT cessation more challenging. Interference also appeared to be a salient factor in 
whether or not women resumed HT.  
 In a study conducted by Rand et al. (2011) of 395 breast cancer survivors who were 
experiencing VMS, greater symptom burden (frequency and severity) led to more perceived 
symptom interference in participants' ADL. Interference predicted more sleep disturbances (ß = 
0.26, p < 0.05) which subsequently predicted lower perceived health (ß = -0.29) and more mood 
concerns (ß = 0.49). A similar theme was noted in the current study: women reporting greater 
symptom interference on the HFRDIS, most of whom had stopped HT, had slightly higher 
psychological symptom scores and lower QoL, including self-reported health. 
 Among a subsample of 184 participants from the Seattle Mid-Life Women's Study 
(Woods & Mitchell, 2011), women who had lower perceived health and higher stress were more 
likely to acknowledge symptom interference in their work or relationships. Depressed mood and 
difficulty concentrating also impacted on both work and personal relationships while anxiety and 
sleep disturbances, which may be linked to a greater degree of arousal and subsequent 
amplification of symptoms, were associated with relationship disruptions. Once again, there were 
similarities to the current study: women described mood swings and irritability when they 
stopped HT, all negatively impacting on job performance and personal relationships. In addition. 
women often reported a sense of uncertainty about HT and the accompanying risks. Intolerance 
of uncertainty has often been associated with anxiety These symptoms may be indicative of 
greater arousal and sensitivity to symptoms in the study sample. 
 Symptom sensitivity, a tendency to focus on and report or seek help for symptoms 
(Hetherington & Hopkins, 1969), has been associated with both somatization and somatic 
amplification of symptoms (Barsky, Goodson, Lane & Cleary, 1988) as well as negative 
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affectivity (Hunter and Mann, 2010). In a study comparing women's self-report of VMS to 
physiologic hot flash measures (skin conductance), women who over-reported VMS had higher 
somatization scores (Thurston, Blumenthal, Babyak & Sherwood, 2005). Greater symptom 
awareness has also been associated with use of HT (Matthews et al., 1996).  
 The term negative affectivity is used to indicate a tendency toward perceiving and 
reporting negative mood (Hunter & Mann, 2010). It is associated with affective symptoms or 
disorders and thus reflected in measures of stress, anxiety and depression (Watson & 
Pennebaker, 1989). Negativity affectivity in turn may lead to an increase in the awareness of 
physical sensations (Kolk, Hanewald, Schagen & van Wijk, 2003) and ultimately to greater 
symptom sensitivity and somatic amplification (Dragos, Tanasescu & Davila, 2009). It would 
therefore not be unreasonable to expect that increased reporting and more negative appraisals of 
vasomotor and other menopause-related symptoms would be associated with negative affectivity 
and this has been demonstrated in the literature. Social stress (Gold et al., 2000), anxiety 
(Freeman et al., 2005; Gold et al., 2006; Thurston, Bromberger et al., 2005), uncertainty 
(Obermeyer, Reynolds, Price & Abraham, 2004) and depressed mood (Thurston et al., 2008) 
have been linked to reporting of more frequent VMS as well as more troublesome symptoms. 
Psychometric testing during the development of the HFRDIS demonstrated that interference 
scores were positively associated with negative affect (Carpenter, 2001). Another study 
comparing self-reported and physiological VMS measures showed that negative affect was 
associated with self-reporting of symptoms but not objective symptom measures (Carpenter & 
Rand, 2008).  
 Negative affectivity may influence symptom reporting through a cognitive as well as an 
affective pathway. Depression, anxiety, pessimism and low self-esteem, have been associated 
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with more negative beliefs about menopause and VMS in general (Avis & McKinlay, 1991; 
Hunter, Coventry, Mendes & Grunfeld, 2009; Hunter & O'Dea, 2001). Negative thoughts and 
catastrophizing during hot flashes (Reynolds, 1997 & 2000), feeling as though one had little 
control over VMS (Hunter & Liao, 1995; Rendall, Simonds & Hunter, 2008) and shame or 
embarrassment with hot flashes (Hunter et al., 2009; Rendall et al., 2008) have been linked to 
more negative appraisals of these symptoms. Thus, negative affectivity has the capacity to play a 
role in women's sensitivity to menopause symptoms through several different mechanisms 
(Hunter & Mann, 2010).  
 Symptom sensitivity, somatization and somatosensory amplification have been further 
linked to greater central nervous system (CNS) arousal and activation (Dragos et al., 2009; 
Hammad, Barsky & Regestein, 2001; Pfaff, Riberio, Matthews & Kow, 2008)). In the brain, 
activation of the insula and/or the anterior cingulate cortex has been postulated to play a pivotal 
role in both awareness of interoceptive sensations as well as corresponding affective and 
subjective responses such as concentration, risk perception, cognitive choices and even self-
image (Craig, 2009). In a study exploring cortical activation with VMS (Freedman, Benton, 
Genik & Graydon, 2006), both the insular cortex and the anterior cingulate cortex were activated 
during hot flashes. These regions may be critical in the mechanistic processes of VMS-associated 
thermoregulation as well as women's subjective responses to VMS. This finding implies a 
common etiology or underlying mechanism for menopause symptom and responses lending 
support to the concept of menopause symptom clusters.  
 It is important to understand the links between symptom sensitivity, cognitive appraisal, 
negative affectivity and CNS arousal as they have implications for how to better support women 
planning to discontinue HT. It may be prudent to assess a woman's general sensitivity to 
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symptoms (Barsky et al., 1988) or her underlying beliefs about menopause (Menopause 
Representations Questionnaire (MRQ), Hunter & O'Dea, 2001) and hot flashes (Hot Flush 
Beliefs Scale (HFBS), Rendall et al., 2008) as part of counseling her about discontinuing HT. 
Interventions, such as Cognitive Behavioral Therapy (CBT) to realign women's beliefs about 
herself, menopause and her capacity to manage her symptoms may be helpful (Hunter & Mann, 
2010). Knobf (2008) found that among breast cancer survivors, women adopting a behavioral 
response of 'making the best of it' were able to more readily cope with and adjust to their 
situation; this attitude may be akin to the 'just deal with it' strategy used by several women in this 
study. Strategies to lower the level of neurological arousal such as paced breathing (Freedman, 
2005) or mindfulness (Carmody et al., 2011) may also be of benefit to decrease the degree to 
which symptoms interfere with women's ability to function day-to-day.  
 The women in this study actually reflected many of the above concepts and linkages. 
Many reported affective symptoms and conditions, some of which preceded entry into 
menopause. Life and work stressors impacted on their appraisal of symptoms and, in turn, 
symptoms interfered with work and personal life, increasing stress and distress and potentially 
increasing CNS arousal as well. CNS arousal may have further intensified their symptoms. 
Indeed, many participants commented that stress seemed to bring on more VMS. In addition, the 
very graphic, impassioned, powerful and negative descriptions of symptoms and the 
embarrassment they wrought may also represent a tendency among the participants toward 
catastrophizing and believing they had little control or ability to manage symptoms. The trend 
for women who resumed HT to assert that 'nothing' would have helped them to manage 
symptoms or remain off HT implies that some women may benefit from more immediate 
initiation of alternate therapies and interventions when they attempt to stop HT. Their 
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discontinuation efforts may also be better supported by more frequent communication with their 
health care providers along the journey.  
 Similarly, women who had more positive expectations of menopause were more 
successful at staying off HT, which may reflect the role of cognitive appraisal in a woman's 
beliefs about her ability to manage discontinuation symptoms. Cognitions may also help to 
explain, in part, why women who expressed a sense of intuition, of 'knowing' that it was the right 
time to stop, tended to notice milder symptoms and were successful at discontinuation despite 
past unsuccessful attempts. This ability to alter one's beliefs about self-management of symptoms 
or perceptions of symptom burden lends support to the efficacy of alternate strategies such as 
CBT (Hunter & Mann, 2010). 
 In the current study, not all women were troubled by their symptoms: several participants 
felt that their symptoms were mild or easily tolerated and did not warrant intervention. A study 
of 165 women conducted by Berg and colleagues (2008) found that the perception of a symptom 
did not always correlate with the distress associated with that symptom (Berg, Larson & 
Pasvogel, 2008). This finding implies that other factors may be also be operational in women's 
appraisal of how burdensome their symptoms were. The interconnectedness of symptoms and 
QoL may be one such factor.  
 Symptoms and QoL were closely connected for the women in this study. For example, 
QoL was diminished when women did not have the energy to function at work or participate in 
social activities because of sleep disruptions. Thus the impact of symptoms on functional status 
may be a determinant in the relationship between symptoms and QoL.  Functional status and 
QoL have long been associated in the fields of oncology and cardiology but less so in menopause 
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despite the fact that women have reported their main reason for starting HT was not being able to 
function (Woods, Falk, Saver, Stevens, Taylor, Moreno & MacLaren, 1997). 
 Women were also very concerned about the impact of frequent hot flashes on their 
appearance and the potential negative reactions of colleagues to the physical manifestations of 
their hot flashes. Women's worries about this may actually be unfounded: in a recent study 
exploring the reactions of women's co-workers to observed VMS, the co-workers did not readily 
attribute flushing and sweating to menopause and their responses were mostly neutral or 
compassionate (Smith, Mann, Mirza & Hunter, 2011). Nonetheless, feeling embarrassed or self-
conscious at work had a detrimental effect on the self-esteem of the women in the current study. 
This was critical to how they perceived their QoL in the workplace and may have further 
impeded their ability to function in their very stressful and public work roles.  
 Mood symptoms influenced QoL by interfering with relationships, especially intimate 
relationships. Several women commented upon not being able to be physically close to their 
partners or enjoy sexual activities when they were experiencing VMS. Sexuality-related 
symptoms such as vaginal dryness, dyspareunia and decreased libido also contributed to lower 
QoL: on the HFRDIS, the greatest frequency of severe scores was on the interference with 
sexuality item. There is increasing awareness in the menopause literature of the deleterious 
impact of sexual dysfunction on QoL. Sexual dissatisfaction has been associated with lower 
well-being (Davison, Bell, LaChina, Holden & Davis, 2009) as well as poorer self-reported 
health and greater depressed mood (Gallicchio, Schilling, Tomic, Miller, Zacur & Flaws, 2007). 
However, in a multinational study of 4246 women, 77% were uncomfortable discussing 
symptoms with their providers (Nappi & Kokot-KIerapa, 2010). Because sexual dysfunction 
may lower QoL, providers must be cognizant of the fact that a discussion of urogenital and 
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sexual health is pertinent to providing care for mid-life women. Providers should broach the 
topic themselves, especially among women who have discontinued HT. In the present study, 
most of the women noting urogenital/sexual symptoms were those who stopped HT which is not 
surprising given their lower estrogen levels. 
 Although QoL was clearly influenced negatively by discontinuation symptoms, other 
factors may have been involved in women's assessments of QoL. Several women described a 
sense of joie de vivre or 'shine' that they experienced while on HT but which disappeared when 
they stopped. It is possible that the reduction in symptom burden and interference in ability to 
function may account for this sense of energy or well-being. However, the  'shine' that women 
experienced was sometimes expressed as being more than just a product of symptom reduction: 
several women commented that they resumed HT not only to reduce their symptoms but also to 
feel better overall and to regain their energy. The use of HT to feel better was noted in prior 
qualitative studies on HT and menopause (French et al., 2006; Kolip et al., 2008). 
 It is possible that this HT-induced joie de vivre and sense of 'feeling good' may be related 
to estrogen which is known to have a positive influence on well-being and mood, perhaps 
through its effect on increasing serotonin levels (Amin, Canli & Epperson, 2005). In addition, 
estrogen may impact on mood by increasing norepinephrine which may foster a sense of well-
being. However, the stimulatory effect of norepinephrine can, in some individuals, lead to an 
increase in anxiety or fear. This could account for the several women in this study that reported 
feeling more irritability while on HT.  
 Differences in reports of well-being while taking HT are one example of the variable 
impact of HT discontinuation on the QoL of the study participants. Not all women believed that 
HT made their QoL better. Also, several women specifically reported that their QoL was not 
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linked to symptoms but was more reflective of other factors in their lives such as finances or 
employment. Smith-diJulio et al. (2008) also found that women's sense of well-being was 
positively related to social support and inversely related to negative life events while the 
menopause transition and associated symptoms had no impact on well being.  
 Woman who experienced HT-related side effects and those with concerns about long-
term health risks from HT constituted another group who reported better QoL after stopping 
medication. Concern and worry about both side effects and future risks have often been 
associated in the menopause literature with discontinuation of HT (Reynolds et al., 2002). Early 
discontinuation of HT in particular has been attributed to the occurrence of side effects; this was 
also noted in the present study. The impact of these two factors on a woman's QoL may be one 
of the mechanisms that prompt HT cessation.   
 The variability in both overall QoL, as well as variations among women as to which QoL 
domain they deemed most pertinent to their HT discontinuation experience, may partially 
explain some of the discrepancies in findings from other studies of HT and QoL. HT may 
enhance QoL through symptom reduction and improved functional capacity, however, it may not 
necessarily impact on overall QoL which may be more related to other life factors. HT may also 
decrease QoL by causing worry about side effects or risks. It has been suggested that measuring 
symptom burden alone may be sufficient in both practice and research (Cleeland, 2007). 
However, the present study findings demonstrate that there are clearly women for whom 
symptoms are not the primary component of their QoL. Thus, measuring symptoms may not be 
sufficient for determining the full impact or outcome of a medication or therapeutic intervention. 
Research on HT and QoL needs to measure multiple domains of QoL, both qualitatively and 
quantitatively, or be more specific as to which domain is being measured.  
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 QoL is clearly an important factor in the overall symptom experience. Symptoms 
associated with HT discontinuation (or with HT-induced side effects) appeared to interfere with 
QoL. Diminished QoL further contributed to the perception of symptoms as being more 
burdensome and interfering. When symptom burden and interference were high, women's 
appraisals of the risks associated with symptoms also increased. 
Risk Appraisal 
 Much has been written with regard to the manner in which women appraise risks and 
benefits when making decisions about HT.  As previously noted, they take into account factors 
such as health, family history, beliefs about menopause and medications, and perceived 
advantages and harms of HT (Bravata et al., 2002; Hunter et al., 1997; Marmoreo et al., 1997; 
Theroux, 2009; Walter & Britten, 2002). The women in this study engaged in a similar analysis 
as they weighed their options for managing interfering and 'risky' symptoms. However, for many 
women, their analysis centered on risks with less consideration of benefits. Appraising risk was 
another subtheme in this study.  
 Focusing on risks rather than benefits is not unusual in the complicated process of risk-
benefits analysis. The focus on risk is often emotionally driven, specifically by fear, a critical 
component in risk perception (Sjoberg, 2000). As fear increases, so too can negative affectivity, 
symptom sensitivity, CNS arousal and somatosensory amplification as previously discussed. 
Factors associated with fear and risk perception include dread or the conviction that something 
negative will happen, personalizing the risk, perceptions of having control and choice, whether a 
risk is old or new, man-made or natural, the level of awareness of the risk and trust in the 
communicator of the risk (Centocor, 2011). Ultimately, fear has a deleterious impact on the 
ability to make decisions (Griffiths, 1999).  
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 Several qualitative studies focusing on women's decision-making during the menopause 
transition (Bravata et al., 2002; Marmoreo et al.,1997; Walter & Britten, 2002) have also 
demonstrated the same focus on risks among women contemplating the use of HT. Among the 
women in this study risk appraisal often preceded choosing a path to travel therefore these 
studies help illuminate how these factors come into play in women's risk appraisal. For example, 
in some of these studies (Hunter et al., 1997; Theroux, 2010; Wathen, 2006; Welton et al., 2004; 
Woods et al., 1997) the degree to which symptoms were troublesome influenced women's 
decisions. Women weighed the risks of menopause or discontinuation symptoms against 
medication-induced side effects and symptoms (dread, awareness, personal, old or new) and 
made evaluations as to which might be more manageable (control and choice) (Theroux, 2010).  
 In a similar fashion, women in this dissertation study were expecting that their symptoms 
would recur, particularly those who had already made attempts to stop. They felt they had less 
control over HT-induced side effects and chose to live with menopause symptoms instead. 
Women who had to stop HT because of financial considerations felt that having less control over 
the options available to them added to their symptom distress. As previously noted, perceived 
lack of control may play a role in women's evaluations of symptom severity.  
 In other studies, participants perceived symptoms as risky (dread) (French et al., 2006; 
Walter & Britten, 2002) and worried about the negative impact of symptoms on their ability to 
do their jobs (dread, control) (Kolip et al., 2008; Woods et al., 1997). These study participants 
also evaluated the impact of symptoms on their QoL (personal, control) (Schapira et al., 2004; 
Wathen, 2006; Welton et al., 2004).  
 Similarly, in the present study, there were some women who very much feared the 
possible recurrence of their symptoms and how those symptoms might interfere in their lives, 
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especially work and relationships. A few acknowledged that they had actually resumed HT at the 
very first indication of symptom recurrence, not because the symptoms were already severe, but 
because they feared the symptoms would escalate. 
 Uncertainty about HT risks and lack of personalized definitive answers and information 
(dread, choice, personal, control) (Bond & Bywaters, 1999; Griffiths, 1999; Reece, 2002) 
contributed to women's fears in some of the studies about HT decision-making. Attitudes about 
menopause, HT and medications (man-made or natural) also influenced the amount of distress 
women experienced as they evaluated their options (Hunter et al., 1997; Kolip et al., 2002; 
Schapira et al., 2004; Walter & Britten, 2002). Ever-evolving recommendations for HT use (old 
and new) as well as changes in personal or family health also impacted on women's risk 
perceptions and decisions, underscoring the contextual nature (Marmoreo et al., 1998) and 
iterative process (Woods et al., 1997) of making HT decisions.  
 These same concerns were also apparent in the current study participants who described 
ongoing uncertainty about current HT evidence and continued changes. They also spoke of how 
their attitudes and beliefs influenced their experience and choices and how their fears about their 
own risks were influenced by both their personal and family health.  
 Family health history, looking to the past to inform future choices, was indeed a strong 
influencing factor in several prior studies (Bravata et al., 2002; Walters & Britten, 2002) as well 
as the current one. Obviously family health history is salient in assessing risks: it provides 
evidence of health concerns that may be more likely for an individual because of shared genetic 
patterns. In the present study, women's family history influenced the disease process -- breast 
cancer, heart disease, stroke -- they most feared when they were assessing their HT-related risks.  
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 However, Walter and Britten (2002) suggest that family history may also be critical 
because it represents the influence of lay beliefs about health and illness. These beliefs are akin 
to the social and culturally constructed explanatory models proposed by the organizational 
framework supporting this study (Woods & Mitchell, 2005). The models provide information 
about how individuals perceive disease states, the likelihood of illness, strategies for coping or 
managing symptoms and when/where to seek health care and support (Chrisman & Kleinman, 
1983; Mechanic, 1962; Mechanic, 1986). Because they are rooted in the context of community 
and family, an individual's beliefs and perceptions of risk are value and emotionally laden which 
heightens the fear and dread surrounding the perception of certain risks and may consequently 
increase the level of emotional and cortical arousal. Thus family history can influence risk 
perception thorough both cognitive and emotional mechanisms (Walter & Britten, 2002). 
 The emotional context may help explain why risk perceptions are not easily changed, 
even in the presence of contrary evidence (Slovic, 1987). It may also explain why individuals 
can differ in the risk they assign to a given health concern or treatment despite being presented 
with the same information. Many of the women in this dissertation study spoke of the influence 
of the WHI on their decision. Yet despite having similar understandings of the study findings, 
women's perceptions of their personal risks were quite varied and often situated in the context of 
their family health history. 
 The emotional nature of risk perception begs the question of how best to help women 
understand their risks in order to choose between their options with regard to discontinuing HT 
ad managing symptoms. Two important considerations are framing and  trust. Framing refers to 
the manner in which potential harms are presented. Almost half of US citizens are thought to 
have limited health literacy, which includes an inability to understand numbers and percentages 
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(Herxheimer, 2005; Rudd, Anderson, Oppenheimer & Nath, 2007; Torres & Marks, 2009). 
Innumeracy certainly played a role in women's understanding of the WHI findings, influenced in 
part by the manner in which the findings were reported in the media and translated by health care 
providers to their patients (Genius, 2006; Haas et al., 2006). Although subsequent studies have 
explored models and frameworks for explaining risks to women (Johnson et al., 2006), some of 
the women in the current study, including several health care providers, expressed conflicting 
and inaccurate knowledge about their perceived risks. A few women even acknowledged distrust 
or skepticism as to the accuracy of the information they were given by their providers.   
 Although perceived risk may be increased by fear, it may be dispelled by trust. It is 
important, therefore, that women receive information about HT and HT discontinuation from 
providers that they trust. Unfortunately, women in this study did not always believe that the 
information they received from their providers was accurate, adequate or took into account their 
personal situations and needs. These concerns are not conducive to the development of a trusting 
and therapeutic relationship.  
 Sadly, some of the findings in the current study are not markedly different from those of 
the pre-WHI and early post-WHI studies. Despite the increase in awareness of the challenges 
women encounter when stopping HT, there appears to be little change in the way that women are 
supported as they attempt to discontinue HT. Many of the women received their menopause 
related care exclusively from MDs. In a recent qualitative study exploring women's decision 
making about HT (Theroux, 2010), women described feeling empowered by engaging in a 
shared decision making process with a nurse practitioner (NP). Care for midlife women 
attempting to discontinue HT may be enhanced by including nurses and NPs knowledgeable 
about menopause and skilled in decision coaching (Carpenter, Byrne & Studts, 2011; Theroux, 
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2010). Several women in this study did actually comment that the counseling and support they 
received from they received from an NP was a positive and calming influence on their 
experience. 
 Also disturbing in the current study were the discrepancies in discontinuation 
recommendations given by health care providers as well as women's reluctance to seek support 
and advice within their social circle for fear of negative comments. This points to an increasing 
polarization in current opinion about HT in both the lay and health/research literature. Many 
other women's health issues, such as childbirth and breastfeeding, have also been dichotomized. 
This leads to inconsistencies in women's health care and diminishes the quality of their care. 
Providers, researchers and policy makers need to develop strategies to bridge these divides in 
order to ensure that women receive health care that is safe and equitable. 
Implications 
 The findings of the study led to the development of recommendations that could be 
implemented in order to promote better health care for women discontinuing HT. 
Table 20.  
Practice, Research and Policy Implications 
Practice Research Policy 
Assessing readiness to stop 
Assessing beliefs 
Closer monitoring and support 
Improved communication with 
providers 
Improved access to alternate 
symptom management strategies 
Shared medical appointments 
Decision making and lifestyle  
coaching competency 
Individualized risk assessment and 
counseling 
Theories and models 
Symptom clusters 
Symptom interference 
Non-VMS Interference 
scales 
Longitudinal studies 
Discontinuation 
methods 
Health promotion for mid-life 
women 
Health literacy initiatives 
Partnering with the 
community 
Industry standards 
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Implications for Practice 
 Several practice implications have already been discussed in the previous discussion. For 
example, it may be helpful to assess women's beliefs about menopause and VMS using 
established measurements prior to initiating HT discontinuation. Determining a women's 
readiness to stop may decrease the rate of resumption related to women not being fully prepared 
or committed to discontinuing. General decision models such as the stages of behavior change 
(Prochaska et al., 1994) or HT-decision specific models (Woods et al., 1998) may be useful to 
guide understanding of a woman's beliefs about stopping at a given time. Developing better 
decision coaching skills would enhance providers' ability to counsel and support women at this 
crossroad.  
 Lifestyle coaching would also be an important skill (Theroux, 2010): despite the fact that 
women stopping HT have greater risks of developing osteoporosis and CVD, only about half the 
women said their providers offered this information. Assumptions were made that women 
already knew what to do but this may not always be accurate. Studies have also shown that 
providers are not always knowledgeable about how to educate about exercise (Anis et al., 2003; 
Rogers et al., 2002).  
  Both decision-making and lifestyle coaching must be based upon a thorough assessment 
of each woman's risks. Women were very emphatic in their desire for counseling and care that 
was personalized and relevant to their individual needs and life status. Providers must also strive 
to provide information that is up-to-date, accurate and balanced so that women develop more 
trust in providers' ability to support them.  
 Many women clearly wanted more support from their providers when stopping HT. This 
would be especially critical for women with a history of affective disorders who may have a 
higher risk of developing clinical depression. Support need not always be face-to-face but could 
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come in the form of telephone or online communication therefore providers need to be able to 
offer a variety of communication methods to their patients. Health care providers may also wish 
to consider alternative forms of providing care to these women. For example, shared medical 
appointments may provide a mechanism for women to receive more support and education from 
their providers (Thacker, Maxwell, Saporito & Bronson, 2005) as well as build connections with 
other women, another desire that women expressed. Women in the past have described a feeling 
of isolation as they traversed HT discontinuation (Bond & Bywaters, 1999), 
 Women stopping HT may benefit by learning about relaxation strategies or receiving 
other therapies such as CBT which may help them to 'just deal with' their symptoms, that is, 
foster a sense of self-efficacy in symptom management. However, not all providers are equipped 
to offer the range of therapeutic options that may be helpful. Providers may need to build 
networks of community resources that offer alternate therapies so that women discontinuing HT 
will have better access to a variety of modalities and symptom management strategies.  
Implications for Research 
 Health practice could be enhanced by the development of menopause-specific theories 
and models for decision-making and symptom management. The organizational framework 
(Woods & Mitchell, 2005) used in this study may provide a good start in this endeavor but it has 
several limitations that became apparent during the data analysis. For example, in the framework 
symptom perception and evaluation are depicted as linear processes. In reality, women described 
perceiving and evaluating symptoms as though they were occurring simultaneously thus the two 
processes may actually overlap. The experience of symptoms was also iterative: women moved 
back and forth through the stages. Finally the list of potential influential factors was limited and 
did not allow for factors that may bridge both physiologic and sociocultural definitions.   
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 It may also be possible to adapt existing models from other disciplines to be more 
menopause and HT-specific. For example, the Commonsense Model (Leventhal, Weinman, 
Leventhal & Phillips, 2008) may be particularly useful in understanding women's appraisals of 
risks as it specifically incorporates representations of fears and dangers as salient to choices for 
coping strategies. This model has already been successfully used in other menopause-based 
research (Hunter & O'Dea, 2001) and may be applicable for further HT discontinuation research. 
An uncertainty framework (Mishel, 1990) could also serve to support research on this topic. 
 Research also needs to be directed toward explorations of symptom burden, symptom 
clusters and symptom interference to better understand their impact and where interventions need 
to be targeted to minimize symptom distress. As variations in reporting of interference among 
the women in this study testify, it would be important to assess these factors using both 
quantitative and qualitative methods. The HFRDIS was limited because it did not capture 
interference from non-VMS; therefore instruments for measuring interference from multiple 
symptoms would be helpful for understanding the disruptions wrought by other menopause and 
HT-induced symptoms. 
  Longitudinal studies incorporating both physiological and self-report measures of VMS 
would help to elicit a more detailed understanding of the entire HT-discontinuation experience 
and the changes that occur over time. Further studies on various methods of discontinuation 
would also be pertinent. Finally, grounded theory could provide a better understand the complex 
process that women undertake in deciding to stop or resume HT. 
Implications for Health Policy 
 The findings from this study underscore the need for changes in health policy. First, there 
needs to be a greater emphasis in both health care and society on health promotion initiatives for 
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mid-life women. These initiatives must be available and accessible to all women regardless of 
ethnicity, location, insurance or financial status in order to eliminate existing disparities and 
barriers to quality health care. This may require more partnering with resources within 
communities, as previously discussed, in order to build health care teams that promote and 
provide health and illness prevention strategies specific to the needs of the women within those 
communities. However, it also speaks to the need for the development of regulations and 
standards of practice for other health-related industries such as exercise-fitness training and 
mind-body practices.      
 In order to improve health outcomes, there is a need to improve health literacy so that 
women can understand basic health information and make more informed health care decisions 
(Genius, 2006). This includes not only improving women's capacity to understand health 
information but also helping providers and researchers realize that the way they communicate 
information and risk may result in confusion, misunderstanding and distrust of both the 
messenger and the message (Herxheimer, 2005).   
Limitations 
 There were a number of limitations to this study. The cross-sectional design prevented 
exploring changes in women‘s experiences over time. Because some participants stopped HT 
over one year ago, their responses may have been subject to recall bias. Social desirability bias in 
responses must also be considered with any research using a volunteer sample. 
 The smaller number of women who resumed HT also limited the ability to make 
quantitative comparisons across strata. Another limitation was related to the fact that one-third of 
the sample was health care providers; this particularly limited the findings of Specific Aim 4 as 
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many women were already knowledgeable about health promotion strategies they needed to 
initiate once stopping HT.  
The participants in this study were a relatively homogenous group despite the fact that 
they came from multiple states. Many researchers believe that the potential for recruiting 
participants from varying ethnic/cultural/racial populations is enhanced with Internet research 
(Best & Krueger, 2004; Im et al., 2008; Mann & Stewart, 2004). Im and colleagues (2008) were 
able to obtain an ethnically diverse sample of 192 mid-life women through study announcements 
posted at Internet discussion groups for mid-life women. However, it has also been noted that 
non-Caucasian women use HT with less frequency than European-Caucasian women therefore 
recruiting from the Internet and using a web-based survey, as well as limiting participation to 
English-speakers (Im & Chee, 2002), may have made it more difficult to recruit a diverse 
sample. It was hoped that placing advertisements on websites visited by non-Caucasian women 
would foster a diverse sample however no participants were recruited from these sites. Diversity 
of participants was an important goal for this study as sociocultural contexts are key concepts in 
the organizational framework. Thus the relative homogeneity of participants may limit 
qualitative generalizability (Morse, 1999) or the ability to make extrapolations from the findings 
to similar situations in women‘s health care (Patton, 2002).  
Another limitation that arose from the on line format was the tendency for women to 
make abbreviated responses to the open-ended questions. This necessitated more email 
correspondence to elicit further information as well as more telephone interviews than were 
originally anticipated. Future studies using an on line format could be improved by using a series 
of email correspondence for the open-ended questions, or perhaps developing a website site 
where the study questions could be posted. On line focus groups (asynchronous) could also be 
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used and may perhaps enhance connection and communications between the researcher and 
participants as well as among participants. This could foster intersubjectivity which would 
improve the validity of the study.   
Conclusions 
The findings from this study show that women discontinuing HT still encounter many 
challenges in the form of troublesome symptoms and diminished QoL with little to guide them as 
to the best strategies to manage their symptoms. Consequently some resume HT while others 
endure much disruption in their personal and professional lives and QoL. Confused and uncertain 
because of conflicting research findings and recommendations, women feel that they travel this 
path alone as evidenced by the overarching theme a solitary journey. Factors that may make this 
experience more distressful are primarily related to the symptoms themselves and include 
symptom burden and interference, symptom clusters and sensitivity to symptoms. Women's 
beliefs about menopause, reasons for stopping HT and readiness to stop may also influence the 
outcome of their efforts. All of these factors are salient in women's risk appraisal and the choices 
they make as to how to navigate the path of HT discontinuation. In addition, there continue to be 
inconsistencies in the amount and quality of information and support that women receive from 
health care providers during this journey adding to women‘s distress.  
These findings lay the foundation for implementing changes in practice and policy to 
improve care and support for women choosing or needing to discontinue. There is a great need 
for individualized counseling about symptom management and health promotion and better 
communication between women and their providers. Strategies that enhance efficacy for coping 
with symptoms may be of benefit during this challenging transition. More research is needed to 
develop better guidelines for counseling and caring for women as they are discontinuing HT.  
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Appendix A 
 
Glossary 
 
Menopause—a women‘s final menstrual period (FMP) defined after 12 months of amenorrhea 
 
Menopause transition—the time between the onset of menstrual and endocrine changes and the 
FMP 
 
Perimenopause—early menopause transition through 12 months post FMP, sometimes used 
synonymously with the term climacteric  
 
Premenopause—literally ‗before menopause,‘ ambiguous; term should not be used 
 
Postmenopause—after the FMP (Early postmenopause is defined as five years since the FMP 
marked by ovarian hormone function dropping to a permanent level as well as accelerated bone 
loss. Late postmenopause goes from 5 years post-FMP to demise.)  
 
Induced menopause—due to removal of ovaries or ablation of ovarian function 
 
Premature menopause—FMP at or under age 40 
 
Early menopause—FMP at or under age 45 
Estrogen Therapy (ET)—unopposed estrogen, estrogen-only; primarily for women who have 
had a hysterectomy 
 
Estrogen plus progestogen therapy (EPT)—a combination of estrogen and a progestogen 
(either progesterone or progestin, a synthetic form of progesterone) 
 
Hormone therapy (HT)—may encompass both ET and EPT but more frequently used for EPT 
Bioidentical hormones—chemically identical to those produced by the body 
Custom compounded hormones—bioidentical hormones that are compounded in variable 
doses and mediums based on individual women‘s preference and tolerance 
Cyclic EPT—either or both estrogen and a progestogen given for specific days each month 
 
Continuous EPT—estrogen and/or progestogen given every day each month 
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Appendix B 
 
STRAW Stages/Nomenclature of Normal Reproductive Aging in Women 
Menopause  12 months of amenorrhea following the final menstrual period (FMP). reflecting a near 
complete, natural decrease of ovarian hormone secretion. 
Menopausal 
Transition  
Encompasses both Stages -2 (early) and -1 (late) defined by menstrual cycle and endocrine 
changes. The menopausal transition begins with variation in menstrual cycle length occurring 
in a woman who has a monotropic FSH rise and ends with the FMP.  
Postmenopause  Encompasses Stages +1 (early) and Stage +2 (late).  
Early postmenopause is defined as five years since the FMP and reflects a further dampening of 
ovarian hormone function to a permanent level as well as the period of accelerated bone loss. 
Stage +1 was further subdivided in segment "a" -- the first 12 months after the FMP and "b" the 
next four years.  
Stage +2 begins at 5 years post FMP but the duration is variable since it ends with the woman's 
death. Further divisions may be warranted as women live longer and more information is 
accumulated. 
Perimenopause  Literally means "about or around the menopause." It begins with Stage -2 and ends 12 months 
after the FMP. Climacteric is sometimes used synonymously with perimenopause, however 
neither should be used in scientific papers but only with patients and in the lay press. 
 
 
 
* Stages most likely to be characterized by vasomotor symptoms, : elevated. 
Adapted from Soules, MR et al. Fertil Steril 2001; 76:874. (©2009 UpToDate
®)
 
 
 
 
 
 
 
 
 
 
 282 
 
Appendix C 
 
Hormone Therapy Timeline 
TIME PERIOD HORMONE THERAPY EVENTS 
1920-1929 
1928 – Progesterone identified 
1928 – Searle introduces estrogen patch 
1929 – Estrogen identified 
1929 – Attempts to treat menopause using amniotic fluid from              
cattle 
1930-1939 
1930 – Pregnant mares‘ urine found to contain estradiol 
1933 – Emmenin, made from pregnant mares‘ urine, becomes first 
HT 
1938 – Estradiol synthesized 
1939 – DES replaces Emmenin a more potent estrogen; it was used 
for the next 30 years to treat threatened miscarriage 
1939 – progesterone synthesized  
1940-1949 
1941 – Mexican yams first used for progesterone 
1942 – Premarin introduced 
1950-1959 
1952 – First synthetic progesterone 
1959 – Barbara Seaman, feminist & women‘s health advocate, 
recognizes link between use of estrogen and endometrial cancer 
Link found between low estrogen and osteoporosis 
1960-1969 1966 – Robert Wilson writes ‗Feminine Forever‘ 
1970-1979 
1971 – FDA withdraws approval for DES 
1973 – Clinical trials using estrogen in men were halted due to 
increasing heart attacks in men 
1975 – Ads by Wyeth for Premarin 
1980-1989 1988 – Robert Wilson‘s wife dies of breast cancer 
1990-1999 1996 – WHI begins 
2000-2011 
2002 – EPT arm of WHI stopped in July due to a decrease in global 
health index based on increased in CVD, stroke, breast cancer and 
thromboembolism risks 
2004 – ET arm of WHI stopped 
2007--Report of decrease in breast cancer among women stopping 
HT after the WHI 
2007-2011--Subgroup analyses of WHI show evidence for a 'window 
of opportunity' for cardiovascular benefits with early initiation of HT 
as well as no increase in breast cancer rates in women on ET only  
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Appendix D 
 
Websites for posting study advertisement 
SITE TYPE OF SITE 
NUMBER OF 
MEMBERS 
PERMISSION 
www.minneapauz.com Discussion groups/forums at 
menopause information website 
4100 Granted 
Peri/Menopause Special interest group on Facebook 
(social networking site)  
400 Granted 
BoomerWomenSpeak Discussion groups/forums at nidlife 
women‘s information/networking 
website 
Unknown Granted 
Linked-In Power 
Women 
Special interest group for women on 
Linked-In (networking site) 
883 Granted 
Linked-In Women of 
Wisdom 
Special interest group for midlife 
women on Linked-In (networking 
site) 
185 Granted 
Ethnic Majority Information website for African-
Americans, Asian-Americans, and 
Latinos  
Unknown Granted 
Asian-Nation Information website for Asian 
Americans 
Unknown Granted 
LatinoLA Information website for African-
Americans, Asian-Americans, and 
Latinos 
Unknown Granted 
Perimenopause Blog Blog related to menopause health 
issues 
Unknown Granted 
Journey to Wellness Information website related to 
African-American health 
Unknown No response 
Asians in America Website/online magazine for Asian 
Americans 
Unknown No response 
Menopaus Listserv Unknown Granted 
Red Hot Mamas Discussion groups/forums at 
menopause information website 
8600 No response 
Craig‘s List Social networking site Overall site: 50 
million 
hits/month 
NA 
UMass/Worcester 
Message Board 
University intranet message board  Unknown Granted 
Clinician 1 Online professional networking 
group for advance practice 
clinicians 
Unknown Granted 
Nurse Practitoners in 
Women's Health 
Online professional networking 
group for women's health NPs  
Unknown Granted 
NHNPlistserv Listserv for NPs in New Hampshire Unknown Granted 
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APPENDIX E 
 
Advertisement on Internet Website 
 
Menopause Research Study!!  
 
I am a Nurse Practitioner and also a doctoral student at the University of Massachusetts Graduate 
School of Nursing in Worcester, MA. For my dissertation, I am conducting a research study 
about women‘s experiences with discontinuing menopause hormone therapy. 
 
Currently there is little information to support women who are stopping menopause hormone 
therapy. This study will explore women‘s experiences with discontinuing menopause hormone 
therapy. The results will provide information for developing programs to educate and support 
women during hormone therapy discontinuation.  
 
Women who have attempted to discontinue menopause hormone therapy within the past two 
years are eligible. Participation in the study will involve one 30-60 minute interview (either 
online through a protected server at the university or by telephone). During the interview, 
participants will be asked to describe their experiences of discontinuing hormone therapy and 
then answer a short questionnaire. Compensation will be provided.   
 
This study has been approved by the Committee for the Protection of Human Subjects in 
Research at the University of Massachusetts/Worcester and is being supported by a grant from 
the American Academy of Nurse Practitioners. 
 
If you are interested in participating in this study please call (508-877-3316) or email me at 
mary.fischer@umassmed.edu. You may also respond via (insert appropriate website name such 
as Facebook or LinkedIn). 
 
Thank you for your consideration and I look forward to hearing from you soon. 
Mary Fischer 
Women's Health Nurse Practitioner 
Certified Menopause Practitioner  
University of Massachusetts/Worcester 
Graduate School of Nursing 
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Appendix F 
 
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 
COMMITTEE FOR THE PROTECTION OF HUMAN SUBJECTS IN RESEARCH 
 
FACT SHEET 
 
The title of this research study is: 
 
Women's Experiences of Hormone Therapy Discontinuation  
 
A. You are participating in a research study. 
B. The purpose of this research study is to explore women‘s experiences of discontinuing 
menopause hormone therapy. This study has been approved by the Committee for the Protection 
of Human Subjects in Research at the University of Massachusetts/Worcester is being supported 
by a grant from the American Academy of Nurse Practitioners 
 
C. You will be enrolled in this research study for up to 12 months. The primary portion of the study 
will consist of an interview and responding to a questionnaire which will take about 30-60 
minutes and may be conducted either online or by telephone. There is a possibility that we may 
need to contact you again to clarify your responses to the questions or for the purpose of verifying 
the findings. 
 
D. As part of this research study, you will be required to complete a short questionnaire as well as an 
interview describing your experiences while stopping menopause hormone therapy.  
 
E. The risks associated with participating in this research could be emotional distress from recalling 
your experience of discontinuing hormone therapy. 
 
There is a very small risk to your privacy and confidentiality as no website or computer system is 
100% safe from hacking. To minimize this risk, the study questions will be located at a secure 
Intranet website with restricted access. Contact with the researcher will be through the firewall-
protected University of Massachusetts email system.   
 
There are also some steps that each participant can take to decrease this risk. Whenever possible, 
do not use a shared computer to contact the researcher or access the study as records of these 
exchanges may be saved in the Internet service provider‘s (ISP) logs or in hidden cookies on the 
computer‘s hard drive. Be sure your system has adequate antivirus protection. When responding 
to questions from the researcher, if possible insert your responses into a Word document and send 
this document as a password-protected attachment (check your operating manual for instructions 
on how to password protect a document).  
 
F. You can choose to withdraw (quit) from this research study at any time without any penalty 
to you.  If you choose to withdraw from this research study, the care you receive at UMass 
Memorial Medical Center will not be affected.  
 
G. If you have any questions about this research study, you can call Mary Fischer MSN WHNP-BC 
NCMP at 508-877-3316. If you prefer to speak with someone not associated with this research 
study, please call the Committee for the Protection of Human Subjects in Research at the 
University of Massachusetts Medical School.  The telephone number is (508) 856-4261.  
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Appendix G 
 
Sample Flyer (with/without tabs) 
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Appendix H 
Sample Brochure 
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Appendix I 
 
Fact Sheet for Clinical Staff 
 
Women's Experiences of Hormone Therapy Discontinuation  
Mary Fischer MSN WHNP-BC NCMP (Doctoral Student) 
University of Massachusetts Graduate School of Nursing/Worcester 
 
Overview: a mixed methods study to explore women‘s experiences discontinuing hormone therapy (HT) 
for menopause 
 
Goal:  
 to develop a better understanding of the factors that influence recurrent symptoms, quality of life 
(QoL) and discontinuation outcome 
 This information will help to develop counseling and support interventions for women 
discontinuing HT 
 
Principal Investigator: Rosemary Theroux WHNP-BC PhD, Associate Professor (advisor) 
Co-Investigator: Mary Fischer MSN WHNP-BC NCMP, Doctoral Student 
(This study is the doctoral dissertation research of the co-investigator.) 
 
Sample: 40 women who: 
 are 45 years of age or older;  
 are in good health; 
 are in either the late menopause transition or postmenopause;  
 have used HT for a minimum of 3-4 months; 
 have attempted to discontinue HT (by any method of discontinuation) within the past 2 years, 
regardless of outcome; 
 are able to read, speak and write English; and, 
 have Internet or telephone access. 
 
Procedures:  
 Informed Consent and screening questionnaire reviewed and returned to co-investigator 
 Online Participants sent email with password, participant ID and link to Survey Tool or telephone 
call to participant to schedule telephone interview 
 Participant logs into study and completes interview questions and questionnaire or co-investigator 
contacts participant at scheduled time and administers interview questions and questionnaire 
 Participant may be recontacted by co-investigator for clarification of responses 
 Participant may be recontacted by co-investigator for member checks 
 
Compensation will be provided. 
 
Human Subjects Protection. This study has been approved by the Human Subjects Committee at the 
University of Massachusetts Medical Center/Worcester. The welfare, privacy and confidentiality of all 
participants will be considered at all times. No identifying information about participants will appear in 
the transcripts or dissertation. Participation is voluntary. No harm to participants is anticipated. 
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Appendix J 
 
 
    Participant recruitment sources  
Recruitment Number 
Health care provider referral 4 
Colleague referral 2 
Community posting 2 
Facebook 1 
Menopaus Listserv 1 
UMassMed Intranet 2 
Minniepauz 1 + 1 referral   
New Hampshire NP Listserv 3 
Nurse Practitioners for Women's Health 4 + 1 referral 
Craig's List 12 
 
 
 
     Location of participants 
Location Number 
Massachusetts 9 
New Hampshire 3 
Maine 3 
New Jersey 1 
Delaware 1 
Maryland 1 
Georgia 1 
Florida 1 
 Pennsylvania 1 
Ohio 1 
Illinois 1 
Missouri 1 
Louisiana 1 
Texas 1 
Nevada 1 
Idaho 1 
California 4 
Hawaii 1 
Canada 1 
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Appendix K 
 
Screening and Demographic Questionnaires 
 
Screening Questions (accompanying consent) 
 
Date: ___/___/____                                                                    Study ID #_____________   
                                      
Name  
Date of Birth  
When was your Final Menstrual Period?  
Have you ever taken hormone therapy for 
menopause? 
              
        How long did you take hormone  
        therapy? 
 
       What type of hormone therapy did     
        you take? 
Yes □ 
No □ 
  
______years 
 
 
Pill □ 
Patch □ 
other__________ 
Have you attempted to stop hormone 
therapy? 
               
 
                   How? 
Yes □ 
No □ 
 
Cold turkey □ 
Tapered □ 
What is your current hormone therapy (HT) 
status? 
No HT □ 
Resumed HT □ 
Taper in process □ 
Can you read and write English? Yes □ 
No □ 
Do you have any health issues that would 
prevent you from completing the 
questionnaires and interview? 
Yes □ 
No □ 
Have you ever been told you have cancer, 
heart disease or any other serious medical 
condition? 
Yes □ 
No □ 
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Demographic, Health  & Menopause-related Questionnaire 
 
DEMOGRAHIC & HEALTH 
INFORMATION 
RESPONSES 
Age at last birthday _____years 
Race/Ethnic-Cultural background 1 = African-American 
2 = Hispanic 
3 = Asian American 
4 = Native American 
5 = Caucasian 
6 = Other (specify: ______________________) 
Location of residence 1 = city 
2 = suburbs 
3 = rural 
Education level ___years completed 
Occupation Specify: ____________ 
Occupational status 1 = working full-time 
2 = working part-time 
3 = on disability 
4 = retired 
5 = seeking employment 
6 = student 
7 = other (specify: ____________) 
Financial strain (difficulty paying for 
basics) 
1 = Very hard 
2 = somewhat hard 
3 = not very hard at all 
4 = don‘t know 
5 = refused 
6 = other (specify: ____________) 
Marital status 1 = Married 
2 = widowed 
3 = single 
4 = separated 
5 = divorced 
6 = living with partner 
7 = other (specify: ____________) 
Gravity/Parity Number of pregnancies:_____________  
Number of births:______________ 
Children Number:__________________ 
Age at final menstrual period _____years 
Type of menopause 1 = natural 
2 = surgical 
3 = induced 
When started hormone therapy Year: _________ 
Reason for starting hormone therapy 1 = symptom relief  
2 = prevent bone loss 
3 = prevent heart disease 
4 = recommended by health care provider 
5 = suggested by family or friend 
6 = other (specify:_____________) 
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Type of hormone therapy 
(more than 1 answer possible)  
1 = oral/pill 
2 = patch 
3 = spray 
4 = gel 
5 = estrogen alone 
6 = both estrogen & progesterone 
7 = combined (taking both everyday) 
8 = cyclic (taking probesterone intermittently)  
Dose (if known):___________ 
Length of time on HT _________years 
Health care provider for menopause 
concerns  
1 = MD (medical doctor) 
2 = DO (osteopathic physician) 
3 = NP (nurse practitioner) 
4 = CNM (certified nurse midwife) 
5 = PA (physician‘s assistant) 
6 = Homeopath 
7 = ND (naturopathic physician) 
8 = Traditional Chinese Medical Practitioner 
9 = Chiropractor 
10 = Other (specify:_________________) 
Number of office visits in the past year 
for menopause-related concerns 
 
_____number of visits 
Sources of information about 
menopause  
1 = health care provider 
2 = family member 
3 = friend 
4 = TV 
5 = newspapers, magazines, books 
6 = Internet 
7 = Other (specify:____________) 
Please list any current health problems ___________________________________ 
___________________________________ 
___________________________________ 
Please list any other medications ___________________________________ 
___________________________________ 
___________________________________ 
Please list any over-the-counter or non-
prescription medications  
___________________________________ 
___________________________________ 
___________________________________ 
Please list any complementary therapies 
(such as herbal medications, massage, 
acupuncture)  
___________________________________ 
___________________________________ 
___________________________________ 
Please describe your location during 
this interview 
Place: (work/home/other)___________ 
Weather:________________________ 
Time of day:_____________________ 
How did you hear about this study? 1 = website (specify: ______________) 
2 = health care provider (who:_____________) 
3 = referred (by whom: _____________) 
4 = community flyer (where:______________) 
5 = other (specify:_________________) 
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Appendix M  
Hot Flash Related Daily Interference Scale 
 
Please circle one number to the right of each phrase to describe how much DURING THE 
PAST TWO WEEKS, hot flashes have INTERFERED with each aspect of your life.  
 
  Do not Completely 
 interfere interfere 
1. Work (work outside the 
home and housework) 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
 
2. Social activities (time spent 
with family, friends, etc) 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
 
3. Leisure activities (time 
spent relaxing, doing 
hobbies, etc.) 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
 
4. Sleep 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
5. Mood 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
6. Concentration 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
7.   Relations with others 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
8.   Sexuality 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
9.   Enjoyment of life 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
10. Overall quality of life 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
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 Appendix N  
Well-being Scale 
 
QUESTION RESPONSE 
How have you been feeling in general during 
the past month? 
5 = in excellent spirits 
4 = in very good spirits 
3 = in good spirits mostly 
2 = I have been up and down in spirits a lot 
1 = in low spirits mostly 
0 = in very low spirits 
How happy, satisfied or pleased have you been 
with your personal life during the past month? 
5 = extremely happy, could not have been 
more satisfied or pleased 
4 = very happy most of the time 
3 = generally satisfied, pleased 
2 = sometimes fairly satisfied, sometimes fairly 
unhappy 
1 = generally dissatisfied, unhappy 
0 = very dissatisfied, unhappy most of the time 
My daily life was full of things that were 
interesting to me during the past month. 
5 = all of the time 
4 = most of the time 
3 = a good bit of the time 
2 = some of the time 
1 = a little of the time 
0 = none of the time 
I felt cheerful and lighthearted during the past 
month. 
5 = all of the time 
4 = most of the time 
3 = a good bit of the time 
2 = some of the time 
1 = a little of the time 
0 = none of the time 
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Appendix O 
General Health Status and QoL Questions 
 
QUESTION RESPONSE 
How would you rate your overall quality of 
life? 
5 = very good 
4 = good 
3 = neither poor nor good 
2 = poor 
1 = very poor 
How satisfied are you with your health? 
5 = very satisfied 
4 = satisfied  
3 = neither satisfied nor dissatisfied 
2 = dissatisfied 
1 = very dissatisfied 
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Appendix P 
Qualitative Interview Guide & Additional Prompts 
 
SPECIFIC AIMS QUESTION PROMPTS/PROBES (postulated a priori) 
Explore women‘s experiences 
of HT discontinuation   
Please tell me about your 
experience when stopping 
hormone therapy 
Why did you start HT? 
Why did you decide to stop? 
Tell me about any symptoms you had when you were 
discontinuing HT.  What symptoms do you have now? 
Were the symptoms better, worse, same as before you 
started HT? 
What did your symptoms mean to you? What did 
stopping HT mean to you? 
Was this experience what you expected? Was there 
anything that surprised you about this experience? 
How has your life changed since stopping HT? 
Describe the personal 
characteristics and 
sociocultural contexts that 
influence symptom perception, 
evaluation and response 
among women who have 
attempted to discontinue HT 
Please tell me what you 
think might have 
influenced this 
experience and your 
decision to stay off 
/resume HT 
 
Describe what or who helped you when you were 
stopping hormone therapy. Describe what or who 
made the experience difficult. 
 
Looking back, what would have made this experience 
better or more tolerable for you? 
Explore the impact of HT 
discontinuation on women‘s 
quality of life (QoL) 
Please describe your QoL 
while you were stopping 
HT.  
Please tell me about your 
QoL now. 
What does QoL mean to you? What is the most 
important part of QoL to you?  
 
How did stopping HT impact on your QoL? How did 
your QoL impact on your decision to remain 
off/resume HT?  
Discuss women‘s preferences 
for counseling and support 
during HT discontinuation 
Please tell me what 
information your health 
care provider gave you 
when you were stopping 
hormone therapy 
How did you feel about the information you received? 
Was it enough?  
 
What else would have been helpful for you to know? 
What do you think women stopping HT should know 
before they stop? 
 
Where do you get information about menopause? 
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Follow-up Questions/Prompts Evolving with Interview Analysis 
I would like to learn more about your discontinuation experience but first I'd like to back up a bit 
and ask you about your experiences before beginning hormones and while you were taking them. 
First, please describe what menopause means to you. For example: some women think of it 
negatively (getting older for example) while other women think of it positively (no more worries 
about getting pregnant). What do you think influenced your beliefs about menopause? 
I've found that some women going through menopause are very interested in taking hormone 
therapy, some are very much against it and some are undecided or prefer to keep an open mind 
and re-evaluate their decisions as time goes on. Please tell me what your thoughts were about 
hormone therapy before you started taking it and what you think influenced your beliefs about 
hormone therapy? Had you ever considered taking hormone therapy before your provider 
recommended it to you? Was it recommended for symptom relief or health promotion?  
Did any friends or family or co-workers encourage you to take hormone therapy or try to 
discourage you from taking it? Why or why not? 
You mentioned that you started hormone therapy for symptom relief. Please tell me more about 
those (and any other) symptoms: for example, how long you had them, how troublesome they 
were, what you had been doing to manage them before hormone therapy?  
Did you notice any other symptoms or changes that you thought were related to menopause? If 
so, can you also tell me more about those? 
Some women notice triggers for their hot flashes (caffeine, stress, heat and so on). Have you 
noticed any triggers? If yes, what are they?  
Please describe how you felt after you started taking the medication? Did you notice any changes 
or improvement in your symptoms or overall health? Did your family or friends notice any 
changes? Were your symptoms completely relieved?  
Did you have any negative effects from the hormones and if so what were they? How did you 
manage them? How did they impact on your feelings about hormone therapy? 
How long did it take you to make the decision to stop? Was it a difficult or easy decision to 
make, and why? Did anyone help you to make your decision?  
What influenced you decision to stop the way you did? If you had to discontinue again, would 
you do it the same way? Why or why not? 
What was the reaction of your family/friends/co-workers when you stopped hormone therapy? 
Please tell me more about the symptoms you had when you were discontinuing HT:  for 
example, how soon did they resume, how long did they last, were the symptoms better, worse, or 
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the same as before you started taking hormone therapy? What did you do to help you manage 
these symptoms? How did you feel when the symptoms came back? Were you surprised that 
some symptoms came back or were you expecting this?  
Did you notice any new symptoms or changes that you attribute to stopping hormone therapy? If 
so, were you surprised to experience new symptoms or changes? What did you do to help you 
manage these symptoms?  
On a scale of 1 to 10, with 10 being the worst you have ever felt, how would you rate your 
experience of stopping hormone therapy and why? Was this experience what you expected? Was 
there anything that surprised you about this experience? Did this experience change your feelings 
or beliefs about menopause and how? Why? 
How has your life changed since stopping HT? Did you 'learn anything new about yourself' as a 
result of this experience? 
****************************************************************************** 
Some women have described certain factors that have made the experience of stopping hormone 
therapy easier or more difficult, for example, the weather, stress, beliefs about hormone therapy, 
other health issues, support from family or friends, exercise or meditation, or other medications, 
to name just a few. Looking back, please describe any factors that you think made the experience 
more difficult or made the symptoms more uncomfortable. How did they make it worse?  
 
Can you think of anything that might have made stopping hormone therapy easier for you or 
helped you to manage the symptoms and if so, how?  
 
Many women who stop hormone therapy resume taking it. What has helped you to remain off? 
You mentioned that you are still symptomatic -- what are you doing to manage or cope with your 
symptoms now? 
 
Is there anything that would make you consider resuming? If you had to stop hormone therapy 
again, what would you do differently? 
 
What would make you consider stopping hormone therapy again? 
 
Some women have discussed that they knew intuitively or had a sense that it was right time to 
stop. Did you have a similar sense and if so can you describe what factors or issues made you 
feel that this was the right time? 
****************************************************************************** 
Please tell me what quality of life means to you or how you define quality of life? In general, 
what makes your quality of life better or worse? Some people say that quality of life is made up 
of many different parts such as health, symptoms, ability to participate in daily living activities, 
social support and so on. What do you consider to be the most important aspects(s) of your 
quality of life and why?  
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Please rate your quality of life before you started hormone therapy? How did it change when you 
were taking hormone therapy? Which aspect of your quality of life was most affected by starting 
hormone therapy and how? Which aspect was most affected by stopping hormone therapy? 
 
Does your quality of life impact on your decision to remain off/continue taking hormone 
therapy? 
 
How long had you been tapering/how long after you stopped before you noticed that your quality 
of life was changing?  
 
Some participants have described a type of hormone 'energy' or increased enjoyment in life that 
just was not there before or after taking hormones -- have you noticed anything like that? Please 
tell me more about this. 
 
You indicated that you are currently having some symptoms that moderately interfere with your 
work, mood, sleep and sexuality. Many women who have symptoms such as yours report that 
their quality of life is very low. Yet you reported that your overall quality of life is good. How 
would you explain this difference? What makes your quality of life good even though you are 
having some interfering symptoms? 
 
What would it take to make your quality of life very good? 
****************************************************************************** 
Did you feel your health care provider supported your decision to stop hormone therapy? 
How did you feel about the information you received from your health care provider about 
stopping hormone therapy? Was it enough? Please tell me what information would have been 
helpful for you to know when you were stopping? 
 
When you started hormone therapy, did your provider make any recommendations to you about 
how long to stay on hormone therapy? 
 
When did your health care provider learn that you stopped hormone therapy? How did your 
health care provider react when you told him you had stopped? Did he support resuming 
hormone therapy or has he tried to encourage you to stop again? Did you feel your health care 
provider supported your decision to stop hormone therapy, even though s/he may not have 
agreed with it?  
 
Did s/he provide you with any additional support or counseling (phone calls, prescriptions for 
other medications and so on) during or after this process? Did you provider discuss any other 
recommendations such as making changes in your exercise or diet? 
 
What else would have been helpful for you to know? What do you think women stopping HT 
should know before they stop? 
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You also said you saw a health care provider ___ times in the past year for menopause issues. 
Can you tell me more about those issues: which symptoms or concerns did you have and how 
you and your provider decided to manage them. 
What advice would you give to other women stopping hormone therapy? 
What advice would you give to women who are thinking about starting hormone therapy? 
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Appendix Q 
 
DISCONTINUING MENOPAUSE HORMONE THERAPY STUDY 
MEMBER CHECK 
The Member Check is a very important part of Qualitative research: it helps the researcher to know 
that s/he has been true to the voice of the participants when analyzing the data. Below is a 
summary of the preliminary findings from the open-ended question and interview components of 
this study. Please review this summary and provide your feedback to let me know if I have 
accurately represented your experiences with discontinuing hormone therapy. Please also provide 
any additional comments or thoughts that come to mind as you read these findings and if your 
hormone therapy status has changed (stopped or resumed) please provide any updates. 
 
Before Hormone Therapy 
 Women's expectations and beliefs of menopause were mixed: either looking forward 
positively or worrying about negative changes. 
 Many women were surprised when they started having uncomfortable symptoms during 
menopause. The most common symptoms mentioned were hot flashes/night sweats, lack 
of sleep, and moodiness. Most women had more than one symptom. 
Voices: 
"Menopause always carried a negative connotation for me--'old', finality, loss of youth, loss of sex 
appeal & sex drive, body changes, loss of fertility/sexuality." 
"I thought it was going to be a breeze, it's kind of like you are not going to have any more periods, 
you are not going to have any more worries..." 
"I didn’t really think the hot flashes would be as bad as they are...so even though it was winter I had 
the window open and I was sleeping on ice packs and I would be awake most of the night flipping the 
pillow over...Besides the hot flashes, lack of sexual desire, just general sleeplessness." 
 
Comments:________________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________
____________________________________ 
 
Deciding to take Hormone Therapy 
 Before menopause began, women also had mixed feelings about hormone therapy: some 
believed it could be helpful if necessary while others expressed concerns about risks they 
had heard in the media. 
 Although a few women took hormone therapy only for health promotion purposes, the 
majority of women eventually decided to take hormones because of symptoms that were 
interfering with women's daily activities and impacting on their quality of life. 
 Women carefully considered hormone  therapy benefits and risks before starting these 
medications. 
 
Voices:  
"I decided to take hormone replacement therapy way before I reached menopause ...." 
"Prior to menopause, I was opposed to HRT due to my strong opposition to any meds... " 
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"...then I started not sleeping ... one day I was walking in the city and I was so exhausted I was 
holding on a wall to walk because I was really ready to fall over and I just stopped myself and I 
thought, okay this is not normal..." 
"...they were coming almost like on schedule all of the time...it was embarrassing at work but the 
worst part was I just wanted to get some sleep...I was emotional, I felt beaten..." 
 
Comments:________________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________
____________________________________ 
 
Hormone Therapy: Relief or Worry? 
 Most women found that hormone therapy relieved their symptoms and gave them back a 
sense of normalcy or control. 
 Several women described an increase in energy or interest in life that was not present off 
hormones. 
 Some women developed side effects or concerns while taking hormones  (bleeding, 
bloating, or weight gain) and a few women did not get complete relief of their symptoms. 
 Women who had concerns about hormones before menopause expressed worries about 
continuing to take hormone therapy even though they felt better on it.  
Voices:  
"I loved the elimination of the hot flashes and my memory seemed to be a bit better." 
"...my husband notices that I am not waking up as much, not waking him up... I am much more level 
now...." 
"On hormone therapy, I’m the way I’ve always been – enjoying life, finding pleasure in both big and 
little things in my days. Off therapy, everything lost its shine. I could be in a beautiful garden but 
would have no interest in smelling the roses – I would just feel annoyed over the heat, thorns, etc." 
"I was getting a lot of headaches while taking HT..."  
"I had irregular bleeding & staining for days/weeks at a time."  
 
Comments:_______________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________
_____________________________________ 
 
Deciding to stop Hormone Therapy 
 There were many reasons why women stopped hormone therapy: advice from providers, 
curiosity, convenience, cost, incomplete relief or concerns about side effects or risks.  
 Some women described having an intuition or feeling as to whether or not it was the right 
time to stop. 
Voices:  
"I began weaning off hormone therapy ... because my GYN had recommended discontinuation..." 
"The prescription ran out and...this really isn’t making that big of a difference and I don’t want to 
spend the money and also ... I don’t know how much of a danger it is." 
"I knew that I would intuitively know when it was time to come off and it would feel right to me... " 
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Comments:________________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________
____________________________________ 
 
A Personal Journey: The Experience of Discontinuing Hormone Therapy 
 Although a few women had no symptoms after stopping, most women had a recurrence of 
symptoms and in some instances even noted new symptoms that were not present before 
hormone therapy. 
 Most women who noticed symptoms thought they were the same or a little milder than 
before taking hormone therapy but several women reported that their symptoms were 
worse when they stopped. 
 For many women, the recurrent symptoms greatly interfered with their daily activities and 
quality of life. 
 After careful consideration of the benefits and risks, about a third of the women resumed 
hormone therapy.  Some of them were still worried about risks and hoped to stop 
completely some day; several had stopped and started multiple times.  
 Many but not all women who remained off hormones found that their symptoms eased or 
disappeared with time. Although some women stated they would go back on hormones if it 
were not for the side effects or risks,  others reported feeling better being off hormones and 
happy that they stopped.  
Voices:  
"When I stopped HRT, the hot flashes and problems sleeping started up again within 3-4 days. They 
were both horrible – wet hair from the hot flashes and the need to change bedding 2-3 times a 
night." 
"I went back on...mostly because I wasn't able to sleep. It was a tough decision because I hate to be 
on anything..."  
"...actually stopped and started several times before I "finally quit" Each time I tapered down to quit, 
my symptoms would roar back in a vengeance... I would be dysfunctional at work sometimes..."  
"I resumed because I was always miserable. What kind of life is it when one is always miserable and 
trying to hide the hot flashes from others?"   
"I feel a lot better without the patch. I feel a lot more healthy." 
"One less worry in my life, worrying about the long term effects of the medication that I'm taking." 
 
Comments:________________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________
____________________________________ 
 
Women's Words of Wisdom 
 Some women discussed stopping hormone therapy with their health care providers but 
many stopped without mentioning it to their providers. 
 Information given by providers was inconsistent and often limited and most women did not 
receive any ongoing support or counseling during discontinuation even if they were having a 
difficult time. 
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 Women offered suggestions for what health care providers should offer to other women 
stopping hormones: specific information about what to expect, more support from health 
care providers, support groups, peer support. 
 Women also made suggestions for women starting or stopping hormone therapy: evaluate 
symptoms, get more information,  weigh risks and benefits carefully, and get support along 
the way. 
Voices:  
"I would make sure that they know what they are doing, do your research, talk to your doctor. I wish 
my doctor did talk to me a little bit more about it to put me more at ease rather than saying oh just 
don’t worry about it." 
"I would love to have groups where women talk to each other...."  
"Make sure it is something you want to do because you need to know the side effects as well as the 
good benefits." 
"I just wish that my doctor would have taken more time to listen to my concerns..." 
 
Comments:________________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________
____________________________________ 
 
Updates or additional information: 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
If you would like to receive a summary of the final results, please indicate whether you prefer to 
receive it by email or as a hard copy and provide your contact information below:  
 
_________________________________________  Email copy □   Paper copy □ 
_________________________________________   
_________________________________________ 
_________________________________________ 
 
Thank you once again for your participation! 
Mary Fischer MSN WHNP-BC NCMP, Doctoral Student 
mary.fischer@umassmed.edu 
1-508-877-3316 
Rosemary Theroux WHNP-BC PhD, Associate Professor (advisor) 
University of Massachusetts Graduate School of Nursing 
55 Lake Avenue North 
Worcester, MA 01655 
 
